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ABSTRACT  
The importance of studying angiogenesis is underscored by its involvement in diseases such as cancer, 
heart disease, arthritis and diabetes. Researchers have developed disease treatments that target the 
molecules that drive angiogenesis in therapeutic ways. The mechanisms of angiogenesis, however, are 
under-characterized, and the gaps in our understanding of angiogenesis invariably limit the develop-
ment of new and the efficacy of existing disease treatments. Consequently, a better understanding of 
angiogenesis will require new angiogenesis assays.  Current angiogenesis assays strip away important 
components of the angiogenic process and/or limit control of the variables that direct angiogenesis. This 
problem is more pronounced in studies of the interaction between mechanical signals engendered in 
blood flow and angiogenesis. To address some of the limitations of the current armamentarium of angi-
ogenesis assays, vascular explant assays (e.g. the aortic ring assay) were developed. Considered the best 
in vitro mimic of in vivo angiogenesis, the “ex vivo” vascular explant assay synergistically combines quali-
ties of in vitro and in vitro angiogenesis assays to provide precise control over a biological system that 
recapitulates almost all of the mechanism and steps of physiological angiogenesis. However, the vascu-
lar explant assay lacks mechanical stimuli engendered in blood flow. The goal of this research was to 
develop a more physiologically realistic platform for studying angiogenesis by incorporating intraluminal 
fluid flow within the vascular explant assay. A perfused vascular explant bioreactor was developed and 
implemented to facilitate long-term culture and angiogenic outgrowth from a perfused mouse thoracic 
aorta in vitro. The aorta was subjected to a flow rate that would generate shear stress comparable to 
that experienced in post capillary venules. Finite element analysis of the reactor predicted perfusion of 
the aorta lumen would also cause perfusion of the abluminal space, provided the aorta contained holes 
through with fluid could exit. The vascular explant bioreactor developed in this study supported long-
term culture of a perfused and/or perfusible thoracic aorta in vitro, and also demonstrated angiogenic 
outgrowth from the explant. When the aorta lumen was loaded with fluorescent microspheres, regions 
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of the angiogenic outgrowth fluoresced, suggesting that some of the nascent vasculature was patent to 
the aorta. However, in response to intraluminal perfusion and culturing in our bioreactor, we observed 
an as-yet unexplained increase in the hydraulic impedance of the aorta. The device designed in this 
study may allow researchers to investigate the interaction between hemodynamic stimuli and angio-
genesis in an in vitro model that recapitulates nearly all of the mechanisms and steps of angiogenesis. 
Application of this technology may produce insights necessary for developing new drugs that treat dis-
eases by targeting angiogenesis. 
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CHAPTER I 
 
INTRODUCTION 
 
 
Heart disease, cancer, and stroke lead in causing death in the U.S., accounting for over half of the deaths 
in America in 20091. Together they account for $700 billion in yearly health care and lost productivity 
costs in America2, 3. Further, for the patients battling these diseases, current treatments only marginally 
and temporarily improve the quality of life. Heart disease, cancer, and stroke vary widely in their mech-
anisms of action but share one commonality: Angiogenesis, the sprouting and subsequent stabilization 
of blood vessels from pre-existing blood vessels, plays a pivotal role in their pathogenesis. Angiogenesis 
is a hallmark of several diseases, including cancer, ischemia, hypertension, and inflammatory disorders4. 
For this reason, understanding angiogenesis is crucial to understanding, preventing, and treating many 
diseases. Years of study have vastly expanded the knowledge of angiogenesis but gaps remain. These 
gaps redound to limitations in the efficacy of available treatments for several diseases. The study of an-
giogenesis draws upon an armamentarium of in vitro and in vivo assays, but there is no “gold standard” 
angiogenesis assay. In vitro assays provide a platform for detailed study of biological systems that poorly 
mimic or recapitulate angiogenesis in humans, while in vivo assays provide a more relevant model at the 
cost of access to and control of variables that affect angiogenesis. This is especially evident in studies of 
the interaction between mechanical stimuli and angiogenesis.  
Some diseases (e.g., tumor malignancy and hypertension) have an impact on both the mechanical forces 
experienced by blood vessels and angiogenesis; however, little is understood about the interaction be-
tween mechanical forces and angiogenesis or how this interaction drives the pathology of these diseas-
es. In vitro mechanotransduction assays (which study the cellular response to mechanical perturbations) 
typically limit investigations to individual cells or two-dimensional cell monolayers in conditions that de-
viate greatly from their physiological context. In vivo angiogenesis assays offer minimal control over me-
chanical stimuli, and in vivo control of a mechanical stimulus in isolation is difficult. Blood vessels inter-
pret the mechanical forces and biochemical cues communicated via their constant contact with flowing 
blood. However, blood flow and consequences of blood flow are not well mimicked in vitro, nor are they 
precisely controlled in vivo. Recently, improvements have allowed the introduction of blood flow mim-
icking mechanical stimuli to three-dimensional angiogenesis assays, but even these assays do not repre-
sent or recapitulate human angiogenesis to the full capabilities afforded by current in vitro angiogenesis 
assays.  
The best in vitro mimic of angiogenesis in vivo occurs in the vascular explant angiogenesis assay, for ex-
ample the aortic ring assay, in which new vessels sprout from segments of explanted vessels and to 
some extent stabilize. This assay presents multiple cell types with a spatial organization that is most sim-
ilar to that in in vivo angiogenesis. In the vascular explant angiogenesis assay, the vascular explant re-
tains more of its endogenous character than do cells used in other in vitro angiogenesis assays. For ex-
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ample, angiogenesis only occurs when solicited, and the cells that carryout angiogenesis (endothelial 
cells) are typically quiescent. Isolation of endothelial cells relinquishes cell quiescence, whereas explant-
ing vasculature does not. This assay recapitulates nearly all of the steps of in vivo angiogenesis while re-
taining much of the precision and control offered by in vitro angiogenesis assays. For this reason, the 
vascular explant angiogenesis assay overcomes several of the limitations typical of in vitro and in vivo 
angiogenesis assays. Unfortunately, the vascular explant angiogenesis assay does NOT accommodate 
simulation of blood flow or associated mechanical stimuli. In consideration of this drawback, I propose a 
perfused vascular explant bioreactor (PVEB) which facilitates angiogenic outgrowth from a perfused vas-
cular explant in long-term in vitro culture.  
The proposed PVEB would allow perfusion access to the lumen of a vessel in long-term culture and 
whose endothelial cells are undergoing angiogenesis. This advantage would potentially permit investiga-
tion of the influence of stimuli engendered in blood flow within the vascular explant angiogenesis assay 
by providing a means of monitoring and controlling intraluminal fluid composition and flow. Valuable 
features of the vascular explant assay (i.e. the physiological relevance of its angiogenic environment and 
the nearly complete angiogenic process it recapitulates) would be maintained in the PVEB. Since in vivo 
angiogenesis occurs from patent microvasculature, the addition of perfusion to the vascular explant po-
tentially makes the PVEB angiogenic culture a better in vitro mimic of the in vivo angiogenic environ-
ment than conventional vascular explant assays. The PVEB will allow potentially more detailed and phys-
iologically relevant study of the interactions between mechanical forces and biochemical phenomena 
engendered in blood flow and angiogenesis. I hypothesize that the PVEB will facilitate angiogenic out-
growth from a vascular explant whose lumen is accessible to perfusion, and that this enhancement will 
allow measurement and actuation of mechanical and chemical stimuli (those accompanying blood flow) 
in a vascular explant angiogenic culture. Insights gained by using the PVEB to study angiogenesis may 
prove necessary to the development of drugs and therapies that effectively target angiogenesis in the 
treatment of a host of diseases. The following briefly summarizes angiogenesis and reviews the assays 
that researchers utilize to investigate angiogenesis. Based upon this, we propose that the perfused vas-
cular explant bioreactor as a valuable addition to the armamentarium of angiogenesis assays. 
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CHAPTER II 
 
BACKGROUND 
 
B.1. Angiogenesis 
In a biological system, vital nutrients typically passively diffuse only a few hundred microns from their 
source. This implies that large organisms, some spanning several meters, must have an extensive net-
work of nutrient-carrying conduits (e.g., blood vessels) in order to exist. The human circulatory system, 
for example, consists of miles of blood vessels assembled into a network that efficiently meets the im-
mensely diverse needs of the body’s tissues – all while maintaining fairly constant and moderate pres-
sures and flow rates throughout. A properly functioning circulatory system is absolutely essential to hu-
man development and health. The circulatory system starts functioning before any other system in the 
vertebrate5. This incredibly adaptive and complex system assembles, maintains, and remodels itself in 
part via sprouting angiogenesis, commonly referred to simply as angiogenesis, which is the process of 
growth and subsequent stabilization of new blood vessels that bud from pre-existing ones6-8.  
Angiogenesis first occurs in early embryogenesis and continues until adulthood. During adulthood, most 
blood vessels remain quiescent (i.e., they do not participate in angiogenesis) until solicited to initiate 
angiogenesis by local ischemia, wounding, endometrial repair, or malignant tissues. Other processes 
(e.g., vasculogenesis and arteriogenesis) participate in vessel formation and remodeling, but angiogene-
sis plays the most active role in establishing and maintaining a mature circulatory system – particularly 
in the microcirculation domains. While the “steps” of angiogenesis are not concretely defined, one 
might consider angiogenic sprouting, vessel formation, adaptation to tissue needs, and stabilization as 
four roughly sequential events in angiogenesis. Orchestrating these steps requires the cooperation of 
cell types, matrix molecules, growth factors, and cytokines, each responding to certain genetic, metabol-
ic, mechanical, and chemical cues in processes not fully understood. Researchers expect that creative 
innovations in assays and techniques will prove necessary for expanding the knowledge of angiogenesis. 
Keeping the technologies commonly utilized to study angiogenesis in mind, the following briefly over-
views the current description of angiogenesis in health and disease.  
 
B.1.1. Vascular Development and Quiescence  
The first vasoformative events occur in the mesoderm of an embryo right after gastrulation9, 10. Here, 
vasculogenesis (discussed below) gives rise to a series of interconnected capillary-like tubes called the 
primordial blood vessel network or vascular plexus. The vascular plexus develops onward into adult-
hood, expanding and organizing – via angiogenesis and other vasoformative processes – into a mature, 
immensely complex and multifunctional vasculature. The adult vascular network is largely quiescent and 
arranged into blood vessels that accommodate high volume. These vessels connect to the heart and ar-
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borize into smaller arteries, veins, and capillaries that populate all tissues. Anatomical and physiological 
features vary throughout the vascular tree and take on functional specializations to suit the needs of 
nearby tissues and organs. Therefore, the microenvironments that facilitate angiogenesis carry distinct 
cell and matrix compositions, and the cell types that most actively participate in angiogenesis vary in 
origin, morphology, gene expression, and responsiveness to angiogenic factors. Spatial-temporal varia-
tions of the vasculature in its quiescent state affect the likelihood and nature of angiogenesis. There ex-
ist, however, several properties that are consistent throughout the vasculature, and the quiescent vas-
cular system, though constantly engaged in a diversity of vital tasks, stands poised to rapidly initiate an-
giogenesis in response to stimuli. The following describes the vascular system in its quiescent state: how 
the vascular system arises, what qualities define the quiescent state, and what processes maintain a 
quiescent vasculature until angiogenesis is induced.  
 
Vascular system development  
Vascular development begins in the embryo with vasculogenesis. In this process, endothelial cell precur-
sors differentiate into endothelial cells – which line the entire internal surface of the vessel network – 
and amalgamate to form a network of primitive capillary-like tubes called the vascular plexus9, 10. Em-
bryonic vasculogenesis is triggered in the mesoderm by the accumulation of fibroblast growth factors 
(FGFs). Cells in the mesoderm differentiate into angioblasts (embryonic precursors of endothelial cell 
precursors) and assemble into cell clusters called blood islands. The blood islands coalesce during vascu-
logenesis to form a vascular plexus. Embryonic vasculogenesis is required for organogenesis, as organs 
begin growing around the nascent vessels of the vascular plexus9.  
Initially thought to occur only in embryos, vasculogenesis has been observed in postnatal juveniles and 
adults9. In adult vasculogenesis, endothelial progenitor cells, mesoangioblasts, multipotent adult pro-
genitor cells, and/or side population cells in the bone marrow assume the role that angioblasts take in 
embryonic vasculogenesis9. This has sparked interest in developing cell therapies that stimulate vasculo-
genesis in treating ischemia and other diseases. Embryonic and adult vasculogenesis occurs alongside 
angiogenesis and initiates in response to proangiogenic factors such as FGFs and vascular endothelial 
growth factor (VEGF)9, 10. In fact, embryonic models of angiogenesis can also be used to study vasculo-
genesis (e.g., avian embryo chorioallantoic membrane, or CAM, assays)9. Vasculogenesis-capable cells 
promote angiogenesis by secreting proangiogenic paracrine signals and by transdifferentiating into en-
dothelial cells and vascular supporting mural cells9, 11.  
Angiogenesis begins to remodel and expand the nascent vascular plexus shortly after it arises in the em-
bryo. Angiogenic remodeling of the vascular plexus utilizes several processes common in angiogenesis in 
adults (section B.1.2.) although some distinctions exist. A notable difference between embryonic and 
adult angiogenesis, for instance, is that embryonic angiogenesis occurs (prior to organogenesis) in antic-
ipation of local oxygen and nutrient demands and adult angiogenesis occurs in response to it. G. Breier 
reviews the distinct mechanisms of embryonic angiogenesis10. Neuropilin and Notch signaling pathways 
direct embryonic angiogenesis. Angiogenic sprouting and migration (particularly in arterial fated endo-
thelial cells) occur in response to VEGF-A signaling from the notochord and nascent neurons10. VEGF-A, 
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expressed primarily in embryos, binds to vascular endothelial growth factor receptor 2 (VEGFR2) in en-
dothelial cells and induces expression of Notch proteins and Notch protein ligands10. It is suspected that 
VEGF-A signaling to the Notch pathway explains why arteries and neurons run alongside each oth-
er4,10,11. The dependence of endothelial cells on VEGF-A for angiogenesis wanes after birth10.  
Notch signaling also specifies the arterial and venous phenotype in embryonic endothelial cells. Arterial 
specification equips arteries, arterioles, and arterial capillaries to carry pressurized, oxygenated (except 
in pulmonary or umbilical arteries) blood at higher flow rates. Arterial specification coats the vessels 
with elastic matrix materials, pericytes, fibroblasts and smooth muscle cells which strengthen the ves-
sels. Veins do not accommodate higher pressure flow and as a result lack some of the arterial features. 
Arterial/venous specification is an important step in the maturation of the vascular system and has con-
sequences on angiogenesis. For example, arteries do not as readily respond to pro-angiogenic molecules 
as do veins, and it was hypothesized that tumors tend to attract angiogenic sprouting on the venous side 
of capillaries because of the differences that arise in arterial/venous specification. VEGF-A, secreted 
from notochord and neurons, suppresses venous specification and promotes stabilization of nascent 
arteries. Notch proteins specify the arterial phenotype, prior to blood flow10, 11. Notch signaling induces 
expression of Ephrin B2 and EphB4 (a receptor for Ephrin B2) in arterial and venous endothelial cells, 
respectively. EphrinB2-EphB4 signaling is critical for arterial and venous anastomoses, which demark the 
boundary between the arterial and venous sides of the vascular system. Researchers once suspected 
that Notch signaling in arterial-venous specification is nonfunctional in adults. However, endothelial cells 
can take on an arterial or venous phenotype in neonatal retina and even in the adult heart11,12. Nicosia 
et al. have observed arterial-venous anastomoses in vitro13 . Directing the arterial/venous fate of endo-
thelial cells might benefit angiogenic therapies in tissue regeneration and engineering.  
Intussusceptive angiogenesis is a vascular remodeling process that causes transluminal endothelial pil-
lars to form within the small vessels and capillaries and subsequently fuse, thereby delineating two new 
vessels14. Sprouting and intussusceptive angiogenesis expands the vascular plexus, but subsequent 
growth and remodeling occur via intussusceptive angiogenesis14. In adults, intussusceptive angiogenesis 
remodels the nascent vasculature arising from sprouting angiogenesis14.  
Once anastomotic connections between the arterial and venous trees of the vascular system form, 
blood flow begins6 and arteriogenesis starts modifying the vascular system. Arteriogenesis (also termed 
collateral growth) is the proliferative dilation and muscularization of arterial vessels15-17. This process 
begins with activation of the endothelial cells that line arterial vessels17. Prolonged increases in shear 
stress and transmural pressure difference in the vasculature stimulate arteriogenesis. Increases in shear 
stress and transmural pressure that accompany arterial occlusive diseases and vascular development 
induce arteriogenesis, but are difficult to imitate in vitro. As a result, fewer of the biomolecular mecha-
nisms of arteriogenesis have been uncovered. Ex vivo organ cultures have been developed and are be-
ginning to be utilized to investigate the effects of fluid flow on endothelial and smooth muscle cell pro-
liferation (i.e. markers of arteriogenesis)18, 19. Arteriogenesis also occurs by chemical induction. For ex-
ample, basophilic fibroblast growth factor (bFGF) causes endothelial cells to proliferate and express cell 
adhesion molecules important for recruiting pro-arteriogenic monocytes from circulation16,17. Arterio-
genesis occurs almost always in the presence of ischemia but it is not caused by ischemia17. Angiogene-
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sis alone is only modestly effective at treating large regions of ischemia. Angiogenesis increases the vas-
cular content in a tissue, while arteriogenesis increases the volumetric flow rate into the tissue. Treat-
ment of coronary ischemia and blood perfusion demands in tissue regeneration applications have 
sparked interest in therapies that induce both angiogenesis and arteriogenesis.  
Vasoformative processes that participate in the pathological vascularization of malignant tissues include 
vessel co-option, vessel mimicry, and tumor endothelial cell differentiation6. Lymphogenesis and the 
formation of the heart are major occurrences in the development of a functioning vascular system20.  
 
Vascular System Function 
The mature vascular system features two closed-loop conduits: the systemic and pulmonary circulation 
loops. The systemic circulation loop extends from the heart via the aorta. The aorta branches into other 
major arteries (e.g., carotid, subclavian, femoral arteries, etc.). These arteries arborize further into arte-
rioles, metarterioles (in some cases), and capillaries. Capillaries consist of arterial and venous sides that 
form anastomotic connections. Capillaries connect to venules which debouch into larger veins, and ulti-
mately the superior vena cava (which connects to the right atrium of the heart). The pulmonary arteries 
carry deoxygenated blood from the right ventricle into the lungs and branch ultimately into alveolar ca-
pillaries. Oxygenated blood returns to the heart via the pulmonary veins. Anatomical and physiological 
features of the vascular system vary with position along the vascular tree21. The anatomy and physiology 
of the vascular system is reviewed in medical and human physiology text books (e.g., The Review of 
Medical Physiology edited by W.F. Ganong provides detailed chapters). This has important functional 
consequences in angiogenesis. The walls of large arteries contain three layers: the tunica adventitia, rich 
in elastic connective tissue; the tunica media, populated by smooth muscle cells; and the intima, com-
prising a single layer of endothelial cells and underlying basement membrane21. The elastic walls of large 
arteries passively distend in response to hydraulic pressure of inflowing blood21. The cyclic distention of 
arteries dampens pressure variations in downstream smaller arteries and arterioles21. Arterioles contain 
more smooth muscle cells than arteries, which allows them to actively constrict to resist blood flow12,21. 
The majority of the vasculature’s hydraulic resistance arises in the arterioles12,21. This function of arteri-
oles protects downstream capillaries from mechanical damage. The vascular tone of arterioles responds 
to noradrenergic and cholinergic nerve fibers which regulate the distribution of blood flow to different 
organs. Arteries and arterioles are sensitive to nitric oxide (NO) and other vasodilators12,21, 66.  
Pre-capillary sphincters regulate flow into capillaries by contricting and dilating in response to mechani-
cal stresses (e.g. hydrostatic pressure) and metabolic demands of the surrounding tissue21, 139. The tran-
sition from arterioles and metarterioles to capillaries features a two- to tenfold reduction in luminal di-
ameter (from 10-50 µm to 5 µm)21. But blood moves slowly through the capillaries at 0.07 m/s, with 
erythrocytes flowing “single file” down the capillary and having a residence time in the capillaries of 1-2 
seconds21. This results from the tenfold increase in total cross-sectional area between arterioles and ca-
pillaries21. As a result, capillaries will often lack flow and exist in a collapsed state (e.g., in instances 
where the luminal pressure is less than the interstitial pressure, luminal diameter is less than the eryth-
rocyte diameter, or elongation of surrounding tissue such as the alveoli or bladder applies tension on 
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the capillary)21. The capillaries in vascularized tumors contain several structural irregularities and as a 
result, blood flow is irregular and at times oscillatory71.  
The primary goal of the circulatory system, to affect adequate mass transfer between the blood and tis-
sues, is met within the capillaries. Several thousand square meters of vascular endothelium lining capil-
laries function as a semipermeable barrier between the blood and tissue. The microvascular walls con-
sist of a single cell layer of endothelial cells underlined with supporting pericytes and ensheathed by 
basement membrane. Vascular permeability mediates mass transport across the endothelium that lines 
capillaries and varies to suit the local demands and functions of the surrounding organ/tissue. Many 
vascular beds contain a continuous endothelium with 10 nm spaces between the endothelial cell junc-
tions. Small molecules diffuse into the surrounding interstitial space through these junctions. The blood 
brain barrier achieves greater selectivity via its tighter junctions. The endothelial cells in some organs – 
particularly those that produce or remove large macromolecules (e.g., intestinal villi, kidneys, endocrine 
glands, etc.) – have attenuated cytoplasm, creating transendothelial pores, or fenestrae, that range from 
20-100 nm. Liver sinusoidal capillaries are highly fenestrated, containing 600-3000 nm pores21. The ex-
istence of fenestrae is also a feature of malformed vessels grown in pathological angiogenesis (e.g., tu-
mor vasculature). Vasicular transport and diapedesis mediate transendothelial transport of biomacro-
molecules and cells, respectively. Researchers assess the functional qualities of vessels grown in vivo 
angiogenesis assays by injecting fluorescent dyes and nanoparticles into the vasculature (a technique 
not generally amenable to use in vitro).  
Post-capillary venules feature thin pliable walls that contain few smooth muscle cells. Veins and venules 
can distend greatly without pressurizing their lumens. This property protects capillaries from back pres-
sure or fluid accumulation upstream of the venules. Low venous intraluminal pressures create a chal-
lenge to venous blood flow. Overcoming this involves skeletal muscle contractions which propel fluid in 
the veins and venous valves that prevent retrograde flow. Fluid entering the interstitial space from the 
capillaries drains into the lymphatic system and reenters the circulation at the subclavian veins. Blood 
flow is propelled through the circulatory system mainly by the heart, although diastolic recoil, compres-
sion of veins by skeletal muscles, and negative pressure in the lungs during inspiration also propel blood.  
Blood consists of cells (erythrocytes, granulocytes, leukocytes, and platelets) suspended in plasma. 
Erythrocytes carry oxygen through the vasculature on hemoglobin. In the immune response to infection, 
granulocytes utilize the vasculature to reach a site of inflammation. Neutrophils influence vascular biol-
ogy by insinuating themselves through the endothelium, degrading surrounding matrix materials, and 
releasing reactive oxygen species. Monocytes participate in angiogenesis by releasing proangiogenic fac-
tors and differentiating into vasosupportive cells. Leukocytes secrete immune active interleukins which 
activate immune cells as well as endothelial cells. Platelets facilitate clotting of the blood and influence 
inflammation, wound healing, and vasoformative processes (e.g., angiogenesis). Plasma contains protein 
biomacromolecules (e.g., antibodies, growth factors, and clotting factors), small molecules (e.g., amino 
acids, fatty acids, hormones, glucose, oxygen, etc.), ions, metals, and water. The vasculature responds to 
blood composition. Ionizable amine and carboxyl groups on proteins and cells in the blood give rise to 
oncotic pressure differences across the endothelium, and the resulting force influences endothelial cell 
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function. Clotting factors initiate thrombosis upon binding the vascular endothelium. Local oxygen con-
centrations regulate the initiation of angiogenesis.  
The behavior of the vascular endothelium is tailored to its position along the vascular tree. This has 
therapeutic, tissue engineering, and disease consequences. Drug delivery is organ-specific and depend-
ent on local vasculature properties. Fenestrated blood vessels of the liver cause the bulk of oral-
ly/intravenously administered drugs to accumulate in the liver. Vascular fenestrae also prove useful in 
targeting vascularized tumors. When vascularizing a tissue-mimicking biomaterial, researchers and engi-
neers note the influence that mechanical forces have on the phenotype of the endothelium in vivo. This 
has proved critical in regenerating lung tissue, for example. Susceptibility of the endothelium to disease 
(e.g., arteriosclerosis and diabetic retinopathy) is a result of the spatial-temporal properties of the vas-
cular endothelium. For these reasons it is important to study the distinct biology of individual regions of 
the vasculature as well as the general properties of the entire vasculature. During the quiescent state, 
the vascular endothelium is largely engaged in managing the mechanical forces of blood flow and carry-
ing out transendothelial mass transport. But other processes frequently occur in the vasculature (e.g., 
vasodilation and constriction, hemostasis, immune response, and inflammation (reviewed elsewhere) 
and permeability). 
 
B.1.2. Physiological Angiogenesis 
An angiogenic stimulus will cause regions of the vasculature endothelium to undergo the drastic remod-
eling “steps” of vascular sprouting, vessel formation and stabilization or regression to generate new ca-
pillaries. These roughly sequential steps elicit the involvement of diverse cell types, extracellular matrix 
materials (ECM), growth factors and cytokines. The involvement of these angiogenic factors is reviewed 
in detail elsewhere6, 22-26. The signals that drive angiogenesis vary temporally. In fact, several inhibitors of 
the early steps of vessel sprouting promote later steps of vessel maturation. This poses interesting chal-
lenges and opportunities to researchers who investigate ways to interrupt disease processes by target-
ing angiogenesis.  
 
Sprouting 
Angiogenesis in adults begins with endothelial cell proliferation. In the absence of pro-angiogenic stimu-
li, endothelial cells will exist for years in a quiescent (i.e., non-proliferating) state. Endothelial cell quies-
cence in microvasculature is maintained by the autocrine action of endothelium derived VEGF, angio-
poietin-1 (Ang-1), and fibroblasts growth factors (FGFs). Angiogenesis initiates when endothelial cells 
receive pro-angiogenic paracrine signals from an ischemic or growing tissue, or from injured vasculature. 
Potent initiators of angiogenesis, expressed by tissues demanding increased blood flow, include VEGF, 
FGFs and Ang-2.  
Cells can sense ischemia via hypoxia inducible factors (HIFs)27. HIFs are a heterodimeric transcription 
factor composed of alpha and beta subunits. In normoxic conditions, proline residues on the alpha sub-
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unit (e.g., HIF-1α) become hydroxylated by HIF prolyl hydroxylases which use oxygen as a substrate. Hy-
droxylation targets HIF-1α for ubiquitination and degradation. Hypoxia depletes the oxygen substrate 
required for HIF-1α hydroxylation. Other, metabolic consequences of hypoxia also inhibit HIF-1α hy-
droxylation. As a result, HIF-1α accumulates and dimerizes with HIF-1β. The HIF-1 dimer is a transcrip-
tion factor that directs the expression of VEGF, Ang-2 and several other pro-angiogenic molecules. Tu-
mor xenographs in in vivo angiogenesis assays contain hypoxic cells, and use the HIF pathway, in part, to 
generate pro-angiogenic signals. Cancer treatments that target angiogenesis by inhibition of the HIF-1 
pathway have been developed28.  
In several in vitro and in vivo angiogenesis assays (vascular explant assay, in vivo Matrigel invasion assay, 
and the cornea angiogenesis assay) angiogenesis can occur in response to wounding. The wound healing 
response begins with vascular or tissue injury. Expression of a Glucose Analog of Blood Group H Antigen, 
(H-2g also called 2-fucosyl lactose) increases in endothelial cells exposed to damaged tissue. H-2g induc-
es endothelial cell release of bFGF and VEGF29. The resulting, short-term surge in bFGF and VEGF initi-
ates angiogenesis. H-2g also induces endothelial cell expression of intercellular adhesion molecule 1 
(ICAM-1) which attracts leukocytes and other immunologically active cell types30, 31. Several pro-
angiogenic factors are synthesized by immunologically active cells, including tumor necrosis factors 
(TNFs), interleukins, bFGF and VEGF32. In the vascular explant assay, resident adventitial macrophages 
secrete these growth factors as part of the wound healing response, and ablation of macrophages from 
the aortic ring assay, for example, abrogates the angiogenic potential of the explant33. Platelet activation 
during wound healing causes expression and activation of plasminogen activator (PA), a fibrin degrading 
protease. NO also has a pro-angiogenic effect as it elicits VEGF expression34. 
Upon angiogenic activation of a vessel, pericytes (in response to Ang-2) detach, proliferate and migrate 
into the interstitium. Pericytes burrow through the basement membrane by expressing matrix metallo-
proteases (MMPs) which degrade the ECM. Fibroblasts also migrate outward, laying a provisional extra-
cellular matrix (composed of collagen, fibronectin, and heparan sulfate proteoglycans) for the growing 
angiogenic sprout. In addition, fibroblasts secrete pro-angiogenic signaling molecules (e.g., VEGF, tumor 
growth factor (TGF-β), and platelet derived growth factor (PDGF)). Various in vitro co-culturing and vas-
cular explant assays have provided insights about involvement of pericytes and fibroblasts in angiogenic 
sprouting. 
Endothelial proliferation and migration occur in the presence of pro-angiogenic cues (e.g., VEGF, Ang-2 
and bFGF). So that endothelial cells do not migrate en masse toward the angiogenic stimuli, delta-like 4 
(Dll4) -Notch1 signaling pathways select a tip cell to lead the angiogenic sprout35. The Notch signaling 
pathway is active in differential cell fate decisions such as the selection of a tip cell phenotype. Tip cells 
express increased levels of VEGFR2, platelet-derived growth factor B (PDGFB), and the Notch ligand DLL4 
over those of adjacent endothelial cells36. The increased VEGFR2 in tip cells makes them more respon-
sive to the chemotaxis stimulus, VEGF36. DLL4 secreted by the tip cell has an inhibitory effect on adjacent 
stalk cells. Tip cells chemotax toward VEGF, while adjacent stalk cells proliferate and migrate behind the 
tip cell to form the growing sprout.  
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Several of the existing angiogenesis assays incorporate a means for investigating the mechanisms of en-
dothelial cell proliferation and migration. When studying endothelial cell proliferation, researchers note 
that the in vitro angiogenesis assays (discussed in section A.2.) utilize endothelial cells that upon isola-
tion have lost their quiescence and with culturing have been selected for their proliferative ability. 
 
Vessel Formation 
Endothelial cells acquire a lumen once they have migrated outward from their parent vessel. In this pro-
cess, endothelial cells and stalk cells form vacuoles via pinocytosis. These vacuoles coalesce into larger 
contiguous lumens which eventually span the multiple endothelial cells.  
Fibroblasts induce tube formation in the angiogenic sprout. Fibroblasts deposit extracellular matrix mol-
ecules which signal to stalk cells. Interstitial collagen-I and fibrin/fibronectin signal to endothelial cells 
through integrin pathways37. Vascular endothelial cadherin which establishes intercellular junctions be-
tween endothelial cells also mediates tube formation38. Fibroblasts secrete tubulogenesis-stimulating 
molecules when co-cultured with endothelial cells (without direct contact between them)37. Fibroblasts 
secrete VEGF, TNF and PDGF, but these alone did not induce tube formation in collagen in vitro. In co-
culture with endothelial cells, fibroblasts produced several diffusible extracellular matrix precursors and 
it is suspected that these matrix precursors were required for tube formation37, 39. Tube formation oc-
curs in the absence of fibroblasts when human umbilical vascular endothelial cells (HUVECs) are plated 
on Matrigel (a gelled murine tumor basement membrane extract)40.  
Branching in angiogenesis is thought to have mechanistic similarities to tip cell activation and migration. 
Endothelial cells in the stalk of an angiogenic sprout may assume a tip cell phenotype. Geudens and 
Gerhardt describe competition between endothelial cells in an angiogenic sprout for the role of tip 
cell36. It is suspected that branching utilizes this mechanism. Notch signaling suppresses tip cell migra-
tion, which in turn limits branching41, 42. Inhibition of Notch signaling induces hyperbranching41. Much of 
the work elucidating the mechanisms of vessel lumen and branch formation was carried out in in vitro 
tube formation assays and in zebrafish embryos. 
 
Adaption to Tissue Needs and Stabilization 
Once angiogenesis has produced a network of endothelial tubes, the angiogenic outgrowth undertakes 
key steps of vascular regression (which prunes parts of the angiogenic outgrowth) and vessel stabiliza-
tion/maturation (which equips the nascent vessels to function long-term). Nascent angiogenic sprouts 
must decide whether to regress or stabilize. An abrupt loss of pro-angiogenic factors coupled with a lack 
of blood flow prompt endothelial tubes to regress and undergo apoptosis43. Signals that prompt vessel 
stabilization include angiogenic signaling molecules, PDGF and Ang-1, and blood flow.  
Angiopoietin-2, which enhances vessel formation, also actively promotes vessel regression. Effects of 
Ang-2 signaling include detachment of pericytes (which promote vessel stability) and generation of 
MMPs (which inhibit endothelial cell viability by proteolytically degrading extracellular matrix proteins 
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that support endothelial cell adhesion). The effect of Ang-2 on vessel stability depends on the overall 
composition of growth factors. Together, VEGF and Ang-2 promote vessel formation but, in the absence 
of VEGF, Ang-2 causes vessel regression44. Prolonged exposure to other pro-angiogenic growth factors 
(e.g., VEGF and bFGF) inhibits stabilization of endothelial tubes can causes persistent formation of mal-
formed vasculature45, 46. A cleavage fragment of collagen XVIII, endostatin, causes vessel regression by 
disrupting endothelial cell bFGF and VEGF signaling47. Vessel regression is observed in vivo and in angio-
genesis assays that generate endothelial tubes/vascular sprouts in vitro.  
Stabilization/maturation of nascent vessels involves processes that are the opposite of those that carry 
out the early steps of angiogenesis. During vessel stabilization, the endothelium abandons its prolifera-
tive and invasive phenotype in order to recover a non-proliferative state, with tight adhesion between 
cells and to the extracellular matrix, characteristic of quiescent vasculature. Pericytes and other mural 
cells get recruited to the vessel, matrix degradation is inhibited and new matrix materials are deposited 
to generate a basement membrane for the vessel. Attached pericytes and extracellular matrix proteins 
inhibit further migration and proliferation of and provide pro-survival signals to the endothelial cells. 
Eventually, anastomoses between the vascular sprouts allow blood flow in the capillaries. Hemodynamic 
forces engendered in blood flow are suspected to also stabilize the capillaries.  
Four signaling molecules have been identified as playing a significant role in vessel stability48. PDGF se-
creted by endothelial cells causes recruitment and proliferation of pericytes, smooth muscle cells, fibro-
blasts and other mural cells. Sphingosine-1-phosphate-1 is released from endothelial and mural cells and 
also causes mural cell recruitment48, 49. Ang-1, expressed by pericytes and other mural cells, stabilizes 
nascent vessels by promoting the interaction between endothelial cells and pericytes, and stimulating 
monocyte recruitment6, 48. Pericytes recruited to the nascent vessels supply the endothelium with pro-
survival and proliferation inhibiting signals. Pericytes also inhibit leakage of the endothelium. Monocytes 
are recruited to and immobilize where the ends of two vascular sprouts come in contact and promote 
anastomosis50. TGF-β inhibits extracellular matrix degradation and stimulates production of the extracel-
lular matrix molecules that compose the basement membrane (e.g., collagen IV and laminin)48. The ex-
tracellular matrix plays a dynamic role in stabilizing a vascular sprout. The extracellular matrix harbors 
angiogenic signaling molecules that become liberated as regions of the extracellular matrix get degraded 
by MMPs. As a result, the composition of the available angiogenic signals varies spatially and temporally 
about the growing vascular sprout. Tissue inhibitors of metalloproteases become active and slow extra-
cellular matrix degradation by inhibiting MMPs51. This helps stabilize the nascent vessels. As vessels ma-
ture, they become invested in a layer of laminin and collagen IV (i.e. the basement membrane)48. Colla-
gen-endothelial cell binding promotes endothelial cell survival26.  
Blood flow aids vessel stabilization by generating potent pro-survival signals. Shear stress is mechanically 
transduced into the PI3K/Akt pathway in ways that mimic signaling by VEGF and Ang-1. Nitric oxide, 
produced by endothelial cells subjected to shear stress, inhibits endothelial cell apoptosis43. 
Angiogenesis gives rise to vessels that meet the organ-specific needs of their surroundings. The mecha-
nisms involved in tailoring the nascent vasculature to suit its tissue needs are largely uncharacterized, 
though it appears to result from the concerted actions of VEGF and distinct signals from the host52.  
   
12 
 
Hemodynamic force in angiogenesis 
Hemodynamic forces engendered in blood flow (shear stress, pressurization and vessel wall tension) 
have an impact on angiogenesis in vitro and in vivo; for instance, administration of an adrenoreceptor 
agonist, prazosin, causes increased capillary shear stress. Increased shear stress induced by prazosin re-
sults in high capillary content and increased VEGF53, 54. High and low shear stress conditions also gener-
ated capillaries with differing morphologies in skeletal muscle55. Hemodynamic signals in angiogenesis 
have attracted research interests. It is suspected that mechanotransduction of blood flow-generated 
forces plays a more prominent role in physiological angiogenesis than in pathological angiogenesis, 
whereas chemotransduction directs more of the pathological angiogenic processes than the physiologi-
cal angiogenic processes56. Studying hemodynamic effects on angiogenesis may allow researchers to 
piece together the molecular mechanisms that form the basis for adequate feedback control of capillary 
expansion and rarefaction to suit local tissue needs56. The impact of hemodynamic properties on angio-
genesis is poorly understood in part because of the limitations of current in vitro and in vivo angiogene-
sis assays. Still, some mechanisms have been elucidated. Endothelial cells detect hemodynamic forces 
and in response cause increased expression of pro-angiogenic cytokines.  
Endothelial cells detect shear stress via mechanosensory molecules in the extracellular matrix and in 
cell-extracellular and cell-cell adhesion complexes57. For example, in response to shear stress, platelet 
endothelial cell adhesion molecule (PECAM or CD31), VE cadherin and VEGFR2, assemble into a mecha-
no-sensory complex and activates, via Ras and Src signaling cascades, pro-angiogenic genes56. PECAM is 
thought to serve as the primary shear stress transducer. VE cadherin functions here as an adapter that 
brings VEGF receptor 2 into the complex56. Glycocalyx, a dynamic polymeric coating on the luminal side 
of the endothelium, plays a role in regulating vessel permeability, leukocyte extravasation and mechanic 
transduction. Glycocalyx was shown necessary for flow-induced nitric oxide production56. Caveolae, in-
vaginations in the cell membrane of cells, may contain mechanosensory molecules. Caveolin-1, a trans-
membrane protein that causes formation of caveolae, mediates blood flow-dependent vascular remod-
eling and vasodilation57. Flow-induced release of endothelial nitric oxide synthase (eNOS), which 
catalyizes the production of nitric oxide, was observed to initiate with local Ca+2 increases in the vicinity 
of the caveolea58.  
Shear stress promotes expression of potent pro-angiogenic molecules: PDGF, bFGF and TGF-β59-62. Nitric 
oxide is considered a principal mediator of flow-induced changes in the endothelium that give rise to 
angiogenesis. Nitric oxide is produced by three isoforms, in mammals, of the nitric oxide synthase pro-
tein family: eNOS, iNOS and nNOS. The current understanding of how nitric oxide promotes angiogene-
sis is incomplete. Nictric oxide has been linked to increased VEGF and bFGF expression63, 64. Shear-stress-
induced nitric oxide increases the permeability of the endothelium. This causes blood-borne proteins to 
flow into the interstitium, where they would provide a scaffold for migrating endothelial cells. Nitric ox-
ide also suppresses expression of the angiogenic inhibitor, angiostatin65. Nitric oxide may transmit flow-
induced vasostimulatory signals in resistance arteries to downstream vessels. Nitric oxide can bind he-
moglobin in red blood cells and therefor travel to downstream sites of slowed blood flow and/or low 
oxygen tension, where it is released66. The physiological consequence of this phenomenon is controver-
sial67, 68.  
   
13 
 
B.1.3. Angiogenesis in Disease 
The vascular network exists predominantly in a quiescent state. Therein, endothelial cells retain the ca-
pacity to create new vasculature in response to a physiological stimulus: endometrial repair during ovu-
lation, vascularization of the placenta during pregnancy and vascularization of the skeletal muscle after 
exercise. Angiogenesis is controlled by a balance of endogenous pro- and anti-angiogenic signaling mol-
ecules (i.e. an angiogenic switch)69. In disease, the angiogenic switch is frequently disregulated or sub-
verted by the pathology. Cases where the angiogenic switch is “on” include cancer, retinopathies, and 
inflammatory disorders69. These diseases generate powerful inducers of angiogenesis, some of which 
are distinct to the diseases (e.g. HIV-1 Tat protein activates endothelial cells)70. Ischemia elicits an angio-
genic response to several diseases. Tumors expand until they have regions that can no longer access ad-
equate nutrient and oxygen exchange. Retinal diseases damage fragile retinal vessels and, as a result, 
they poorly perfuse regions of the retinal tissue. Vasculature produced as a result of pathological angio-
genesis lacks morphological and functional features of healthy vasculature. Tumor vasculature, for in-
stance, is characterized by leaky, disorganized vessels (many tumor angiogenic sprouts terminate and 
are non perfusable)71. Tumor cells may also line the walls of tumor vessels and differentiate into endo-
thelial-like cells in a process called vascular mimicry70, 71. Flow in tumors is irregular and at times even 
oscillatory71. The high morbidity of diseases that induce angiogenesis has prompted more attention from 
researchers than have diseases that suppress angiogenesis. Research efforts have been successful gen-
erating anti-angiogenic compounds that disrupt these diseases and have been applied in clinic. Cases 
where the angiogenic switch is “off” or insufficient to support local demands for oxygen and nutrients 
include cardiac ischemia, neurodegenerative disorders, and hypertension70.  
 
B.2. Angiogenesis Assays 
Recognizing its involvement in several pathologies, researchers have begun investigating angiogenesis to 
identify potential targets in the treatment of disease. Great strides have been made in elucidating the 
complex mechanisms of angiogenesis, but large gaps in the current knowledge base still exist. Diseases 
employ or disrupt the angiogenic process in ways not yet fully defined. The development of therapies 
that intercept disease actions on angiogenesis requires a more thorough understanding of the angiogen-
ic process. Researchers use an array of in vitro and in vivo assays in their study of angiogenesis72-74. 
There is no “gold standard” angiogenesis assay. Therefore, angiogenesis studies rely heavily on the ap-
propriate selection of multiple assays. In determining how well suited the assay is for a particular study, 
researchers consider the nature of the study and what is being investigated. Investigations of the mo-
lecular mechanisms of angiogenesis require assays that resolve individual components of the angiogenic 
process with high precision and recapitulate the particular mechanism being investigated. In vitro angio-
genesis assays only recapitulate a few steps of the angiogenic process. In contrast, in vivo models facili-
tate the whole angiogenic process but key aspects cannot be controlled or studied. Investigating the 
action of a particular pro- or anti-angiogenic substance requires an assay whose overall angiogenic be-
havior best mimics angiogenesis in humans. In general, in vitro angiogenesis assays offer high precision 
and control of components of the angiogenic process isolated from confounding variables resident in 
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the whole organism. In contrast, in vivo assays trade precision for increased predictability/translatability 
and relevance to angiogenesis in humans. Results of angiogenic studies may vary depending on the as-
says utilized (e.g., observations in vitro that do not occur in vivo, and vice versa). Therefore, researchers 
carefully consider the relevance of the model organism, tissue type, test site, matrix material, and cell 
type to human angiogenesis in the physiological or pathological context being investigated. Typically an 
angiogenesis study pairs in vitro and in vivo angiogenesis assays to harness the power and overcome the 
limitations of both. Still, the current armamentarium of angiogenesis assays presents a gap between the 
capabilities of the assays and the requirements of some angiogenesis investigations. This gap makes it 
difficult to reach conclusions about key aspects of angiogenesis or design therapies that take these as-
pects into account (e.g., mechanotransduction effects on the long-term development of nascent angio-
genic sprouts cannot be fully investigated in either in vitro or in vivo models). The following describes 
and compares common angiogenesis assays.  
 
B.2.1. Types and Applications of Angiogenesis Assays  
In vitro assays, experimentation on cells and tissues isolated from an organism, permit reduction of 
complex biological processes into units that can be tractably studied in detail. They are usually required 
to resolve the individual functional components of the angiogenic process. Data from in vitro assays in-
form the design of in vivo assays that ultimately translate to innovations in the clinic. However, in vitro 
assays create a synthetic environment that bears little similarity to the physiological environment being 
investigated. Angiogenesis in vitro does not always represent in vivo angiogenesis well (e.g., in several in 
vitro angiogenesis assays vascular maturation steps do not occur). Results of in vitro studies frequently 
do not translate and should be interpreted carefully and confirmed in vivo. In an effort to get more 
translatable results, researchers try to controllably reconstruct the complex mesh of features that exist 
physiologically. Still, no in vitro assay incorporates mural cells, extracellular matrix, flow (shear stress, 
pressure, and tension), and humoral interactions. The following describes common in vitro and in vivo 
angiogenesis assays. 
 
In vitro angiogenesis assays 
In vitro assays of angiogenesis typically study the behavior of endothelial cells within a tightly controlled 
environment, in isolation from other cells or in co-culture with another cell type. This allows researchers 
to study particular mechanisms or drug actions in angiogenesis while controlling nearly all other influ-
encing variables. Such studies identify target molecules and pathways. Several angiogenic signals (cell 
types, matrix materials, mechanical cues, structural organization, etc.) are stripped away in in vitro stud-
ies. Therefore, endothelial behavior in these experiments differs considerably from that in vivo. In vitro 
studies of angiogenesis are highly dependent on the endothelial cell source72-74. As described above 
(Section B.1.1.), endothelial cells vary greatly with respect to position along the vascular tree, organ, and 
age of the donor. Functional heterogeneity of the endothelium brings about diverse findings in vitro75. 
Angiogenesis models should utilize endothelial cells that best resemble the context being studied. How-
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ever, the technical difficulty of isolating endothelial cells from some tissues limits the selection of availa-
ble endothelial cells for in vitro study74. Isolation disrupts the quiescent state of endothelial cells and 
induces proliferation72-74. Quiescence can be recovered via serum starvation74. The proliferative state of 
endothelial cells in vitro is short-lived in culture and endothelial cells become senescent after multiple 
passages74. Prolonged culturing of endothelial cells selects for more proliferative subpopulations74, 75. 
Isolation and culturing of endothelial cells also compromise the organotypic phenotype of endothelial 
cells74. These problems have an impact on the characterization of pro- and anti-angiogenic compounds 
and pathways72,73. Still, in vitro assays of endothelial cell behavior contribute greatly in advancing the 
current understanding of angiogenesis. In vitro endothelial cell assays typically assess proliferation, mi-
gration and tube formation as measures of angiogenesis72-74. 
Angiogenic sprouting involves endothelial cell proliferation and outward migration toward an external 
angiogenic activator. Assays that monitor proliferation of endothelial cells (ECs) in culture have the ben-
efit of being rapid, reproducible, precise, and quantifiable. Measures of endothelial cell proliferation 
include increases in the endothelial cell number and progression of an endothelial cell population 
through a single cell cycle. Experimental designs should also account for observed decreases in cell 
number due to apoptosis in order to avoid mistaking the cytotoxic effect of a test substance for inhibi-
tion of proliferation. Cell number can be measured by various automated cell counters, some of which 
distinguish between live and dead cells. MTT assays measure metabolic reduction of MTT [3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide, a yellow tetrazole, to purple formazan in cells as 
a measure of cell number. However, this assumes that cell metabolism primarily depends on and is 
roughly proportional to cell number. Changes in DNA content also provide measures of cell number. 
Thymidine [H3], BrdU (Bromodeoxyuridine) and various dyes incorporate into or stain DNA, making it 
detectable. However, these molecules become incorporated as a result of DNA repair as well15. Cell cy-
cle progression is measured by allowing incorporation of BrdU and staining with propidium iodide. En-
dothelial cells in G1 stain with only propidium iodide while cells that have progressed through the S 
phase of the cell will stain with both propidium iodide and BrdU. However, DNA repair can inflate this 
readout as well. Proliferation assays typically lack a three-dimensional manifold, non-endothelial cell 
populations, an extracellular matrix, and blood flow (mechanical and humoral stimuli). Researchers also 
note the impact endothelial cell isolation and culturing has on proliferative behavior when conducting 
these studies. These deviations from the in vivo context prevent results of proliferation assays from 
translating to in vivo studies. Mechanical stimulation has been achieved by culturing cells on distendable 
diaphragms and in flow cells77.  
Proliferating endothelial cells in an angiogenic sprout migrate or chemotax in response to a local gradi-
ent of angiogenic stimulus. Boyden chambers position endothelial cells on one side of a filter (that con-
tains an extracellular matrix material) and facilitate chemotaxis toward a chemoattractant on the other 
side of the filter. Boyden chambers and variations thereof provide fast, quantitative, three-dimensional 
assays of endothelial cell chemotactic migration in an extracellular matrix. Quantitation of endothelial 
cell migration is accomplished by measuring the number of cells that completely traverse the filter in a 
finite time. A concentration gradient exists in the filter. Automated counters lose accuracy by mistaking 
pores for cells. Recent advancements allay this error by imaging fluorescently labeled cells against an 
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opaque (black) filter. The high sensitivity of endothelial cell chemotaxis to the magnitude of the gradient 
provides the advantage of allowing detailed mechanistic analyses of angiogenesis migration. Drawbacks 
of the Boyden chamber migration assays include the difficult and time-consuming nature of quantitation 
and loss of the gradient over time. The Boyden chamber does not readily incorporate mechanical stimu-
li, but endothelial cell migration from a perfused and/or pressure-controlled channel into a three-
dimensional collagen layer was accomplished using a microfluidic culturing platform. A two-dimensional 
model of endothelial cell migration in wound healing angiogenesis makes use of the scratch assay and 
variations thereof. In a scratch assay experimenters monitor closure of a denuded area – made in a con-
fluent layer of endothelial cells via scratching or other means – as endothelial cells migrate into the den-
udation. Scratch assays are fast and allow continuous monitoring of angiogenesis. However, the extent 
of confluence and scratch size vary, and quantification methods are arbitrary and prone to bias errors. 
Use of stencils overcomes variations in scratch size (e.g., magnetically attachable stencils or MATs create 
a smooth, controlled denudation area)77. Stencils also permit application of an underlying gradient of 
surface bound ligands, as could advanced protein printing techniques153.  
Endothelial differentiation in angiogenesis is modeled by tube formation. Tube formation assays are 
conducted by placing a layer of endothelial cells on or inside an extracellular matrix (fibrin, collagen, or 
Matrigel) and monitoring tube formation over time. Quantitation is accomplished by counting the 
lengths and number of the formed tubes and the number of branch points. Tube formation assays can 
be two-dimensional (plating on top of a thin layer of extracellular matrix) or three-dimensional (placing 
cells within extracellular matrix). These assays are rapid, reliable, and sensitive to composition and me-
chanical properties of the extracellular matrix74.78. However, the tubes that form are homogeneous in 
length (i.e., not representative of in vivo angiogenesis). Quantitation of tube formation assays requires 
technical skill, and three-dimensional assays have the additional technical challenges of processing con-
focal images. Variations in seeded cell distribution and matrix composition cause variability in the re-
sults74. Biochemical gradients and mechanical stimuli have been incorporated into a tube forming assay 
using a microfluidic culturing platform79.  
A major disadvantage of in vitro endothelial cell assays is the exclusion of non-endothelial cell types. As 
described above, non-endothelial cell types play an indispensable role in angiogenesis. Therefore, re-
sults of angiogenesis studies that lack non-endothelial cell types are less likely to translate to in vivo 
studies. Non-endothelial cell types find utilization in in vitro angiogenesis assays in co-culture setups that 
allow direct contact between the different cell types (for juxtacrine signaling) or separation between the 
cell types (for paracrine signaling). Simply mixing or layering different cell types accomplishes direct con-
tact between cell types. Permeable membranes (e.g., filters and hollow fibers) and layers of extracellular 
matrix provide a physical barrier for separating cell types. In proliferation and two-dimensional tube 
formation assays, non-endothelial cell types can be mixed with or layered on endothelial cells. The addi-
tion of fibroblasts, for example, promotes tube formations that contain lumen and better resemble in 
vivo angiogenesis80. Three-dimensional Boyden chamber migration assays incorporate non-endothelial 
cell types on the opposite side of the filter. Co-culturing organ specific non-endothelial cell types with 
endothelial cells in in vitro angiogenesis assays allows researchers to probe mechanism of angiogenesis 
that are distinct to a particular organ. Martin-Green et al. co-cultured, within the three-dimensional 
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tube formation assay, several cell types present in skin149. By doing so, they were able to recapitulate 
characteristics of skin tissue (e.g., production ECM and cytokines unique to skin tissue)149. The tubes 
formed in this assay better resembled microvasculature in the skin; they organized into tubes with sup-
porting mural cells with karatinocytes and skin specific ECM surrounding149. Fluorescent labels are es-
sential for distinguishing between the different cell types in cell co-culture assays. Some problems with 
co-culturing angiogenesis studies arise from the fact that the secretome of non-endothelial cell types is 
not well characterized. Biochemical gradients and mechanical stimuli have been incorporated into the 
aforementioned in vitro assays wherein multiple cell types were cultured. When suspended in collagen 
gels containing channels to permit perfusion, disintegrated microvascular fragments self-assembled into 
a network of interconnected patent vessel tubes81. Using microfabricated scaffolds, Liu et al were able 
to encourage tube formation in the direction of the structural support provided by the scaffolds150.  
Organ explant cultures provide the best in vitro mimic of in vivo angiogenesis73, 74. Described in detail in 
the following section B.2.2., organ explant cultures facilitate spontaneous angiogenic sprouting, vessel 
formation, and to some extent adaptation to local needs from a slice or piece of vasculature or bone 
cultured in an extracellular matrix material. Organ explant cultures feature near-physiological spatial 
arrangements of multiple cell types and extracellular materials, and isolation of the tissues does not al-
ter the proliferative state (e.g., quiescence) of the endothelial cells. Such assays typically lack the gradi-
ent of angiogenic stimuli and the mechanical/humoral influence of local blood flow that occur in vivo. 
Some limitations include the assays’ requirement for growth serum, variability between animals, and 
difficulty of quantification. The sensitivity and applicability of organ explant assays have not been prov-
en74. 
 
In vivo angiogenesis assays 
In vivo angiogenesis assays, i.e., experiments utilizing an entire organism to model angiogenic behavior, 
present a fully intact and functional angiogenic process that acts alongside a complete set of processes 
maintaining the state of the organism. In vivo models of angiogenesis carry out all the steps of angio-
genesis and vessel maturation to produce fully functional vascular networks or vessels characteristic of 
certain disease states. In contrast, in vitro angiogenesis assays do not produce vascular sprouts capable 
of accommodating blood flow or carrying out other functions of the microvasculature. The complete-
ness of the angiogenic process in in vivo angiogenesis assays makes its response to an experimental 
condition strongly predictive of angiogenic behavior in humans. In vivo angiogenesis assays typically in-
vestigate drug effects on angiogenesis and validate observation about the molecular mechanisms of an-
giogenesis from in vitro studies. The reliability or translatability of in vivo angiogenesis assays comes at 
the expense of precision and access to individual functional components of the angiogenic process. Pre-
cise measurement and control of experimental conditions in and around a test site within the model 
organism are often not possible. In vivo angiogenesis assays typically restrict experimentation to sites 
within a few hundred microns of the surface of the organism. More internal sites of angiogenesis lie out-
side the range of commonly utilized imaging technologies, and access therefore requires less precise, 
indirect measures of angiogenesis. Measurement of internal angiogenesis often requires post hoc ex-
planting, sectioning, and staining of the test site (making repeated/time-course imaging impossible). The 
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angiogenic response of an in vivo angiogenesis assay to an experimental condition or test substance is 
subject to influences (noise) from other processes also functioning to maintain the state of the organ-
ism. A common example involves disturbances due to irritation or inflammation caused by the route of 
administration of the test substance. Metabolic depletion, diffusion, and drainage from the test site and 
dilution in the peripheral blood of a test substance make its concentration and spatial distribution diffi-
cult to control and maintain. Genetic engineering of cells and organisms provides a powerful means of 
elucidating the mechanisms of angiogenesis. However, genetic engineering in vivo presents a limitation 
in that it compromises the viability of the organism. Mechanical stimuli (e.g., tensional forces, pressure, 
and shear stress) are difficult to control in isolation from other variables affecting angiogenesis. Prob-
lems with precision and control in in vivo angiogenesis assays make several mechanisms of angiogenesis 
difficult or impossible to investigate in vivo. Researchers have designed assays that harness the 
strengths of in vivo angiogenesis models while overcoming one or more of the aforementioned limita-
tions. As a result, in vivo angiogenesis assays have proven indispensable to furthering the current under-
standing of angiogenesis and the development of angiogenic therapies.  
Because of their simplicity of use and lack of immune response to exogenous cells and tissues, the chick 
chorioallantoic membrane (CAM) assay has become the most utilized in vivo angiogenesis assay74, 82. In 
the chick embryo, a change in vascular density in and around a test site on the CAM results from the 
topical or intravenous addition of test substances to the CAM. This change in vascularization implies an 
effect on the angiogenesis. Test substances include soluble angiogenic growth factors, angiogenic inhibi-
tors, tumor cells, and tissues. Encapsulation or immobilization of the test substance in polymer pellets, 
gelatin sponges, and air-dried filters accomplishes slowed or controlled release of the test substance. 
The chick CAM assay can be conducted in ovo with the test substance added to the CAM through a small 
hole cut into the shell of the chick’s egg, or ex ovo, where the entire embryo and CAM are cultured out-
side of the shell72,74,15,151,152. In ovo experiments require less maintenance, and angiogenesis can be 
tracked through the later stages of embryo development. Ex ovo models permit repeated administration 
of the test substances, repeated time-course imaging, and multiple test sites per embryo. Angiogenesis 
is measured visually by counting vessels or semi-quantitatively by scoring vascular density. Dyes and flu-
orescent micro- and nanoparticles injected into the vasculature better resolve the sprouts and identify 
patent vessels. Biomolecular analysis of angiogenesis or cell-vasculature interaction can be accom-
plished via RNA and protein extraction. The chick CAM is simple, scalable, and allows repeated/time-
course imaging. Pre-existing vasculature on the CAM makes quantitation of angiogenesis difficult. For 
example, small vessels initially overlooked may widen and become visible during the course of the ex-
periment and could be mistaken for neovascularization. The chick embryo lacks an immune system until 
day 7-8 in culture, which allows administration of exogenous cells and tissues73. However, it should be 
considered when interpreting data that developmental angiogenesis occurs until day 11 in culture74. 
Chemical and physical irritation of the CAM elicits an inflammatory response which gives rise to angio-
genic cytokines.  
The zebrafish model of angiogenesis provides a powerful and inexpensive in vivo screening of angiogen-
esis stimulators and inhibitors. One mating can produce over 200 embryos. Zebrafish angiogenesis as-
says are conducted by injecting a biomolecular test substance into the yolk sac of a zebrafish embryo. 
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Conveniently, lipophilic test substances added to the water can freely diffuse into the embryos. Utiliza-
tion of mutagens and antisense morpholinos facilitates genetic engineering of the zebrafish model for 
investigating the molecular mechanism of angiogenesis. The fact that zebrafish embryos develop outside 
the mother and are transparent allows researchers to measure angiogenesis via visual inspection. Patent 
vasculature is visualized via injection of fluorescent dye, quantum dots, or microspheres, followed by 
confocal microscopy and image reconstruction83. Transgenic zebrafish with GFP-labeled endothelial 
markers (Fli-GFP, mTie2-GFP, and Flk-GFP) grow fluorescent vasculature which eases visualization. When 
using fluorescently labeled zebrafish, however, researchers consider that the GFP-labeled markers may 
confer fluorescence to non-endothelial cell types (e.g., Fli-GFP is also expressed in the neural crest)74. A 
Fli-GFP::GATA-dsRED zebrafish exists with green-labeled endothelium and red-labeled erythrocytes, 
which allows differentiation between nonfunctional and patent vessel formation74. The zebrafish angio-
genesis assay is inexpensive, scalable, rapid, and quantifiable via imaging, but there are some draw-
backs. The relevance of angiogenesis in the zebrafish embryo as a model of angiogenesis in human 
adults has been questioned. In the zebrafish assay, neovascularization results from vasculogenesis and 
angiogenesis. Distinguishing between the two is difficult. Regions that participate only in angiogenesis 
are debated, but angiogenesis is accepted to occur in the subintestinal vein.  
Once considered the “gold standard” assay of angiogenesis, the cornea angiogenesis assay features an-
giogenesis from mammalian vasculature, which better represents angiogenesis in humans72,74. Cornea 
angiogenesis assays are conducted by cutting a pocket into the corneal stroma of a mouse, rat, rabbit, 
etc., and implanting into it a test substance (e.g., tumor (or other) tissue or cells, conditioned media, 
growth factors, etc.). To overcome the difficulty of controllably delivering the test substance to the cor-
neal pocket, various slow-release polymer pellets have been employed72,74. Angiogenesis can also occur 
in response to injury to the cornea, delivered via chemical cauterization or mechanical scraping. Quanti-
fication or analysis of the angiogenic response is accomplished visually, by explanting the cornea and 
counting the number of vessels and measuring the length, caliber, or density of the new vessels. The 
corneal angiogenesis assay is reliable and quantifiable. Genetic engineering in mice allows investigation 
of the molecular mechanisms of angiogenesis using the cornea angiogenesis assay. The initially avascu-
lar cornea permits a low background measurement of angiogenesis. However, researchers question the 
relevance of ectopic angiogenesis into the normally avascular cornea74. The cornea is a two-dimensional 
environment for angiogenesis, while human angiogenesis typically occurs in three dimensions. Other 
limitations of the assay include that it is time-consuming, expensive, and technically demanding to run 
(more so in smaller mammals). Angiogenesis in this assay is not amenable to repeated or time-course 
imaging. There also exist ethical qualms regarding the invasive use of a major sensory organ. 
In vivo matrix invasion assays facilitate mammalian angiogenesis in a natural extracellular matrix bio-
material (e.g., Matrigel)84. Such assays are performed by injecting Matrigel (which gels into a plug upon 
injection) or implanting a polymer scaffold subcutaneously in the mouse, rat, or rabbit, then monitoring 
for angiogenic ingrowth. Synthetic sponge matrices, composed of polyvinyl acid, polyethylene, or polyu-
rethane, have been utilized in the matrix invasion assays as a scaffold. The Matrigel plug or scaffold ma-
terial typically contains a test substance (e.g., growth factor, cells, tumor, and tissue explant). Measure-
ments of angiogenesis occur at the end of the assay, when the matrix material plug or scaffold material 
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is explanted, sectioned, and stained for endothelial markers. The hemoglobin content in the matrix ma-
terial or scaffold provides an indirect measure of angiogenesis, but may become inflated by deposition 
of hemoglobin due to hemorrhaging. Starting with a defined matrix material background allows re-
searchers to investigate in vivo the interaction between the extracellular matrix and angiogenesis. 
Measurements of matrix metabolism and deposition are possible in this assay. The amount of fibrovas-
cular tissue in the matrix plug indicates neovascularization via wound healing. Cell proliferation and 
macrophage innervation can also be monitored. Quantitation of neovascularization is helped by the fact 
that the Matrigel and scaffold implants are initially avascular. Initial concentrations of a test substance in 
the Matrigel plug or scaffold implant can be precisely controlled. The mammalian microenvironment in 
which the assay takes place makes it relevant to angiogenesis in humans. However, the injection of Mat-
rigel creates an undefined geometry that contributes to variability in the results of the assay74. To over-
come this limitation, polymer scaffolds and sponges with defined geometries are implanted. This ap-
proach utilizes unnatural polymers, and the rigid shape of the implant elicits an inflammatory response 
which produces angiogenic cytokines. An alternate approach utilizes Matrigel injected into a polymer 
container (with defined shape) then implanted, providing a natural matrix material, although one still 
subject to inflammation85. Other limitations of the assay include the difficult and time-consuming nature 
of quantitation. The measurement of angiogenesis in this assay is destructive and repeated/time-course 
measurements are not possible. The assay is also expensive, and angiogenesis that occurs in the assay is 
strongly sensitive to the shape, material, rigidity, porosity, etc. of the Matrigel plug or scaffold material 
implant. 
The dorsal air sac model of angiogenesis is constructed by lifting the dorsal skin on a mouse, injecting 
air, and implanting a chamber through a transverse section cut on the back86. The chamber is loaded 
with a test substance such as tumor tissue or cells or angiogenic cytokines. The angiogenesis response is 
assessed upon explantation of the chamber by counting the newly formed vessels. In this approach, it is 
difficult to distinguish neovascularization from the pre-existing vasculature. Indirect measures of angio-
genesis are accomplished by injecting dye or 51Cr erythrocytes into the mouse and measuring the vol-
ume of dye or 51Cr that accumulates in the chamber. This assay is simple, amenable to genetic engineer-
ing, and permits facile administration of the test substance. However, the dorsal air sac assay is difficult 
to quantitate and does not permit repeated or time-course measurement of angiogenesis.  
Efforts to overcome these limitations resulted in the use of chamber assays. Chamber assays are pre-
pared by assembling a chamber around a region of thin tissue (e.g., rabbit or mouse ear, and dorsal skin-
fold). The chamber is typically loaded with a test substance (e.g., tumor (or other) tissue or cells, growth 
factors, cytokines, and angiogenic inhibitors). The thinness of the tissue inside the chamber allows re-
peated/time-course measurements of angiogenesis to be performed visually via translumination. Vessel 
density and diameter are measures of angiogenesis utilized in the chamber assay. Injection of fluores-
cent dyes allows nonfunctional and patent vasculature to be distinguished and can be used to measure 
vascular permeability. Transgenic mice expressing GFP-labeled proteins are employed to analyze gene 
expression during the angiogenic process. A significant advantage of the chamber assay is that it allows 
repeated measurements on a mammalian model of angiogenesis. Windows implanted into the cranial 
bone or across the mouse femur window allow visualization of angiogenesis in organotypic sites (the 
   
21 
 
brain and femur). The chamber assay and dorsal air sac assays are reliable and amenable to genetic en-
gineering; however, they are prone to irritation from the surgery and implant. As a result angiogenesis is 
subject to influences (noise) from cytokines released by inflammatory and wound healing responses to 
the surgery. The assay is also expensive, difficult, and invasive.  
In vivo models of pathological angiogenesis include tumor mouse models and premature and diabetic 
retinopathy models, and rheumatoid arthritis mouse models74, 87-89. These models incorporate test sub-
stances or conditions that establish, within the model, aspects and symptoms of the disease being inves-
tigated. For instance, tumors form via excessive cell proliferation that occurs as a result of mutations 
that relinquish proliferative control of the cell. Avascular tumors grow until they encounter a size limita-
tion where oxygen, metabolites, and wastes no longer adequately transfer to and from all the regions of 
the tumor. Some tumor types form avascular dormant lesions where cell proliferation rates match cell 
apoptosis rates90. Tumor growth and progression beyond this size limitation and into subsequent patho-
logical stages rely heavily on angiogenic neovascularization of the tumor. Vascularization permits further 
growth of the tumor and provides the route by which tumor cells metastasize into the rest of the body. 
The dependence of tumors on vascularization and angiogenesis, combined with the fact that an epige-
netically homogeneous vascular endothelium (relative to tumors) is more amenable to growth inhibition 
than are tumor cells, attracts research interests in therapies that target angiogenesis in the treatment of 
cancer (e.g., Bevacizumab). Investigation of tumor angiogenesis generally involves direct/indirect incor-
poration of tumor cells, tumor tissue, or conditioned media to the in vitro and in vivo assays described in 
this section. Mouse tumor angiogenesis assays are conducted by subcutaneously implanting a tumor, 
injecting tumor cells orthotopically, or utilizing transgenic mice that overexpress a particular oncogene. 
Quantitation of angiogenesis occurs after explanting the tumor. The tumor is sectioned and stained for 
endothelial markers, then scored for extents of angiogenesis, tumor size, etc. Subcutaneous implanta-
tion, though easy, does not create the tumor microenvironment representative of tumorigenesis in hu-
mans. Orthotopic injection of tumor cells overcomes this limitation but is harder to perform. Transgenic 
oncogene overexpressing mice typically form and vascularize tumors at about the same age. This allows 
analysis of the angiogenic response to test substances. Quantitation of this assay is time-consuming and 
difficult, and hence prohibitive for repeated measurements. The use of fluorescently labeled tumor cells 
in the nude mouse (i.e., AngioMouse®) allows repeated non-invasive measurements of tumor size and 
observation of metastases96. Quantitation of angiogenesis is accomplished by imaging. Under stereo mi-
croscopy, non-fluorescent vessels appear as dark networks against a green background73. Use of GFP 
fluorescently labeled mice (e.g., Flk-eGFP) with RFP-labeled tumors allows further analysis of tumor-host 
interactions. Monitoring tumor angiogenesis via fluorescence suffers the limitation that light absorption 
and scattering by the tissue and skin reduce the image resolution. Tumor cell expression of GFP de-
creases in hypoxia, thereby influencing quantitation74.  
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Table B.1. Angiogenesis Assays 
Assay Description Uses References 
In Vitro Cell Prolif-
eration Assay 
Measure EC proliferation at baseline or in 
the presence of angiogenic factors. 
Investigate effect of test substance on 
angiogenic initiation (specifically EC pro-
liferation). 
Investigate the molecular mechanisms of 
EC proliferation. 
74,  
In Vitro Migration 
Assay 
Scratch assay; ECs migrate across a 2D de-
nuded area. 
Boyden chamber assay with ECs migrating 
across a filter/matrix within a gradient of 
angiogenic factor. 
Investigate molecular mechanisms of EC 
chemotaxis, wound healing.  
74, 92, 
In Vitro Tube For-
mation Assay 
ECs plated on 2D or in 3D matrices and 
quantification of a representative measure 
of tubule formation.  
Investigate effect of test substance on EC 
differentiation as marked by tube for-
mation.  
Investigate in vitro angiogenic potential.  
40,  
Organ Explant 
Assays 
Segments of vessels cultured in 3D matri-
ces are monitored for angiogenic out-
growth. 
Investigate effect of test substance on 
angiogenesis. 
Investigate the molecular mechanisms of 
angiogenic sprouting, vessel formation, 
and regression. 
73-74, 93, 94 
Chorioallantoic 
Membrane Assay 
(CAM) 
Test substances (e.g., xenograft material, 
cell, or tissue) are applied on or within the 
CAM, in order to continuously monitor 
local angiogenesis. 
Investigate the effect of test substances 
on angiogenesis.  
Investigate the interaction between CAM 
vasculature and the test substance. 
72-74, 82 
In vivo Matrix 
Invasion Assay 
Test substances (e.g., xenograft material, 
tissue, cell, cytokine, or small molecule) are 
loaded into Matrigel or matrix containing 
polymer scaffold. The Matrigel or polymer 
scaffold is loaded subcutaneously. Explant-
ed Matrigel plugs or polymer scaffolds are 
evaluated for invasion of angiogenic 
sprouts post-hoc. 
Investigate the effect of test substances 
on angiogenesis. 
Investigate the molecular mechanisms of 
angiogenic sprouting, vessel formation, 
regression, and stabilization. 
72-74, 84 
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Table B.1. Angiogenesis Assays (Continued) 
Assay Description Uses Cited 
Retinopathy of 
Prematurity Model 
Retinopathy is induced in neonatal mammals 
by exposure to hyperoxia followed by normox-
ia. Explanted retina are evaluated for angio-
genesis post hoc.  
Investigate the effect of test substanc-
es on angiogenesis in retinopathy. 
Investigate the molecular mechanisms 
of angiogenic sprouting, vessel for-
mation, regression, and stabilization in 
retinopathy. 
87 
Fluorescent 
Zebrafish Assay 
Live transgenic fluorescent embryo is exposed 
to small molecule angiogenic inhibitors and 
extent of angiogenesis is measured via fluores-
cence confocal imaging.  
Investigate the effect of test substanc-
es on angiogenesis. 
Investigate the molecular mechanisms 
of angiogenic sprouting, vessel for-
mation, regression, and stabilization. 
83, 95, 
Dorsal Air Sac 
Model and Cham-
ber Assay 
A chamber is implanted across dorsal skin of 
the mouse, or (in some chamber assays) across 
thin layers of tissue (e.g., the ear or mouse 
femur). Test substances are introduced in the 
chamber. Local angiogenesis is measured post 
hoc (dorsal air sac model) and throughout the 
experiment (chamber assay). 
Investigate the effect of test substanc-
es on angiogenesis. 
Investigate the molecular mechanisms 
of angiogenic sprouting, vessel for-
mation, regression, and stabilization. 
74, 86 
Tumor Mouse 
Model 
 
Fluorescent tumor cells are implanted subcu-
taneously in nude mice. Other test substances 
are administered as well.  
Vascularization and growth of the tumor is 
monitored throughout the experiment, as well 
as occurrence of metastases. 
Investigate the molecular mechanisms 
of tumor angiogenic sprouting, vessel 
formation, regression, and stabiliza-
tion.  
Investigate tumor-host interaction. 
74, 91, 96 
 
    
 
 
B.2.2. Aortic Ring Assay and Other Organ Explant Angiogenesis Assays 
In 1982, Roberto Nicosia’s lab published its first observation of spontaneous angiogenic outgrowth from 
a rat aorta in vitro97. From this observation, the aortic ring assay and other organ explant assays arose 
and have since developed into the most complete in vitro mimic of in vivo angiogenesis72-74. Table B.2. 
lists organ explants that are utilized as a platform for studying angiogenesis. In a vascular explant assay, 
the explanted vessel is carefully cleaned of surrounding fibroadipose tissue, cut into 1 mm slices, and 
imbedded in collagen, fibrin, or Matrigel93, 94, . With culturing in media (some vascular explants do not 
require media with serum) vascular outgrowths spontaneously occur from the vascular explant93. Other 
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organ explant cultures are performed similarly. Organ explant assays provide a convenient, cost-
effective, reliable way to investigate the mechanisms of angiogenesis and the effects of test substances 
(e.g., potential therapeutic agents) on angiogenesis72-74. Qualities that define these assays as in vitro 
mimics of in vivo angiogenesis include the near-physiological spatial organization of endothelial and 
non-endothelial cell types, paracrine and juxtacrine signals, and endogenous matrix materials72-74, 93. Or-
gan explant assays permit the study of more of the “steps” of angiogenesis than any other in vitro as-
say73, 93. Endothelial cells in vascular explants retain their endogenous quiescent phenotype after ex-
planting, a feature that allows investigation of aniogenesis initiation72-74,. Vascular sprouts originating 
from an organ explant contain lumen, supporting pericytes, and basement membrane. Considered es-
sentially the same as capillary sprouts arising from angiogenesis in vivo, these vessels feature nearly all 
the functional similarities to those in vivo except vascular maturation brought on by blood flow93.  
Angiogenic outgrowth from a vascular explant is typically ana-
lyzed via visual inspection93. The number of sprouts resulting 
from a vascular explant provides a measure of the extent of angi-
ogenesis93. Vascular sprouts can be counted manually or using 
image processing software. The count includes vessels appearing 
at different depths in the sample via focusing93. The number of 
branch points in the outgrowth also provides a useful measure of 
the extent of angiogenesis74. A more rapid quantitation of the 
extent of angiogenesis comes from measuring, via image pro-
cessing software, the area covered by the angiogenic out-
growth74. Quantitation of the organ explant assay is non-
standard, difficult, and subject to bias, and is a limitation of the 
assay. Vessel maturity is assessed by the number of pericytes lining the vessel and by the vessel caliber74, 
93. Whole mount immunostaining of the angiogenic sprouts is possible in vascular explants cultured in a 
0.5 mm layer of collagen98. RNA and protein isolation from angiogenic sprouts allows biomolecular anal-
ysis of nascent sprouts, but multiple samples are often required to yield an analyzable amount of RNA or 
protein.  
Organ explant assays offer several advantages in angiogenesis research because they readily combine 
the capabilities of common in vitro and in vivo angiogenesis assays93. The native endothelial phenotype 
retained in organ explant assays allows researchers to study in vitro the early steps of angiogenesis initi-
ation72-74, 93. The presence of non-endothelial cell types supplies the complex signaling events necessary 
to carry out the steps of angiogenesis72-74, 93. The near-physiological spatial organization of endothelial 
and subjacent non-endothelial cell types and extracellular matrices provides a strong representation of 
in vivo angiogenesis72-74, 93. Organ explant assays lack confounding variables that influence in vivo stud-
ies, such as inflammation, hemostasis, and uncontrolled blood flow93.  
Limitations of organ explant assays in angiogenesis research include the use of vascular explants that 
poorly represent the microvasculature (where angiogenesis occurs), the difficulty of quantitation, and 
variability in the results. Described in section A.1.1., notable differences in the morphology and function 
of endothelial cells exist between the microvasculature, which participates in angiogenesis in vivo, and 
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larger arteries, which do not. In consideration of this, researchers have cultured the mouse and rat vena 
cava, placental vein, chick embryonic aortic arch, and mouse embryonic metatarsals73. Veins bear more 
similarities to the microvasculature than do arteries. Embryonic vessels are more similar to the micro-
vasculature than veins in postnates. However, these tissues are harder to isolate, and differences be-
tween them and the microvasculature still exist. Mouse embryonic metatarsals contain plugs of highly 
vascularized marrow tissue. Angiogenic outgrowths from the fetal metatarsals sprout from the micro-
vasculature. However, embryonic endothelial cells are actively proliferating while adult microvascular 
endothelial cells are not. Human vessels are difficult to acquire. As a result, organ explant assays cannot 
fully represent angiogenesis in vivo in humans. As discussed above, quantitation of angiogenesis in the 
organ explant assays is difficult and prone to error. Variability in angiogenesis in the organ explant cul-
tures arises from variability in the matrix and serum utilized in the assay and the difference between 
animals utilized in the study. While the rat aortic ring will spontaneously produce angiogenic sprouts, 
the mouse aortic ring and several other vascular explants require serum, whose protein content is not 
completely defined74, 93. Exposure of the organ explant to subphysiological temperature and alkalinity 
arising from low carbon dioxide pressures during preparation of the organ explant assay impedes angio-
genesis and may give rise to variations in the results of the assay94. Variations between organ explants 
from the same animal are small compared to variations between animals. In mice, for example, age and 
genetic background strongly influence the results of the organ explant assay99. Provided the variations in 
endothelial phenotype along the vascular tree, discrepancies in the results between studies may arise 
from differences in the vessel type utilized100.  
While other animals are utilized, the mouse model provides advantages which have popularized its use 
in organ explant assays. The mouse genome has been sequenced, and its human homologues have been 
identified99. A repository of transgenic and knockout mice is readily available. Genetic background influ-
ences the amount of angiogenic outgrowth in the assay, with C57 mouse aortic rings producing more 
angiogenic sprouts in culture than aortas from other mouse strains99. The smaller size of aortic rings re-
trieved from mice necessitates the use of serum in aortic ring assays101.  
Organ explant cultures are tenable to adjustments that permit detailed investigation of the mechanisms 
of angiogenesis and overcome some limitations of common organ assays. Organ explants produce angi-
ogenic sprouts in response, in part, to wound healing mechanisms induced during explanting. When in-
vestigating some mechanisms of ischemia-induced angiogenesis in the organ explant assay, researchers 
may halt the wound healing response by inducing an “angiogenically quiescent state” wherein the aorta 
no longer spontaneously produces angiogenic sprouts. Suspending the rat aorta in media without serum 
for 14 days induces an angiogenically quiescent state capable of identifying initiators and enhancers of 
angiogenesis from the set of ischemia- (or other process)-induced angiogenic cytokines33. Angiogenic 
initiators (e.g., VEGF) induce angiogenesis in angiogenically quiescent aortic rings, but angiogenic en-
hancers (e.g., Ang-2) alone do not induce sprouting in this model. Genetic manipulation of vascular ex-
plants can be accomplished via gene transduction via virus prior to embedding in matrix104. Electro-
poration of DNA plasmids through the matrix containing the vascular explant accomplishes genetic ma-
nipulation of vascular explants in culture102. The cellular composition of vascular explants can be tracta-
bly controlled. For example, the use of liposomal clondronate, which is selectively cytotoxic to mi-
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crophages, ablates them from vascular explants assays101. The vascular explant assay has also accom-
modated direct and indirect addition of organ-specific non-endothelial cell types (e.g., microglial) using 
techniques employed in in vitro co-culture assays103. Co-culturing the rat aortic and vena cava rings pro-
duced more mature vascular sprouts than either of the vascular explants alone and with arterial/venous 
anastomoses100. Significant limitations of conventional vascular explant assay are the lack of a main-
tained external gradient and the lack of mechanical stimuli (e.g., intraluminal blood flow). Occurring in 
vivo, these phenomena have an impact on angiogenesis, and researchers recognize the importance of 
studying their effect on angiogenesis in vitro. Researchers have used microfluidic devices to enhance the 
vascular explant assay by imposing a defined exogenous concentration gradient around the vascular ex-
plant105. Perfusion of vascular explants has been accomplished in the short term as a way to analyze the 
extent of functional angiogenesis in vivo and to investigate vascular tone of resistance arteries. Short-
term perfusion of an intact mouse resistance artery was accomplished by fixing the artery within a mi-
crofluidic device and perfusing the lumen and abluminal space with media106. Long-term culture of per-
fused rabbit and porcine thoracic aorta was carried out in efforts to study arteriogenesis18, 19. These 
techniques, however, maintain the artery in a fluidic bath (in the abluminal space) that does not permit 
angiogenesis. The perfused organ cultures utilized in arteriogenesis studies are carried out in reactors 
that position the aorta beyond the working distance of optical microscopes. These reactors rely on ves-
sels dissected from larger animals that are not amenable to genetic manipulation. To my knowledge, 
long-term perfusion of a vascular explant (i.e., allowing angiogenic outgrowth) has not been accom-
plished. 
 
B.2.3. Mechanical Stimulation in Angiogenesis Assays 
Angiogenesis is a mechanical process. As cells carry out the steps of angiogenesis (proliferation, migra-
tion, etc.), they interact mechanically with their surroundings. The growing cells exert forces on the 
ECM, which presents opposing forces that resist the generated forces of and provide traction to motile 
cells. Adjacent and nearby cells answer these mechanical perturbations by generating their own forces. 
Meanwhile, the chemical processes that drive much of angiogenesis act and cooperate with the me-
chanical processes. Information conveyed via mechanical force gets transduced and relayed throughout 
the tissue via mechanochemical signaling pathways. This information ultimately directs angiogenic be-
havior. Angiogenesis responds to mechanical cues, thus aberrant mechanical stimulation of endothelial 
cells is a hallmark of many diseases, including those that influence angiogenesis (e.g., hypertension). 
Unfortunately, there exists a dearth of information about the influence of mechanical forces and signals 
on angiogenesis. Few in vitro assays currently permit detailed study of the effect of mechanical stimula-
tion on the later steps of angiogenesis. In vivo angiogenesis assays offer only limited control over the 
mechanical forces acting on the endothelium. Researchers are working to expand the selection of assays 
that allow investigation of mechanical signaling in angiogenesis. The following describes ways in which 
researchers have incorporated controlled mechanical stimulation in angiogenesis assays.  
The cells and supporting extracellular matrix materials that compose a tissue exhibit a range of mechan-
ical properties. Tissues passively (i.e., without expending metabolic energy) respond to an applied force 
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or physical deformation according to their viscoelastic properties. Viscoelasticity is the property of tis-
sues that causes them to initially deform or strain under an applied force and then gradually strain or 
creep further as long as the force is applied. The deformed tissue also relaxes so that the amount of 
force needed to maintain the deformed state gradually diminishes. The Maxwell, Kelvin-Voigt, and 
standard linear models of viscoelastic deformation approximate the passive mechanical behavior of bio-
logical materials107. Extracellular materials can only produce a passive response to mechanical forces, 
but cells can respond passively or actively (i.e., utilizing metabolic energy in their response). Cells in-
volved in angiogenesis sense local deformations and stresses in their surroundings. In response, they 
may apply tension and compression on subjacent cells, the entire vessel and/or their surroundings. Such 
actions are responsible for vasoconstriction and dilation of arterial vessels and endothelial, mural, and 
smooth muscle cell migration in angiogenesis. The mechanical forces that act in angiogenesis include 
compression and tension, shearing and bending of pliable tissues, and flow-induced hydrostatic pressure 
and shear stress108, 109.  
The introduction of a mechanical stimulus or the measurement of mechanical changes in an angiogene-
sis assay entails three heavily interdependent actions: the application of exogenous force or defor-
mation, the passive response of pliable extracellular matrix materials, and the cell-mediated endoge-
nous force generation in reaction to the study conditions. Studies of mechanotransduction in angiogen-
esis seek to isolate and precisely control and/or measure one of these three actions. As with conven-
tional angiogenesis assays, assays that incorporate mechanical stimulation trade precision and control 
for maintenance of a relevant biological context. The long-established and highly quantitative laws of 
continuum mechanics make mechanical process more amenable to precise measurement and control 
than many biomolecular processes. For example, devices exist that measure the forces acting on and 
generated by biological materials with pico-Newton sensitivity110. Attaining such high precision and sen-
sitivity requires in vitro assays that remove several features of the cells’ endogenous environment, and 
they are therefore poorly representative of in vivo biology. In contrast, in vivo assays are more relevant 
to biological processes in humans, but in vivo mechanical stimulation and measurement methods are 
rare and seldom quantitative.  
In vitro mechanotransduction assays apply a mechanical stimulus to or measure mechanical properties 
of a single cell or a two-dimensional cell monolayer. Micro- and nano-scale BioMEMS (biological micro-
electrical/mechanical system) devices make possible the isolation and study of the mechanics of single 
cells with pico-Newton precision. Addae-Mensah and Wikswo review measurement techniques using 
BioMEMS, while Desmaele and coworkers review actuation techniques using BioMEMS110, 111. The small 
volumes utilized by BioMEMS devices allay solute dilution, thereby allowing detection of rare mechano-
chemical conversion. One drawback of BioMEMS is that it can be time-consuming to load BioMEMS de-
vices. Mechanical stimuli delivered to two-dimensional cell cultures include compression or hydrostatic 
loading, distension, and fluid shear stress76. Hydrostatic loading of cells in two-dimensional culture is 
accomplished by culturing the cells under a controlled pressure. A two-dimensional cell monolayer with 
overlying cell culture media can be incubated in a container pressurized with air and 5% CO2. This simple 
procedure provides quantitative homogeneous, temporally controlled application of pressure to the 
cells. However pressurization of the incubator air increases the partial pressures of oxygen and carbon 
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dioxide beyond their physiological concentrations. Also, purely hydrostatic loading (i.e., in the absence 
of shear or tensional stresses) does not well represent the physiology being modeled. Culturing cells on 
a flexible polymer substrate or diaphragm and applying tension to the substrate or diaphragm accom-
plish controlled distension of a cell monolayer. Pressure differences across the diaphragm or platen 
abutments are commonly utilized means of distending the cell monolayer. Platen abutment techniques 
have been miniaturized for use in BioMEMs110. Various directionalities of distension are accessible; the-
se include in-plane longitudinal, biaxial, radial tension and out-of-plane longitudinal bending, and radial 
curvilinear and irregular shaped distension76. This simple and controllable procedure provides a quanti-
tative mechanical stimulus that is relevant to physiological situations. The technology suffers limitations, 
however, of anisotropy and spatial heterogeneity of distension. This is more so along the edge of the 
culture, where the flexible polymer connects to rigid walls of the culturing dish. Movement of the dia-
phragm also causes movement of the overlying cell culture media, thereby introducing uncontrolled 
shear and normal stresses to the assay112. Application of a fluid shear stress to cells in a monolayer 
commonly utilizes one of two techniques. A cell monolayer is positioned beneath a cone whose central 
axis is perpendicular to the plane of the cell culture. The cone rotates around its central axis, providing 
roughly spatially uniform (because of its conical shape) shear stress to the underlying cell culture. This 
technique, though simple and spatially homogeneous, is cumbersome when imaging the cells. Alterna-
tively, laminar flow is maintained in a parallel plate flow chamber. Pumps or gravity drive fluid flow. Cells 
cultured on the floor of the chamber experience controlled shear stress. Flow chambers have been min-
iaturized for use in BioMEMS110, 111. Cell monolayers established on the inside walls of cylindrical tubes 
(e.g., glass capillary tubes) have provided a more physiological geometry for studying fluid shear 
stress113. Flow chambers offer simple, quantitative delivery of controlled shear stress. Transient shear 
stresses and media sampling and exchange are also possible in flow chambers. Parallel plate flow cham-
bers are also easy to image. However, the edges of the parallel plate flow chamber make shear stress 
spatially nonuniform. Considering that mechanical stimuli rarely act in isolation, researchers have de-
signed ways to controllably deliver, simultaneously, multiple mechanical stimuli76. For example, laminar 
flow over cells cultured in a flexible cylindrical tube provides controlled application of distension and 
shear stress. A pressure gradient down the axis of the cylindrical flow chamber drives flow, while a pres-
sure difference across the flexible wall of the flow chamber actuates distention. Both mechanical stimuli 
can be controlled separately from each other.  
Two-dimensional biological assays lack several aspects of the environments they model. Concomitantly, 
two-dimensional angiogenesis assays do not recapitulate many steps of the angiogenic process. Three-
dimensional angiogenic cell and tissue cultures better represent angiogenesis in humans and model 
more of the angiogenic process. Researchers and engineers have designed strategies for incorporating 
mechanical stimuli into three-dimensional cell cultures. Cells in a three-dimensional matrix material 
generate forces that mechanically deform their surroundings117. Deformations, measured by clamping a 
matrix between a fixed boundary and a force gauge, provide a semi-quantitative assessment of force 
generation by a collection of cells114, 115. More precise measurement of forces generated by cells in a ma-
trix material requires detailed imaging of matrix strain along three axes and computational modeling 
local force generation using the finite element method116. Measurements of cell mechanics in three-
dimensional culture are semi-quantitative or they are time-consuming and complicated. Variability re-
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sulting from non-uniform cell seeding and heterogeneous matrix properties also affects the quality of 
the measurement117. Current techniques do not permit measurement of force generation by individual 
cells in three-dimensional culture.  
Static and dynamic compression of tissues, cells, and extracellular matrix material is accomplished via 
platen abutment 76. Such compression can be unconfined (i.e., space is provided for the material to 
spread out under the platen) or confined (i.e., walls prevent spreading and the deformation decreases 
the specimen’s volume). Compression of three-dimensional cultures better mimics instances of com-
pression in vivo. However, anisotropy and heterogeneity of the surrounding matrix make the delivery of 
compressive stress to cells less precise and controllable. Commercially available devices (e.g., the Flex-
cell®Tissue train® culture system) apply tension or distension to three-dimensional cultures by placing 
them inside a flexible mold or on a flexible diaphragm. The mold or diaphragm is equipped with mesh-
like anchors along the periphery which maintain attachment to the tissue. Bioreactors have been engi-
neered to apply tension or distension to tissues and extracellular matrices while permitting imaging. 
These bioreactors apply tension or strain by clamping thin sheet-like constructs or fibers of extracellular 
matrix material (e.g., collagen) between two moveable connectors118. Attachment or clamping of the 
matrix is non-uniform and subject to variability, and the strength of the attachment can decrease with 
time.  
The interstitial matrix materials surrounding microvasculature accommodate Darcy’s Law flow. In vitro 
perfusion of the matrix materials mimics Darcy’s Law or Starling flow in the interstitium. Controlled per-
fusion of matrix materials is accomplished by placing the matrix against a supporting micropore filter 
and maintaining a pressure difference across the filter119. The filter permits flow of cell culture media 
through the matrix while resisting deformation and displacement of the matrix. Tein and colleagues ap-
plied fluid shear stress to endothelial cells in collagen. A perfusable tube was cast into collagen and 
seeded along its walls with endothelial cells. This setup mimics the microvascular geometry while 
providing a biologically relevant extracellular substrate. However, fluid shear stress is difficult to isolate 
from other mechanical stimuli. The soft material substratum can deform under the pressure driving per-
fusion, which causes distension of the cell layer and introduces spatial heterogeneities of flow. Darcy’s 
Law flow of perfusate through underlying collagen substratum accompanies perfusion of a tube cast into 
extracellular matrix material120. This extraluminal flow mimics a property of interstitial tissue surround-
ing the microvasculature but also introduces variability. Spatial-temporal control of the mechanical 
stimuli is complicated by changes undergone by the matrix as a result of angiogenesis.  
Angiogenesis studies often consider the interaction of multiple cell types. Fluid shear stress can be add-
ed to a study of the interaction between multiple cell and extracellular matrix types. For example, Hoy-
ing and colleagues cast hollow tubes into collagen doped with disintegrated microvasculature81. Upon 
culturing and perfusion of the collagen tube, a network of patent vascular tube was assembled. This set-
up allows the most biologically relevant application of fluid shear stress in vitro currently available. En-
dothelial cells are immediately juxtaposed to physiologically relevant cell and matrix materials. Howev-
er, the device does not accommodate imaging, and the initiation of angiogenesis in the device occurs in 
separation from flow. Three-dimensional mechanotransduction-angiogenesis assays recapitulate more 
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steps of angiogenesis under more biologically representative applied mechanical stimuli, but at the cost 
of precise control of the mechanical stimuli. Three-dimensional assays contain a deformable, perfusable, 
anisotropic and heterogeneous extracellular matrix material which introduces several sources of varia-
bility. Deformation of the extracellular matrix shields the cells from the applied mechanical stimuli. Pres-
sure differences that drive perfusion also deform the matrix material, and matrix deformation has an 
impact on matrix perfusion. Perfusion and deformation, whether intended or not, vary with the aniso-
tropic and heterogeneous nature of the matrix. As a result, some three-dimensional mechanotransduc-
tion assays yield only semi-quantitative information. Despite these limitations, three-dimensional assays 
have a place in biological research because two-dimensional assays cannot mimic the biology well 
enough to provide relevant information about some processes, and in vivo assays do not sufficiently 
permit precise control of the stimuli to investigate the details of some processes. For this reason three-
dimensional mechanotranduction assays are necessary for elucidating the interaction between mechan-
ical stimulation and angiogenesis. 
 
B.3. Summary and Aims 
Angiogenesis is a complex process that is essential to both health and disease. Through angiogenesis, 
blood vessels sprout from preexisting ones and subsequently stabilize to supply local oxygen and nutri-
ent demands. Angiogenesis initiates in response to biochemical/mechanical stimuli that signal the pres-
ence of ischemia, development, wound healing, endometrial repair, and disease. The environments that 
host angiogenesis vary throughout the body and life of the organism. As a result (in part), angiogenic 
mechanisms and features vary spatially and temporally, displaying distinct characteristics at different 
sites along the vascular tree and within different organs, at different ages, and in different physiologi-
cal/pathological states. Endothelial cells conduct angiogenesis with the aid of supporting cells (e.g., fi-
broblasts, pericytes, monocytes, and smooth muscle cells), extracellular matrices, and angiogenic signal-
ing molecules (VEGF, Ang-1 and -2, FGFs, etc.). These factors participate in a complex network of inter-
actions to drive angiogenesis. However, aberrant functions of just a few of these components can derail 
the entire process, giving rise to any of several diseases. The involvement of angiogenesis in diseases 
such as cancer, ischemia, hypertension, and inflammatory disorders demonstrates the value of under-
standing angiogenesis. Great strides have been made in elucidating the details of angiogenesis, but un-
fortunately the process remains under-defined, and the full potential of therapies that intelligently tar-
get angiogenesis has yet to be harnessed. The complexity of angiogenesis is a primary reason for our 
current limited knowledge. Further, several parts of this process cannot be directly accessed (i.e., meas-
ured, quantitated, or actuated). Human tissues are inaccessible in most studies for obvious ethical rea-
sons, so human angiogenesis is modeled in animals or by cell and tissue explants. Test sites within ani-
mals have limited relevance to the angiogenic context they model. Cell and tissue isolates can come 
from a wider range of sites, but the endogenous phenotype of cells distorts upon isolation and distorts 
further with continued culturing. Current technologies permit measurement and actuation of angiogenic 
factors with finite precision and control, and typically precision and control in angiogenesis assays come 
at the expense of relevance to the biological context being studied. In vitro angiogenesis assays offer 
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detailed study of angiogenic cells and tissue components, albeit in synthetic environments that lack sev-
eral of the features experienced in vivo. In contrast, in vivo angiogenesis models present a complete an-
giogenic process capable of producing functional vasculature but suffer from limitations of imaging and 
difficulty measuring angiogenic factors. In vivo assays also pose a challenge to controlling factors that 
drive angiogenesis (e.g., maintenance of gradients of growth factors). The limitations of in vitro and in 
vivo angiogenesis assays are exacerbated in assays that seek to control or study mechanical forces in 
angiogenesis. Measurement and actuation of mechanical influences on angiogenesis are generally re-
stricted to single cells and two-dimensional cell monolayers, which lack several pertinent features of in 
vivo angiogenesis. Mechanotransduction, though most easily investigated in two-dimensional cell mono-
layers, can also be studied in detail in three-dimensional angiogenesis. These assays, however, often 
prohibit certain modes of mechanical actuation and still lack the physiological relevance of in vivo angio-
genesis assays. In vivo angiogenesis assays provide little to no control over the mechanical stimuli that 
affect angiogenesis. Studies of mechanical force in angiogenesis provide a notable example of the gen-
eral limitations of in vitro and in vivo angiogenesis assays.  
As an intermediate method between more physiologically relevant in vivo angiogenesis assays and more 
precise in vitro angiogenesis assays, the organ explant angiogenesis assay has gained wide use. Organ 
explant assays initiate angiogenic sprouting, outward growth and (to an extent) stabilization of new 
blood vessels from explanted segments of vasculature, bone, or embryonic tissue. Often termed an “ex 
vivo” model, organ explant assays are considered the most complete in vitro model of in vivo angiogene-
sis. These assays undergo nearly all the steps of angiogenesis. The in vitro setup has the advantage of 
facilitating repeated imaging and quantitation of angiogenesis, precise measurement of angiogenic fac-
tors, and control of angiogenic stimulators. The ex vivo character of the organ explant assay recapitu-
lates the spatial organization of heterogeneous cell types and extracellular matrices, the multitude of 
paracrine and juxtacrine signaling events, and the endogenously generated spatial-temporal gradients of 
angiogenically active biomolecules of in vivo angiogenesis. Therefore, researchers utilize the organ ex-
plant assays to reliably investigate angiogenic mechanisms (including vessel stabilization and regression 
steps not accessed in the other angiogenesis assay) and the test substances that influence angiogenesis. 
Insights gained from the study of angiogenesis using organ explant assays have informed the develop-
ment of therapies that impact angiogenesis. Still, the organ explant assay suffers limitations common to 
in vitro angiogenesis models (e.g., absent endocrine signals, mechanical stimuli, and local blood flow). 
Mechanical stimuli have been incorporated into various angiogenesis assays but are largely absent from 
the organ explant assay. Local blood flow and mechanical properties of the surrounding tissue signal to 
the angiogenic process. Diseases which pathologically influence angiogenesis also create mechanical 
perturbations. However, the interaction between mechanical stimulation and angiogenesis remains un-
der-characterized. If the organ explant assay with its advantageous in vitro and in vivo characteristics 
were adapted to accommodate some mimic of local blood flow, it would yield new information about 
the interaction between mechanical stimuli and angiogenesis necessary to the treatment of disease. For 
this reason, we have designed and implemented a bioreactor that facilitates angiogenic sprouting and 
outgrowth from a perfused vascular explant.  
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The Perfused Vascular Explant Bioreactor 
The perfused vascular explant bioreactor, shown in Fig B.1 was conceived to address limitations of in 
vitro and in vivo angiogenesis assays, particularly those relating to studies involving hemodynamic stimu-
li. The primary design target of the proposed work was to culture (over the long term) and encourage 
angiogenic sprouting of a vascular explant while maintaining a perfusion access to the lumen of the vas-
cular explant. The successful design also sought to implement this without sacrificing advantageous fea-
tures of the conventional vascular explant angiogenesis assay (e.g., amenability to repeated non-
invasive imaging of angiogenesis). These design targets were put forth with the expectation that a per-
fusable connection to the lumen of a vascular explant would enable researchers to mimic aspects of 
physiological and/or pathological blood flow in the vascular explant angiogenesis assay. Researchers 
recognize the importance of blood flow and the mechanical and chemical signals it generates, and they 
have incorporated stimuli engendered in blood flow into in vitro angiogenesis assays; however, the vas-
cular explant angiogenesis assay has yet to see such enhancement. Our work explores the potential of 
the PVEB to incorporate measurement and/or actuation of mechanical and chemical stimuli (engen-
dered in blood flow) into the vascular explant angiogenesis assay.  
 
The PVEB would allow researchers to study the interaction between signals produced by flowing blood 
and angiogenesis, in a platform that presents potentially the most complete in vitro model of in vivo an-
giogenesis. The PVEB was conceived with the goal of eventually controllably delivering mechanical sig-
nals (e.g., shear stress) to vascular explants undergoing angiogenesis, and measuring changes in me-
chanical properties of blood vessels (e.g., impedance to fluid flow) which accompany long-term culture 
and angiogenesis. An in vitro experimental model such as the PVEB would also allow researchers to fur-
ther probe chemical consequences of blood flow and their impact on angiogenesis. For example, mass 
transport of small molecules, radially diffusing from patent blood vessels, could be better mimicked in 
the PVEB. Similarly, the PVEB would allow the biomolecular properties of the luminal and abluminal 
spaces to be controlled independently of each other. These features may enhance the ability of the vas-
cular explant assay to mimic physiological or pathological features of angiogenesis. 
Constraints considered in the design and fabrication of the PVEB were that it maintain a clean (i.e., free 
of contamination) environment with physiological temperature, pH, pO2, and pCO2. The design should 
provide liquid-tight volume that opens only to the perfusion connection. The liquid-tight seal should 
withstand internal pressures at least as great as physiological pressures. Leaks arising from failure of the 
leak-tight seal introduce uncertain and uncontrolled influence on the angiogenesis and provide route for 
contamination and loss of perfusate. Components of the PVEB should also be inert and withstand sterili-
Figure B.1. Schematic of the perfused vascular 
explant bioreactor (PVEB). A mouse thoracic aorta 
is embedded in Matrigel and housed inside the 
PVEB. Flexible plastic catheter inserts connect the 
aorta to tubing sleeves. The tubing sleeves are 
fixed in the walls of the PVEB via commercially 
available ferrule fittings and nuts. The ends of the 
tubing sleeves that are outside of the PVEB are 
connected to tygon tubing. This assembly allows 
media to be pumped through the lumen of an 
aorta that is undergoing angiogenesis.  
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zation, thereby permitting repeated usage of the device. Quick assembly and facile implementation of 
the PVEB were important design constraints. The explanting and loading of the vascular explant into the 
PVEB should require little or no more time and expertise than the conventional vascular explant assay, 
since prolonged exposure to non-physiological temperature, pH, pO2, and pCO2 threatens the viability 
and angiogenic phenotype of the explant. Finally, the vascular explant should sparingly use matrix mate-
rials and culturing media to minimize the cost of the assay and the dilution of paracrine and autocrine 
signals secreted by the explant.  
We achieved a perfusible connection to the lumen of the aorta by catheterizing the aorta. Commercial 
ferule fittings and nuts were incorporated into the custom-machined polycarbonate walls of the PVEB to 
accommodate perfusion of the catheterized aorta while also maintaining a liquid-tight reactor. The PVEB 
end walls were slanted inward in order to position the aorta near the floor of the bioreactor and within 
the working distance of common microscope objectives. The PDMS gasket placed between the polycar-
bonate walls and the floor of the reactor had an approximately 0.6 x 1.2 cm rectangular cutout that pro-
vided clearance for the aorta to rest against the floor of the reactor and allowed the aorta to be com-
pletely submerged in a small volume of matrix material. Because of their common use in the aortic ring 
assay, endothelial growth media-2 (EGM-2) and growth factor reduced Matrigel were utilized in the 
PVEB culture. The goal of this study was to accomplish as a “proof of principle” angiogenic outgrowth 
from a perfused vascular explant without necessarily investigating specific mechanisms of the angiogen-
ic outgrowth. Considering this, Matrigel was selected over collagen and fibrin because of its ease of use 
and its greater capacity to induce angiogenesis.  
The aorta was perfused at flow rates between 50 and 100 µL/min. This would generate (considering that 
the mouse thoracic aorta is roughly 0.5 mm in diameter) shear stresses along the wall of the aorta that 
were comparable to that in the post capillary venule where angiogenesis typically occurs (~1 dyne/cm2). 
In this way, the perfusate flow rate was relevant to physiological angiogenesis. EGM-2, commonly used 
to investigate effect of shear-stress on endothelial cells in vitro, was utilized as the perfusate in the 
PVEB. The following details the design and implementation of the PVEB. 
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CHAPTER III 
 
METHODS 
 
We now describe the three experimental assays that were utilized: the classic mouse aortic ring assay, a 
whole-aorta angiogenesis assay in a cell culture dish, and the perfused vascular explant bioreactor 
(PVEB) assay. We follow this with the methods for small molecule perfusion experiments, and conclude 
this section by describing a COMSOL model of small molecule diffusion and convection in the PVEB and 
the equipment used in the experiments. 
All experiments conformed to the Guide for the Care and Use of Laboratory Animals published by the 
U.S. National Institutes of Health and were approved in advance by the Vanderbilt Institutional Animal 
Care and Use Committee. 
 
C.1. Mouse Aortic Ring Assay 
A 30-50 µL thick layer of Matrigel was pipetted into each well of a 96-well plate and allowed to cure. 
Thoracic aortas from four-to-ten-week-old wild-type or Tie-2::GFP mice were sectioned into six parts 
and centered, one per well, on top of the Matrigel layer. A second 20 µL layer of Matrigel was pipetted 
into the wells on top of the slices of aorta and allowed to cure. The aortas were cultured for at least six 
days with EGM complete media, in the dark at 37°C with humid 5% CO2, 95% air. The extent of angio-
genic sprouting was inspected visually under a microscope at 4x to 20x magnification.  
 
C.1.1. Equipment List  
1. Corning sterile 100 mm x 20 mm cell culture dishes.  
2. MicrotestTM sterile 96-well flat bottom tissue culture plate. 
3. Syringe needles (24G) were used repeatedly to pin down the euthanized mouse and were there-
fore not sterile.  
4. A 1L Nalgene jar served as a chamber for euthanizing the mouse. Paper towels were placed at 
the bottom of the jar, and a plastic grate was situated approximately 1 cm above them. This as-
sembly was stored in a chemical fume hood when not in use.  
5. A Styrofoam box lid, covered by a sheet of cloth, served as a dissecting tray.  
6. Dissecting tools: Roboz 24 mm carbide blade micro-dissecting scissors, Roboz Bonn 15 mm 
curved sharp tip micro-dissecting scissors, Roboz serrated straight fine tip (0.5 mm) micro-
dissecting forceps and Roboz McCullough cross serrated straight blunt tip (1.5 mm) micro-
dissecting forceps were washed with Roboz surgical instrument cleaner and warm water and 
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then stored in 70% v/v ethanol or under UV radiation for at least 30 minutes prior to use. Feath-
er® sterile stainless steel disposable scalpels were also used. In repeated uses, the scalpels were 
stored in 70% v/v ethanol for at least 30 minutes prior to use. The dissection equipment was 
sterilized via autoclaving whenever yeast contamination was a concern. 
7. P100 and P1000 pipettes. 
8. AmScope 4X magnification desktop dissecting scope.  
9. AmScope 4-40X magnification microscope. 
10. Nikon Ti Eclipse microscope with attached photometric Coolsnap HQ2 digital camera and NIS-
Elements AR software. 
11. Tissue culture incubator. 
 
C.1.2. Materials 
1. BD Biosciences Growth Factor Reduced MatrigelTM Matrix was stored in 800 µL aliquots at -20°C 
until use, which was within 6 months of purchase. The Matrigel was thawed and stored on ice 
no earlier than 8 hours prior to use.  
2. Complete Clonetics® Endothelial Cell Growth Media (EGM-2) was stored in 40 mL aliquots at -
20°C until thawed for use within 6 months. Upon thawing, the EBM-2 aliquot was stored in 
darkness at 4°C until use.  
3. Phosphate buffer solution (1x PBS) was prepared using a standard recipe starting with dry 
FisherReagent® laboratory grade chemicals and DI water. The solution was mixed and sterilized 
via autoclaving weeks or months prior to use.  
4. IsoThesiaTM Isoflurane, USP was stored in bulk at room temperature in the absence of light.  
5. Four-to-ten-week-old C57, BALB-C or SV-129 wild–type or hemizygous Tie2::GFP (Jackson Labor-
atories STOCK Tg(TIE2GFP)287Sato/J mice) were kept until use in standard mouse facilities. 
 
C.1.3. Euthanasia 
Mice were euthanized immediately prior to use via barbiturate overdose followed by cervical dislocation 
(as a precautionary measure). To accomplish this, approximately 0.5 mL of IsoThesiaTM Isoflurane, USP 
was added to a 1L Nalgene jar containing several paper towels; a plastic grate situated above the paper 
towels prevented the mouse from directly contacting the liquid isoflurane. Immediately afterwards, the 
mouse was placed inside the jar and the lid was screwed shut. The mouse was exposed to isoflurane gas 
for 2 to 10 minutes. Immediately after, cervical dislocation was performed manually.  
 
C.1.4. Explanting the Aorta 
The dissection procedures were developed under the guidance of Dr. Masakazu Shiota in arranged indi-
vidual training sessions at Vanderbilt University, and by Dr. Robert Nicosia as part of the National Insti-
tutes of Health and the Foundation for the Advanced Education in the Sciences (NIH/FAES) Analytical 
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Techniques for the Quantitation of Angiogenesis and Lymphoangiogenesis Course, TRAC28, developed 
by Mark Nardone93, 121. During the dissection, when not being used all dissection tools were stored in 
70% v/v ethanol. Immediately following euthanasia, the mouse was pinned to the dissecting tray by in-
serting 25G syringe needles through the fore- and hind-paws with palmar and dorsal surfaces facing up, 
respectively. The ventral side of the mouse was facing up. To reduce the risk of contamination, the 
mouse was sprayed thoroughly with 70% v/v ethanol.  
Carbide blade micro-dissecting scissors were utilized to make an incision into the skin along the sagittal 
axis from the base of the abdomen to the middle of the sternum. Horizontal incisions were made into 
the skin across the base of the abdomen and across the chest. The skin and fur were peeled away from 
the underlying abdominal and thoracic muscle using the micro-dissecting forceps. The skin was pinned 
down using 25G syringe needles. Vertical incisions were made into the abdominal muscle using either of 
the two micro-dissecting scissors. This opened the peritoneal cavity and exposed intestine. The intes-
tine, stomach, liver and kidneys were gently pushed to the dextral side of the peritoneal cavity using the 
blunt tip micro-dissecting forceps.  
In subsequent steps, all dissection tools were rinsed in an approximately 5 mL reservoir of sterile 1x PBS 
(in a 100 mm x 20 mm cell culture dish) before contact with the mouse. This was to prevent ethanol poi-
soning of the vascular explant. The diaphragm was punctured, and the sinistral side of the rib cage was 
cut open using the carbide blade micro-dissecting scissors, to expose the lungs and heart in the thoracic 
cavity. The rib cage was partially cut away. The lungs were gently pulled toward the dextral side of the 
thoracic cavity using blunt tip micro-dissection forceps, thereby exposing the aorta. While grasping the 
posterior end of the thoracic aorta with the fine tip micro-dissecting forceps, the thoracic aorta was cut 
away (using curved tip microdissecting scissors) from the underlying rib cage from the posterior end to-
ward the anterior end. The explanted aorta was stored in 1x PBS until further use. 
Under the 4X magnifying dissecting scope the aorta was cleaned of fibro-adipose tissue. A ~2 mL droplet 
of 1x PBS was placed in the center of the lid of a 100 mm x 20 mm cell culture dish. This dish was placed 
under the objective of the dissecting scope and the aorta was placed inside the 1x PBS droplet. Pieces of 
fibro-adipose tissue were grasped and pulled apart using the micro-dissecting forceps. In an effort to 
maintain the endogenous angiogenic potential of the aorta, this was done with minimal manipulation of 
the underlying aorta. Once there was a break in the fibro-adipose tissue, large segments of it could be 
gently pulled off of the aorta (ideally). On occasion, additional manipulation was required. Care was tak-
en not to disturb the endothelial cell layer in the intima of the aorta. 
 
C.1.5. Culturing the Aortic Ring Assay 
Prior to performing the dissection, a 30-50 µL aliquot of Matrigel was pipetted into each of six wells in a 
96-well plate for each aorta. This layer of matrix was allowed to cure inside the tissue-culturing incuba-
tor for the duration of the dissection. After explanting the aorta, five cuts were made (with the scalpel) 
in planes perpendicular to the axis of the aorta, resulting in six segments of roughly equal size. An aorta 
segment was removed from the 1x PBS using the fine tip micro-dissecting forceps. A small droplet of 1x 
   
37 
 
PBS can be held between the tips of the forceps by surface tension. With the aorta segment enclosed 
inside this droplet it is possible to transfer the aorta from 1x PBS to a well in the 96-well plate without 
the forceps contacting the aorta. One aorta segment was placed on top of the Matrigel and centered 
inside a well on the 96-well plate, and 20 µL of Matrigel was pipetted into the wells on top of the aorta 
slices. The additional Matrigel was allowed to cure inside the tissue-culturing incubator for at least 20 
minutes. Afterward, 150 µL of media was added to the well, and replenished every four to six days in 
culture. Aorta slices were cultured at least six days in the dark at 37°C with humid 5% CO2, 95% air.  
 
C.1.6. Data Acquisition  
The aortic ring assay was used to investigate angiogenesis. Angiogenic sprouting was inspected visually, 
using a 4-40X magnification Amscope microscope and a Amscope camera or a Nikon Eclipse Ti equipped 
with a photometric Coolsnap HQ2 digital camera and NIS-Elements AR software. Fluorescent images of 
the Tie-2 mouse aortas were acquired at the FTIC emission wavelength (515-555 nm), 700 ms exposure 
and 4x gain (10X objective). Excitation of fluorescent materials was accomplished using a Nikon arc lamp 
on its minimum output setting (delivering an excitation wavelength of 475 to 490 nm). 
 
C.2. Whole Aorta Angiogenesis Assays in Cell Culture Dish 
Whole thoracic mouse aortas were placed in a 35 mm x 10 mm cell culture dish and overlaid with a 150 
µL bubble of Matrigel. The aortas were cultured for at least six days with EBM-2 complete media, in the 
dark at 37°C with humid 5% CO2, 95% air. Angiogenic sprouting was inspected visually under a micro-
scope. 
 
C.2.1. Equipment 
The same equipment was used in the Whole Aorta Angiogenesis Assay in Cell Culture Dish as in the 
Mouse Aortic Ring Assay (Section C.1.1). Cell culture (35 mm X 10 mm) dishes were used to culture the 
whole aorta instead of the 96-well plates. In some experiments Exel Safelet shielded 24G catheters and 
Myco silk suture thread were also used.  
C.2.2. Materials 
The same materials were used in the Whole Aorta Angiogenesis Assay in Cell Culture Dish as in the 
Mouse Aortic Ring Assay (Section C.1.2).  
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C.2.3. Explanting the Aorta 
The mouse euthanasia and the aorta explantation in the Whole Aorta Angiogenesis Assay were con-
ducted as in the Mouse Aortic Ring Assay (Sections C.1.3 and C.1.4). After explanting, the aorta was oc-
casionally catheterized as described in PVEB Mouse Aorta Assay (Section C.3.5).  
 
C.2.4. Culturing the Whole Aorta Angiogenesis Assays in Cell Culture Dish 
After explanting and cleaning the aorta, it was transferred to the center of a 35 mm X 10 mm cell culture 
dish using the fine tip micro-dissecting forceps. A 150 µL bubble of Matrigel was overlaid on the aorta 
using a P1000 pipette. The Matrigel was allowed to cure inside the tissue-culturing incubator for at least 
20 minutes. Afterward, 2000 µL of media was added to the well using a micropipetter, and replenished 
every six to eight days in culture. Two thousand microliters of media sufficiently submersed the bubble 
of Matrigel. Whole aortas were cultured at least six days in darkness at 37°C with humid 5% CO2, 95% 
air.  
 
C.2.5. Data Acquisition  
The Whole Aorta Angiogenesis Assay in Cell Culture Dish was used to investigate angiogenesis. Angio-
genic sprouting was inspected visually, using a 4-40X magnification Amscope microscope and a Amscope 
camera or a Nikon Eclipse Ti equipped with a photometric Coolsnap HQ2 digital camera and NIS-
Elements AR software.  
 
C.3. Perfused Vascular Explant Bioreactor (PVEB) Assay 
 
C.3.1. Equipment 
 
Dissection Equipment 
The same equipment was used in the PVEB Mouse Aorta Assay as in the Mouse Aortic Ring Assay (Sec-
tion C.1.1). The PVEB, peristaltic pump, and perfusion tubing were used to culture the whole aorta in-
stead of the 96-well plates. In addition, Exel Safelet shielded 24G catheters were used. Occasionally, My-
co or Ethicon silk suture thread was utilized to secure the aorta on the catheter.  
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Figure C.1. Schematics (A and B) and photographs (C, D and E) of the Perfused Vascular Endothelial Bioreactor (PVEB). Commer-
cial ferrule fittings (1) were fixed, using epoxy, into the polycarbonate walls (2) of the bioreactor. Commercial tubing sleeves (3) 
served as an adaptor between the ferrule fitting and the smaller diameter catheter tubes. A coverglass (0.5 mm thick), the bot-
tom PDMS gasket, PVEB, top PDMS gasket  and glass slide were stacked and clamped to create a liquid tight environment for 
the aorta. Parts are numbered in Table C.1. 
 
The PVEB 
The walls of the bioreactor, ferrule fittings and nuts, and tubing sleeves in the bioreactor were assem-
bled as in Fig. C.1. prior to use. A polycarbonate reactor (2) shell was manufactured by the Vanderbilt 
Physics Department machine shop. The bioreactor featured two sloped walls with circular openings and 
two solid, vertical walls. The walls with openings were tilted inward at 60° relative to the floor of the 
reactor. UpChurch ferrule N-333 fittings (1) were held in each opening by Epoxy. The ends of these fer-
rule fittings were filed at a 120° angle so that they lay flush with the floor of the reactor and the hole of 
the ferrule was 2mm above the floor. This assembly is referred to in this section as the PVEB. PDMS gas-
kets (4 and 5) were made by pouring a ~2 mm thick layer of PDMS elastomer and curing agent mixture 
into a plastic dish. This was cured at 60°C overnight in the absence of light, then cut, using a Feather® 
sterile stainless steel disposable scalpel, into rectangles that matched the dimensions of the top and 
bottom of the PVEB. The bottom gasket had an approximately 5 mm X 1.2 cm rectangle cut out of the 
center. This allowed clearance for the aorta to be positioned against the floor of the reactor. The PDMS 
mixture was prepared by mixing 10:1 Sylgard PDMS elastomer with Sylgard curing agent using a minute-
mixer. Using a stainless steel or brass/plexiglass compression clamp, a liquid-tight seal was created in 
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the PVEB. The PVEB, bottom (4) and top (5) PDMS gaskets, coverglasses, and clamps were immersed in 
70% v/v ethanol for at least 30 minutes prior to use.  
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Table C.1. Parts List for the Perfused Vascular Endothelial Bioreactor (PVEB) 
Part No. Equipment Manufacturer/Other Material 
1 Ferrule fittings and nuts IDEX Health&Science N333 PEEK 
2 PVEB polymer walls VIIBRE Polycarbonate 
3 Tubing sleeves IDEX Health&Science F247X FEP and Teflon 
4 Top PDMS gasket VIIBRE PDMS 
5 Bottom PDMS gasket VIIBRE PDMS 
6 Studs VIIBRE Stainless steel 
7 Compression clamp base VIIBRE Stainless steel  
8 Compression clamp lid VIIBRE Stainless steel 
9 Compression clamp base (alternate) VIIBRE Brass 
10 Compression clamp lid (alternate) VIIBRE Plexiglas 
11 Miniature incubator Bioscience tools NA 
12 Temperature controller Bioscience tools  
13 Persitaltic pump Ismatic NA 
14 Liquid-gas separator VIIBRE Polycarbonate 
15 PVC Solv tubing  Cole-Parmer 95712-26 PVC Solva 
16 CO2 tank AL Compressed Gas  
17 Sterile filter Pall Life Sciences® 0.45µm Supor® Membrane 
18 Reflux trap (flask) Unknown Glass 
19 Humidifier flask Unknown Glass 
20 Media/CO2 Equilibrator (flask) Unknown Glass 
21 Peristaltic pump tubing Cole-Parmer 95712-26 PVC Solva 
22 Polyethylene tubing (CO2 delivery) Bioscience tools Polyethylene 
23 Polyethylene connectors  Bioscience tools Polyethylene 
24 Silicone tubing Bioscience tools Silicone 
25 Luer adaptor Bioscience tools Polyethylene 
26 Polyurethane tubing (bubbler) Bioscience tools Polyurethane 
27 Luer adaptor 2 Bioscience tools Polyethylene 
29 Polyethylene flask lid  Polyethylene 
30 Straight tubing connectors 1/16"ID  Cole-Parmer C0-1HDPE Polypropylene 
31 Luer adaptor 3 Unknown Nylon 
32 Silicone tubing Bioscience tools Silicone 
33 Luer adaptor 4 Value Plastics SMTLL-J1A Kynar PVDF 
34 1/4-20 screw to Luer adaptors Unknown Nylon 
35 O ring Unknown Buna-N 
36 Thumb screws Microplastics 092520050TEG Economy Nylon 
37 25G syringe needles Becton Dickinson &Co 305122 Stainless steel & unspecified 
38 PVEB2 polymer walls VIIBRE PDMS 
39 Hollow fiber Spectrum Technologies Unknown 
40 T-Joint Tubing Connectors 1/16" ID Cole-Palmer 5(53-2032W) PVC Solva 
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Incubation and Perfusion Equipment  
Two approaches were utilized in incubation and perfusion of the mouse aorta in the PVEB. This section 
lists the equipment utilized in each.  
1. An alternate clamp (9 and 10) was designed to accommodate use within the Bioscience Tools 
miniature incubator. The Bioscience Tools miniature incubator was connected to a Bioscience 
Tools temperature controller (12) and a cylindrical tank charged with 5% CO2, 95% air as dia-
grammed in Fig. C.2. The perfusion circuit was connected to a Bioscience Tools incubator 
through ports described in Section C.3.1.4. Gaseous 5% CO2, 95% air was delivered to the minia-
ture incubator at a rate that allowed one bubble to go through the humidifier per sec. At least 4 
hours before use, the perfusion circuit was disconnected from the sterile filter and sterilized 
with ethanol (Section C.3.1.4).  
2. A tissue culture incubator was modified to accommodate a perfused connection to the PVEB it 
contained. Perfusion tubing, described in the next section, was wedged into the door of the in-
cubator. Structural support was provided by plastic syringe pistons which were taped to the in-
cubator, flanking the tubing and also wedged into the door of the incubator. This setup was as-
sembled prior to sterilization of the perfusion tubing (Fig. C.3).  
 
Perfusion Circuit 
The perfusion circuit comprises all the equipment and tubing that carries sterilized CO2 /air and media to 
the miniature incubator and PVEB. Described in Section C.3.4., a modified perfusion circuit delivered 
media to a PVEB that was housed within a conventional tissue culture incubator. Experiments utilized 
the miniature incubator and the larger conventional tissue culture incubator. When sterilizing the cir-
cuit, the PVEB is replaced by a 1/8” piece of tubing sleeve (3). This serves as a place holder and closes 
the loop that will carry media to and from the aorta lumen in the PVEB. The perfusion circuit was as-
sembled as diagrammed in Fig. C.4 prior to use and sterilized by perfusing the closed loop path with 1-2 
mL/min of 70% v/v ethanol for at least 30 minutes. After sterilization, the perfusion circuit was perfused 
at 1-2 mL/min with sterile DI H2O for at least 30 minutes, then perfused at 1-2 mL/min with 1x PBS. The 
CO2 and humid air delivery path in the perfusion circuit is not a closed loop. This path was filled with 
70% v/v ethanol by injecting it (using a 10 mL syringe) directly into the silicone tubing (24), followed by 
DI water. All internal surfaces of the perfusion loop were exposed to 70% v/v ethanol for at least 30 
minutes, followed by DI water for at least 30 minutes.  
 
C.3.2. Materials 
The same culture materials were used in the PVEB Mouse Aorta Assay as in the Mouse Aortic Ring Assay 
(Section C.1.2). The EGM-2 was separated into two allotments, one (10 mL) for perfusing the lumen of 
the aorta and another (2 mL) for culturing in the abluminal space of the PVEB. The latter was stored in-
side the tissue culture incubator for at least 30 minutes to equilibrate it to 5% CO2.  
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Figure C.2. An alternate compression clamp was designed (A and B) that allowed the PVEB to fit inside a Bioscience Tools minia-
ture incubator (11). A 2 mm thick brass compression clamp base (9), in the shape of the incubator stage inset, was made at the 
Vanderbilt Institute for Integrative Biosystems Research and Education (VIIBRE), as were an accompanying plexiglass compres-
sion clamp lid (10) and nuts. As shown in a schematic F) of the Bioscience Tools miniature (11) incubator and supporting tem-
perature controller (12), the miniature incubator was connected to a perfusion circuit which consisted of a peristaltic pump 
(13), liquid-gas separator (14) E) and (depicted in blue) Tygon tubing (15). Gaseous 5% CO2, 95% air was delivered from the 
pressurized cylinder(16) through a 0.02 μm pore-sized sterile filter(17) and reflux trap (18), bubbled through a humidifier (19) 
and media reservoir (20) (C and D) and finally flowed into the miniature incubator. Bubbling 5% CO2, 95% air through the media 
reservoir (20) equilibrated the media to 5% CO2. The resulting color change was noted as an indicator of 5% CO2 equilibration of 
the media. A 15 mL conical tube was placed inside the media reservoir flask. A detailed parts list (Table C.1.) provides the 
names and suppliers of the numbered components in this figure.  
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C.3.3. Initiating the Temperature 
Controller and Perfusion Loop  
After sterilizing and rinsing the per-
fusion circuit, 1x PBS was decanted 
from the media reservoir and re-
placed by 10 mL of complete EGM, 
which was pipetted into the media 
reservoir (which also served as a 
CO2/media equilibrator (20). The 
perfusion circuit was reconnected 
to the sterile filter (17) that is con-
nected to the CO2 tank. The volu-
metric flow rate of CO2/air into the 
reactor was not measured. Flow was slow enough to produce in the humidifier and media reservoir one 
or two bubbles per second. On occasion, to insure adequate delivery of CO2 to the miniature incubator, 
a small culture dish of EBM-2 complete media was incubated inside the incubator for at least 30 minutes 
and inspected visually for the color change that accompanies CO2 equilibration. 
 
The temperature controller was turned on, and the electronic connections of the miniature incubator 
and lid (11) were made at least 30 minutes prior to culturing the aorta. After sterilization and rinsing, the 
perfusion circuit was perfused using the peristaltic pump (13) at 1-2 mL/min with complete EBM-2 for at 
least 30 minutes. 
 
C.3.4. Alternate Assembly of Perfusion and Incubation Equipment 
In some Perfused Vascular Explant Bioreactor (PVEB) Mouse Aorta Assays, the perfusion circuit consist-
ed of a closed loop of Tygon tubing (15) connecting a media reservoir to the peristaltic pump (13), de-
bubbler (14) and PVEB, and then returning to the media reservoir (Fig. C.3). When sterilizing this circuit, 
the PVEB is replaced by a 1/8” piece of tubing sleeve (3). This serves as a placeholder and closes the loop 
that will carry media to and from the aorta lumen in the PVEB. Sterilization was accomplished by perfus-
ing the closed loop path with 1-2 mL/min of 70% v/v ethanol for at least 30 minutes. After sterilization, 
the perfusion circuit was perfused at 1-2 mL/min with sterile DI H2O for at least 30 minutes, then per-
fused at 1-2 mL/min with 1x PBS. Adequate temperature and carbon dioxide concentration were main-
tained for the duration of the assay using a standard tissue culture incubator, as described below (Sec-
tion C.3.7).  
Figure C.3. Schematic depicting the perfusion circuit and PVEB in a large incu-
bator. A tissue culture incubator (depicted by dashed lines) was modified to 
accommodate a perfused connection to the media reservoir and the PVEB it 
contained.  
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Figure C.4. The perfusion circuit was assembled as diagrammed above. The sterile filter (17) was not connected until after steri-
lization of the rest of the perfusion circuit. Sterilization was accomplished by using the peristaltic pump to perfuse the closed-
loop circuit (depicted in blue) with 70% (v/v) ethanol in water, followed by DI water then 1x PBS. The CO2 delivery line which 
connects to the sterile filter was filled with 70% (v/v) ethanol in water, followed by DI water then 1x PBS. The tubing in the CO2 
delivery line was exposed to 70% (v/v) ethanol in water, DI water and 1x PBS by injecting it into the tubing (24). 
 
C.3.5. Explanting the Aorta 
The mouse euthanasia and the aorta explantation in the PVEB Aorta Assay were conducted as in the 
Mouse Aortic Ring Assay (Section C.1.3 and C.1.4). 
B. 
A. 
C. 
E. D. 
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C.3.6. Catheterizing the Aorta 
Exel safelet sterile shield catheters (24G X ¾”) were inserted into the ends of the explanted aorta. These 
catheters feature a flexible ¾” plastic catheter tube that slightly tapers at its end. The plastic catheter 
tube is attached to a “quick connect” syringe tip which is capable of fitting on commercially available 
syringes. Underlying the syringe tip and catheter shield is a 24G X 2” stainless steel needle. The end of 
the needle is beveled (useful for carefully inserting into the aorta), and fixed at the other end to a plastic 
support for safe handling. The needle can be withdrawn from the syringe tip and catheter shield by ap-
plying gentle force. Under the 4X magnifying dissecting scope, the aorta, once cleaned of fibro-adipose 
tissue, was catheterized and loaded into the PVEB. A ~2 mL droplet of 1x PBS, placed in the center of the 
lid of a 100 mm x 20 mm cell culture dish, held the explanted aorta. To accomplish this catheterization, 
one end of the aorta was grasped using the fine tip micro-dissection forceps in the left hand. The right 
hand was used to insert the Exel Safelet shielded catheter into the lumen of the aorta. Using the thumb 
and index finger it is possible to smoothly slide the catheter back and forth along the underlying syringe 
needle. While holding the aorta in place using the fine-tip micro-dissection forceps, the catheter was 
gently slid into the lumen of the aorta. Immediately after, the catheter shield was cut away from the rest 
of the syringe tip using the curve tip micro-dissecting scissors, leaving a 3 to 7 cm long segment of the 
catheter inside one end of the aorta, with the other end of the catheter free and open. The aorta was 
rotated 180° so that the non-catheterized end of the aorta could be grasped using the fine tip micro-
dissection forceps in the left hand, and the catheterization step was repeated for the other end of the 
aorta. Catheterizing the aorta occurred without removing the aorta from the ~2 mL droplet. The cathe-
terized aorta was laid flat inside the droplet and both catheter shields were then cut  in planes 45° from 
the axis of the catheter, such that the whole length of the aorta plus catheters was ~2.5 cm (shown in 
Fig. C.5.A). A ruler was placed under the culturing dish in order to accurately judge the distance between 
the two cuts.  
Occasionally, silk thread suture knots were tied around the aorta in order to secure the aorta-catheter 
connection. In these cases, silk thread was tied into loose double-square knots and sterilized in ethanol 
for at least 30 minutes, followed by immersion in sterile DI water for at least 30 minutes. These knots 
were slid onto the aorta and tightened around the aorta-catheter connection using the micro-dissecting 
forceps.  
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C.3.7. Loading the PVEB 
Prior to loading the PVEB, the coverglass and bottom PDMS gasket were stacked on the floor of the in-
cubator or stainless steel clamp (in that order), and the top PDMS gasket was placed against the cover-
glass. Using the blunt tip micro-dissecting forceps in the left hand, the PVEB was picked up by the left 
ferrule fitting. The left hand is rotated ~180° such that the reactor is upside-down and hovering over the 
thenar space of the hand with the forceps around the now right ferrule fitting. This positioning allows 
added clearance for the right hand and makes it possible to load the aorta without raising the right el-
bow to uncomfortable heights. The catheter was inserted 1-4 mm into the left tubing sleeve inside the 
PVEB using the fine tip micro-dissecting forceps. Immediately thereafter, the PVEB was placed into a 2-3 
mL droplet of 1xPBS. The PVEB was rotated 180°, and the loading of the second catheter was done ex-
actly as the first. Care was taken not to pull the aorta off of the catheters or to stretch or flex the aorta.  
 
C.3.8. Culturing the PVEB Mouse Aorta Assay 
The compression clamp lid was placed above the PVEB and tightened without the top coverglass and 
PDMS gasket. This provided a leak-proof seal between the walls and the floor of the PVEB. Excess liquid 
in the PVEB was aspirated using a P1000 micropipetter. Matrigel (300 µL) was deposited on the aorta 
using a P1000 pipette. The Matrigel was allowed to cure inside the tissue-culturing incubator for at least 
20 minutes. Afterward, the compression clamp lid can be removed momentarily without disrupting the 
Figure C.5.Major steps of 
that assembly of the PVEB: 
A) Extract, clean, and cath-
erize the aorta, (B and C) 
load the aorta into the fer-
rule fittings, D) cover the 
aorta in Matrigel, allow it to 
cure at 37 degrees, and fill 
the remaining volume with 
EGM-2, E) seal the reactor, 
F) perfuse the aorta. On 
average it takes 40 minutes 
to extract and catheterize 
the mouse aorta, connect 
to the ferrule fitting, as-
semble the bioreactor and 
supply it with Mat-
rigel/media.  
 
   
48 
 
seal between the walls and the floor of the PVEB. The compression clamp lid was removed and 1000 µL 
of CO2 equilibrated complete media was quickly added to the PVEB using a P1000 micropipetter. Imme-
diately afterward, the top PDMS gasket and coverglass were gently placed on top of the PVEB and the 
clamp was tightened down. The perfusion circuit was connected to the PVEB by using the forceps to re-
move the tubing sleeve (3) that served as a place holder up until now. The perfusion circuit was con-
nected to the external ends of the tubing sleeves of the PVEB. Finally, the perfusion circuit was recon-
nected to the sterile filter (17) that connects to the CO2 mixer and the peristaltic pump. The aorta lumen 
was perfused inside the PVEB, with media (that contained 75% of the growth factors in complete EGM-
2) from the media reservoir flask or CO2/media equilibrator (20), at 0-500 µL/min continuously for at 
least six days. 
In an alternate approach to the assay, the PVEB, coverglass and PDMS gaskets are held between the 
compression clamp base and compression clamp lid, as shown in Fig. C.3. Instead of incubating the PVEB 
in the miniature incubator, the PVEB is stored in the tissue culture incubator. A peristaltic pump that 
pumps the perfusate through the aorta bioreactor was located outside the incubator. Tubing connecting 
the aorta bioreactor to the perfusate and pump was wedged into the door of the incubator. The incuba-
tor door closed and sealed around the tubing. Plastic syringe pistons served as structural support and 
were situated around the tubing to prevent the door seal from collapsing the tubing. The aorta lumen 
was perfused inside the PVEB, with media from the media reservoir flask or CO2/media equilibrator (20), 
at 50 µL/min continuously for at least six days. The PVEB and perfusate were kept in the dark at 37°C 
with humid 5% CO2, 95% air.  
 
C.3.9. Data Acquisition  
Angiogenic sprouting was inspected visually, using a 4-40X magnification Amscope microscope and a 
Amscope camera or a Nikon Eclipse Ti equipped with a photometric Coolsnap HQ2 digital camera and 
NIS-Elements AR software. Fluorescent images of the Tie-2 mouse aortas were acquired at the FITC 
emission bandpass of wavelengths (500-540), 700ms exposure and 4x gain (10X objective). Excitation of 
fluorescent materials was accomplished using a Nikon arc lamp on its minimum output setting (deliver-
ing a passband of excitation wavelengths, 475-490nm).  
After four to seven days in culture, aortas were retrieved from the PVEB. Using forceps, the aortas were 
manually separated from the glass floor of the PVEB, or from the cell culturing dish. Aortas were fixed in 
10% formalin at room temperature for 24 hours, followed by incubation in ethanol. Fixed samples were 
sliced and hematoxylin and eosin stained.  
 
C.4. Small Molecule Perfusion Experiments 
 
C.4.1. Hollow Fiber Dye Rinse Out Experiment 
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C.4.1.1. Equipment List  
1. Perfused vascular explant bioreactor model 2 (PVEB2). 
2. Ismatec pump and perfusion circuit. 
3. MicrotestTM sterile 96-well flat bottom tissue culture plate. 
4. UV-VIS Spectrometer. 
5. Rubber band. 
 
Perfusion Circuit 
The perfusion setup was assembled 
as schematized in Fig. C.6. A 50 mL 
conical tube served as the reservoir 
for the perfusate. The perfusion 
circuit was sterilized by perfusing 
with 1-2 mL/min of 70% v/v ethanol 
for at least 30 minutes. 
 
Perfused Vascular Explant Bioreac-
tor PVEB 2  
The previous section describes the 
procedures for the final version of 
the PVEB. An earlier implementa-
tion is worthy of note, as it was 
used for dye rinsing experiments. 
The second of five major iterations 
in the evolution of the PVEB was 
assembled prior to experimentation 
as in Fig. C.6. PDMS elastomer and 
curing agent were mixed in a 10:1 
ratio, then poured into a 1 inch X 1 inch square, ring-shaped brass mold and cured at 60°C overnight. 
The resulting PDMS ring (39) was plasma-bonded to a 75 mm X 50 mm X 1 mm glass microscope slide. 
Afterward, a vertical slit was cut partially into opposite sides of the ring using a razor blade. Syringe nee-
dles (24G) were inserted into the ends of an approximately 1 inch segment of 0.5 mm polyacetylnitrile 
hollow fiber (38). The syringe needles were secured by using silk suture thread to tie a square knot 
around the hollow fiber with the needle underneath. The syringe needle/hollow fiber assembly was in-
serted into the slits of the PDMS. This assembly was sterilized prior to use via exposure to UV radiation 
overnight or by submersion in 70% (v/v) ethanol for at least 30 minutes, followed by submersion in DI 
water for at least 30 minutes.  
Figure C.6. An earlier version in the evolution of the PVEB, the PVEB2, was 
fabricated by casting a PDMS square ring (38) and plasma-bonding it to a 
glass slide. The PVEB2 featured a slit in the PDMS ring. Syringe needles 25G  
were tied, using Myco silk suture thread to 0.50 diameter hollow fiber (39). 
The PVEB2 was sealed using a stainless steel compression clamp. Lateral 
compression was occasionally applied, by wedging plastic P1000 pipette tips 
between the PDMS walls of the PVEB and the screws of the compression 
clamp, in an effort to quell leaks from where the needles passed through the 
slits in the PDMS. Above is the schematic of the perfusion circuit utilized in 
the hollow fiber bioreactor dye rinsing experiment (Section C.4.1.) 
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C.4.1.2. Materials 
Non-sterile 1x PBS was prepared months before use and stored at room temperature. A non-sterile 100 
mM stock solution of fluorescein in DI water was prepared months before use and stored at room tem-
perature in the absence of light.  
 
C.4.1.3. Dye Rinsing Experiment 
The P1000 pipette tips (indicated by the arrows in Fig. C.6.D) were wedged between the walls of the 
PVEB2 and the screws of the clamp immediately prior to experimentation (Fig. C.6.D). This was done in 
order to prevent leaks through the slits in the PDMS walls of the PVEB2. The PVEB2 was connected to 
the perfusion circuit. Non-sterile 1x PBS (4500 µL) was pipetted into a microcentrifuge tube and mixed 
via pipetting with 500 µL of fluorescein stock solution. Of the resulting fluorescein solution, 3 mL was 
pipetted into the abluminal space of the PVEB2. Immediately afterward, the glass cover of the PVEB2 
was quickly placed on top of the reactor and the steel clamp was tightened around the reactor. The hol-
low was perfused inside the PVEB2 with 1x PBS from the reservoir at 400 µL/min continuously for at 
most 1 hour. Aliquots (100 µL) of the outflow from the PVEB were taken every minute by allowing it to 
drip into the wells of a 96-well plate. After a sample was dispensed into a well of the 96-well plate, that 
well would be covered with tape to reduce the evaporative loss from the sample.  
 
C.4.1.4. Data Acquisition and Analysis 
Of the samples that dripped into the wells of the 96-well plate, 50 µL of each was transferred into an-
other well. This was done in order to keep the volume of each sample constant. Since it was observed 
that intense fluorescent emissions could scatter into adjacent wells, the 50 µL samples were not placed 
in adjacent wells. Fluorescence intensity of the 96-well plate was measured using a SPECTRAmax Plus 
384 UV/Vis spectrometer. Alternatively, the 96-well was stored overnight at 4°C in the absence of light 
before measuring.  
The fluorescence intensity of the eluent samples were plotted vs. time. The fluorescein concentration in 
the eluate from the reactor approaches pseudo-equilibrium. (If the volume of the abluminal space were 
infinite, the fluorescein would approach a true equilibrium.) The equilibrium concentration can be mod-
eled using equations that describe membrane reactors.  
   
  
       
Here, nA is the molar flux of a reagent, A, L is unit length of the hollow fiber, rA is reactive accumulation 
(zero in our case) per unit volume of the reagent and RA is trans-membrane flux of reagent into the per-
fusate. This equation was simplified, by assuming that the perfusate flow rate and the reagent (fluores-
A. C. 
D. 
B. 
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cein) concentration in the ablumenal space are constant along the length of the hollow fiber. The effect 
of radial variations of the perfusate velocity on trans-membrane fluorescein flux was neglected.  
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)     
QV is the volumetric flow rate of media in through the PVEB2, CA, CA, x = 0, CA, x = L and Cabl are the fluoresce-
in concentration along the length of the hollow fiber, at the entrance, at the exit and in the ablumenal 
space of the hollow fiber. PS is the small molecule permeability per length of the hollow fiber. The con-
centration of the eluite reaches a pseudo-equilibrium. Consequently, the fluorescence intensity is rough-
ly asymptotic. The average fluorescence intensities of the samples that appeared to be close to an as-
ymptote were used in the following calculation in order to get a measure of small molecule permeability 
per length of hollow fiber, Ps,  
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where QV is the volumetric flow rate of media in through the PVEB2, L is the length of the hollow fiber, I 
is the fluorescent intensity of the eluent and I0 is the fluorescent intensity of the solution in the ablu-
minal space at the end of the experiment. This assumes that the fluorescent intensity was directly pro-
portional the fluorescein concentration.  
 
C.4.2. Mouse Aorta Fluorescent Microspheres Perfusion Experiment 
At day 6 in culture and once angiogenic sprouting had occurred in the PVEB, the lumen of the aorta was 
exposed to a 1% w/w solution of 0.04 µm diameter fluorescent (in all channels) microspheres via injec-
tion. This procedure was adapted from Weinstein and colleagues who used fluorescent microspheres to 
image neovascularization in zebrafish83. The aorta was incubated with the fluorescent microspheres so-
lution for 36 hours. The presence of microspheres inside angiogenic sprouts was detected using fluores-
cence microscopy. 
C.4.2.1. Equipment  
The same equipment was used in the Mouse Aorta Fluorescent Microspheres Perfusion Experiment as in 
the PVEB Mouse Aorta Assay (Section C. 3.1). Since this experiment was short-term, lasting only several 
hours, the CO2 controller and CO2 delivery path were not necessarily included in the perfusion circuit.  
 
(1) 
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C.4.2.2. Materials 
The same materials were used in the Mouse Aorta Fluorescent Microspheres Perfusion Experiment as in 
the Mouse Aortic Ring Assay (Section C.1.2). A sterile 5% w/w stock solution of fluorescent microspheres 
in DI water was purchased months before use, and stored at 4°C in the absence of light. A sterile 10% 
bovine serum albumen (BSA) in PBS stock solution was prepared using the standard recipe months be-
fore use, and stored at -20°C.  
 
C.4.2.3. Culturing and Perfusing the Mouse Aorta with Microspheres  
The aorta was explanted, catheterized and loaded into the PVEB as in the PVEB Mouse Aorta Assay (Sec-
tions C.1.3, C.1.4, C.3.5 and C.3.6). The aorta was cultured for six days until the appearance of angiogen-
ic sprouts. 
 
C.4.2.4. Loading Microspheres into the Aorta 
The microsphere stock solution was sonicated using a Heat Systems Ultrasonics Model W-375 Soni-
catorTM (with water bath) on its highest setting, pulsed, for 2 minutes with a 25% duty cycle. A sterile 
solution containing 1% w/w microspheres and 2% BSA in PBS was prepared. The solution was drawn into 
the PVEB (into the aorta lumen). The catheter shield was placed onto a 1 mL syringe. About 150 µL of 
the microsphere solution was drawn into the syringe tip of the catheter shield. The syringe was con-
nected to the upstream tubing sleeve (3) of the PVEB. The syringe was carefully disconnected from the 
syringe tip. Downstream, tubing was disconnected or vented, thereby creating a hydrostatic head of a 
few decimeters. Flow under this hydrostatic head was halted by manually reconnecting the downstream 
tubing once the microsphere solution had flowed down the length of the aorta. The PVEB was incubated 
under this no-flow configuration for 36 hours.  
 
C.4.2.5. Data Acquisition and Analysis 
Microsphere diffusion was inspected visually, using a 10-40X magnification Fluorescence Nikon Eclipse Ti 
equipped with a photometric Coolsnap HQ2 digital camera and NIS-Elements AR software. Images were 
acquired at the TRITC emission bandpass of wavelengths (590-650), 50 ms exposure, and 1x gain (10X 
objective). Excitation of fluorescent materials was accomplished using a Nikon arc lamp on its minimum 
output setting (delivering a passband of excitation wavelengths, 475 -490 nm). 
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C.5. COMSOL Model of Small Molecule Diffusion and Convection in the PVEB 
A mathematical model of small molecule transport via diffusion and convection in the PVEB2 was gener-
ated and solved using the finite element method. The mathematical model of bulk fluid flow utilized Na-
vier-Stokes equations and Darcy’s Law in the luminal and abluminal spaces of the PVEB, respectively. 
Fick’s Law of diffusion and mass transport equations modeled solute mass transfer. COMSOL version 3.4 
was utilized to integrate and solve the modeling equations.  
 
C.5.1. Assumptions 
This mathematical model of the bulk flow utilizes the following assumptions:  
1. Perfusate is incompressible and Newtonian with spatially uniform and temporally constant vis-
cosity.  
2. End effects on axial flow in the hollow fiber or explant are neglected.  
3. The velocity of perfusate leaking from the hollow fiber (i.e., filtrate) is continuous in the direc-
tion normal to the hollow fiber. A slip condition along the wall of the hollow fiber, however, is 
allowed. 
4. The hollow fiber resistance to filtrate flow was considered small in comparison to resistance im-
parted by the matrix.  
5. The matrix in the abluminal space was incompressible. The permeability of the matrix was iso-
tropic, spatially uniform, and temporally constant.  
Assumptions utilized in the solute transport model are as follows: 
1. The small molecule solution is ideal (i.e., the enthalpy of mixing is zero and the solution density 
is independent of concentration).  
2. Density is therefore constant and uniform. 
3. Diffusivity of the solution is isotropic, spatially uniform and temporally constant.  
4. The solute concentration is small enough to allow us to neglect osmotic effects.  
Commonly used assumptions and approximations were also utilized in the model:  
1. Constant and uniform temperature. 
2. The model is at steady state. 
3. Gravitational force is neglected. 
 
C.5.2. Geometry 
The PVEB geometry that was modeled was 1 cm x 1 cm x ~0.5 mm. The centerline of a 0.5 mm diameter 
straight hollow fiber passed through the center of the reactor parallel to the 1 x 1 cm square. The math-
ematical model of the PVEB was solved for a planar cross-section that was through the centerline of the 
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hollow fiber and parallel to the floor of the reactor. The cylindrical geometry of the hollow fiber was ne-
glected. 
  
C.5.3. Equations 
Bulk fluid flow was modeled using the continuity (2), Navier-Stokes (3) and Darcy’s Law (4) equations. 
       , 
  
  
        
 
 
              
    
 
 
      
In these equations, V is the velocity vector, p is pressure and F is force vector acting on the bulk of the 
fluid (assumed to be zero). Constants, ρ, ν, µ and K are fluid density, kinematic viscosity, dynamic viscosi-
ty and matrix permeability, respectively. Solute transport was modeled using the mass transport equa-
tion (5) 
  
  
              . 
C and D are concentration and diffusivity of the solute, respectively; R is a reactive consumption of the 
solute (e.g., metabolism). Boundary conditions were assigned as follows: The inlet was fully developed 
Poiseuille flow (in a cylindrical tube), as given by  
   
   
(  
  
  
)      .  
In this equation, QV is the volumetric flow rate in the tube, and VZ is the fluid velocity in the axial direc-
tion. R and r are the tube radius and radial position of the fluid stream, respectively. The radial compo-
nent of velocity at the inlet is zero. Pressure was also continuous across the hollow fiber membrane. 
Pressure at the outlet is zero. Velocity component normal to the hollow fiber is continuous across the 
hollow fiber membrane. The walls of the reactor are insolating (i.e., the velocity component normal to 
the walls is zero). 
Material properties, density (ρ) and viscosity (µ) of water at 37°C were assigned to the solution. The ma-
trix permeability, K, was assigned that of 1% collagen 1000 nm2. The diffusivity of the small molecule 
was assigned that of sugar in water at 25°C, 0.66 m2/sec × 109. The volumetric flow rate QV and the hol-
low fiber radius were values used in experiments (100 µL/min and 0.25 mm, respectively). Reactive con-
sumption, R, was selected arbitrarily such that the negative values for solute concentration did not re-
sult 1mol/sec × 10-10. 
 
 
(2) 
(3) 
(4) 
(5) 
(6) 
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C.5.4. Numerical Methods 
COMSOL Multiphysics 3.4. was used to integrate and solve Equations 2-6 and boundary conditions. A 
mesh that was fine near the hollow fiber and coarse further away (Fig. D.7 (A)) was created. The mesh 
contained 12000 elements. The fluid flow solution for the Navier-Stokes region was computed for an 
impermeable tube. The pressure in this solution provided the boundary condition for the Darcy’s Law 
region. The Navier-Stokes region was re-solved using the fluid velocity along the edge of the hollow fiber 
(computed via Darcy’s Law). This process was iterated until the solutions for pressure converged exactly. 
The solution for fluid velocity was used in the convective term of the solute mass transfer equation (5).  
 
C.6. Hydraulic Impedance Measurements of a Perfused Aorta In Vitro 
The impedance to fluid flow, imparted by a perfused mouse aorta, was monitored over time. Manome-
ters placed immediately upstream and downstream of the PVEB provided a measure of the pressure 
(head) difference across the PVEB. This pressure (head) difference was used to calculate the impedance 
for a particular flow rate. 
 
C.6.1. Equipment 
 
C.6.1.1 Dissection Equipment 
The same equipment was used in Impedance Measurement Experiments as in the Mouse Aortic Ring 
Assay (Section C.1.1). The PVEB, peristaltic pump, and perfusion tubing were used to culture the whole 
aorta instead of the 96-well plates. In addition, Exel Safelet shielded 24G catheters were used. Occa-
sionally, Myco or Ethicon silk suture thread was utilized to secure the aorta on the catheter.  
 
C.6.1.2. Incubation and Perfusion Equipment  
The same incubation and perfusion equipment was used in the Impedance Measurement Experiment as 
in the PVEB Mouse Aorta Assay (Section C.3.1.2). The perfusion circuit that used the Bioscience Tools 
miniature incubator was used in the Impedance Measurement Experiment. Polypropylene 1/16” ID 
barbed T-joint tubing connecters (41) were added to the perfusion circuit upstream and downstream of 
the PVEB and miniature incubator. A manometer (i.e., Tygon tubing (15) extending vertically for about 
1.5m from the PVEB and opening to the room) was connected to the perfusion circuit at these T-joints 
(40). Prior to experimentation, the perfusion circuit was sterilized and rinsed as in the PVEB Mouse Aor-
ta Assay (Section C.3.1.3). The ends of the two manometers were connected using a 1/8” piece of tubing 
sleeve (2) during the sterilization step. The PVEB was assembled and sterilized as in the PVEB Mouse 
Aorta Assay (Section C.3.1.4).  
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C.6.2. Culturing the Aorta and Measuring its Impedance to Fluid Flow 
The mouse was euthanized and the aorta explanted in the Impedance Measurement Experiment as in 
the Mouse Aortic Ring Assay (Sections C.1.3 and C.1.4). The aorta was catheterized and loaded into the 
PVEB as in the PVEB Mouse Aorta Assay (Sections C.3.6 and C.3.7). The aorta was maintained in culture 
as in the PVEB Mouse Aorta Assay.  
 
C.6.3. Data Acquisition  
Columns of EBM-2 media accrued inside the manometers. The following equation relates the difference 
in the heights of these columns of fluid to the impedance (Z) imparted by the aorta underflow  
  
        
 
, 
where h0 and h are the respective heights of the manometers upstream and downstream of the PVEB, Q 
is the volumetric flow rate of perfusate (as set by the peristaltic pump), ρ is the density of the media 
(approximated as that of water) and g is the acceleration of gravity (9.8 m2/s). The pressure readings of 
the manometers were converted to from Pascals to mmHg by dividing by 133.33 mmHg/Pa.  
 
  
(7) 
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CHAPTER IV 
 
RESULTS 
 
 
Current technologies facilitate the study of angiogenesis in organ explant cultures.  Variations to the or-
gan explant culture, particularly the aortic ring assay, have been implemented to improve mass 
transport in and investigate (in the short term) mechanical properties of the aorta. We further expand 
the capabilities of the organ explant cultures to: 
  1) accomplish long-term culture of a whole aorta,  
  2) facilitate angiogenic outgrowth from the whole aorta,  
  3) maintain a perfusable connection to the aorta lumen, and 
  4) facilitate angiogenic outgrowth from a perfused aorta.  
We accomplished these tasks using the PVEB. We also demonstrated (in principle) the potential of the 
PVEB, or future improvements to the PVEB, to control mass transport and measure mechanical proper-
ties of the aorta.  
 
D.1. Mouse Aortic Ring Assay 
Our study began with the already established technique: the mouse aortic ring assay. This starting point 
for the development and implementation of the PVEB served as a standard with which angiogenesis in 
the PVEB was compared. Representative aortic ring assays are shown in Fig. D.1. While variations in the 
extent and rate of angiogenesis were observed, the mouse aortic ring assay has, by day 6 in culture, 
produced a densely vascularized, roughly continuous tubule network that extended radially from the 
aortic ring. The tubule network was highly branched and branch points occurred uniformly throughout 
the outgrowth. Angiogenesis typically favors the ends of the aortic rings or severed arborizing arterials, 
but angiogenic outgrowth was routinely observed along the sides of the aortic rings as well. Prolonged 
culturing of the aortic ring assays produced angiogenic sprouts that were highly branched and disor-
ganized, with several discontinuities. In Fig. D.1, an example of this is labeled (C6). The morphological 
changes that accompany prolonged culturing typically occur by day 8 in culture. It was observed that the 
rate and extent of angiogenesis assay varies with mouse genetic background (BALB/C, C57, etc.), age 
and sex (data not shown). In an aortic ring assay which used Tie-2::GFP positive mice, fluorescent vascu-
lar sprouts extended from the aortic ring. The fluorescence intensity of the vascular sprouts was much 
less than that of the much larger aortic ring.  
 
 
   
58 
 
 
D.2. Evolution of the Perfused Vascular Explant Bioreactor 
The design of the PVEB underwent several modifications. Concurrently, the vasculature (aorta) explant-
ing and PVEB loading techniques underwent iteration. In this way, the PVEB design and vasculature han-
dling techniques were tailored to each other. While the aorta explantation technique was being devel-
oped, a hollow fiber served as a model of the aorta in initial designs of the PVEB. Problems with initial 
designs included leaks and contamination, excessive use of materials (e.g., Matrigel), difficult and time-
consuming loading of the aorta and poorly maintained temperature and pH. The first design of the PVEB 
(PVEB1) featured a one-inch square PDMS ring that was plasma-bonded to glass. Plastic gel loading tips 
that were pushed through the walls of the PVEB served as perfusion connectors for the aorta. A cover-
glass served as a lid to the PVEB1, and VELAP was utilized to seal the reactor. This design suffered all the 
aforementioned drawbacks. VELAP did not adequately seal the PVEB1, and the perfusion connectors 
were fixed to the walls of the PVEB1 (and often misaligned), making it difficult to load an aorta onto 
them. It was observed that small slits in the PDMS would self-seal, thereby preventing leaks. The PVEB2, 
shown in Fig. C.6, featured a slit in the PDMS ring, allowing catheterization of the aorta (in situ or ex vi-
vo) prior to loading it into the reactor. The slit also accommodated easy loading of the syringe/catheter-
aorta assembly. The slit reduced sample loading times to less than an hour for hollow fibers. VELAP and 
a compression mechanism – utilizing magnets placed on the PVEB2 lid and magnetite dopant in the 
PDMS ring – were explored as means of suppressing leaks through the lid of the reactor. They were un-
successful. A steel clamp was developed to prevent leaks through the lid of the PVEB2, but this design 
had problems too. To prevent leaks the depth of the slit had to be small relative to the height of the 
ring. This situated the aorta toward the top of the reactor (away from the objective of the microscope). 
Simple approaches to sealing leaks through the slit in the PDMS using various lateral compression devic-
es were ineffective. The device was leak–prone, especially when larger slits were cut into the PDMS 
walls. The volume of the reactor was still excessive. Nonetheless, this device was employed in experi-
ments. 
Other PVEB designs sought to accommodate aortas that had been catheterized prior to loading into the 
PVEB. These designs presented movable Luer connectors onto which the catheter could fit. Unfortunate-
ly, these designs also excessively used materials and situated the aorta far from the objective. The most 
recent PVEB designs (described in the Methods sections) were sufficient to culture an aorta and facili-
tate angiogenic outgrowth from an aorta that was connected to an external perfusion setup. Here, we 
adapted the catheterization of the aorta using shielded cannulae to fit commercial ferrule fittings. The 
polycarbonate walls of the reactor were sterilizable via ethanol. The angled design of the bioreactor 
serves two functions: 1) to provide clearance for the forceps when loading the reactor, and 2) to locate 
the aorta closer to the objective. This design, the PVEB5, resisted leaks and contamination and success-
fully maintained and grew angiogenic sprouts from an aorta that was connected to an external perfusion 
setup.  
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D.3. Whole Aorta Angiogenesis Assay 
To investigate biological morphological consequences of culturing the whole mouse thoracic aortas (as 
opposed to sub-millimeter slices used in the aortic ring assay), whole aortas were cultured in Matrigel 
and angiogenic outgrowth was observed. The Whole Aorta Angiogenesis Assay also served as a platform 
for developing and implementing aorta explantation and catheterization strategies. Catheterized aortas 
embedded in Matrigel and cultured in a Petri dish with complete EBM-2 routinely produced angiogenic 
outgrowths from the aorta that consisted of densely vascularized, roughly continuous tubule networks 
similar to those observed in the mouse aortic ring assay (Fig. D.2.). The tubule network was highly 
branched, and branch points appeared uniform throughout the outgrowth. Angiogenesis occurred along 
the side and ends of the aorta and typically favored severed arborizing arterials. Myco or Ethicon suture 
threads were occasionally utilized to secure the aorta on the catheter. Angiogenesis did not occur near 
the sutures. In whole aorta assays lacking suture thread, angiogenesis occurred along the entire length 
of the aorta, including sections that contained the catheter. Although variations in the extent and rate of 
angiogenesis were observed, the whole aorta angiogenesis assay produced angiogenic outgrowth typi-
cally by day 6 in culture. Initial whole aorta angiogenesis assays took more than an hour to assemble, 
but with practice, the technique improved and decreased the amount of time required to 30 minutes or 
less. In earlier assays, angiogenesis occurred more slowly. Prolonged culturing of the whole aorta angio-
genesis assay produced angiogenic outgrowth with disorganized and discontinuous structure similar to 
that in Fig. D.1. (labeled C6).  
After seven days in culture aortas were retrieved from the cell culture dish, fixed in 10% formalin for 24 
hours, sliced and hematoxylin and eosin (H&E) stained (top row of Fig. D.4). Structure features of sur-
rounding angiogenic outgrowths were lost as the aorta was manually separated from the cell culture 
dish. The medial region of the aorta was stained violet and pink with dark spots scattered throughout. 
The medial region also contained layers of ribbon-like folds. In contrast, a dead aorta (i.e. one that suf-
fered prolonged exposure to ambient conditions (room temperature and low CO2 and humidity)) stained 
more orange and lacked the dark spots (Bottom row of Fig. D4). The media was also smooth. The top 
row of Fig. D.4 shows a small puncture or rupture in the medial region of the aorta. The dark dots were 
more frequent in this region. 
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Figure D.1. Demonstrative aortic ring assay. Two slices from the same aorta, embedded in Matrigel and cultured in complete 
150 µL EBM-2 for six days produced angiogenic outgrowths that extended radially from the aorta segment. The tubule network 
was roughly continuous and highly branched, with branch points existing uniformly throughout the outgrowth. In the aortic ring 
assays, angiogenic outgrowth favored the ends of the aorta slice, although angiogenesis occurred on severed arterials and 
along the sides of the aorta slice as well. Angiogenic sprouts tended to become disorganized after prolonged culturing. The 
larger aorta slice in this assay (C6) has a highly branched capillary network with several discontinuities in the tubes characteris-
tic of angiogenic outgrowths subjected to prolonged culturing. This would begin at different points in culture typically after 8 
days.  
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Figure D.2. Demonstrative whole aorta angiogenesis assay. This aorta was catheterized, embedded in Matrigel and cultured in a 
Petri dish with complete EBM-2. Angiogenic sprouting was observed by day 12 (but typically earlier) in culture. Angiogenic out-
growth extended from the aorta, except near the knots in the Ethicon suture thread,indicated by arrows in (A) and (B). The 
outgrowth consisted of densely vascularized, roughly continuous tubule networks similar to those observed in the mouse aortic 
ring assay (Fig. D.1). The tubule networks were highly branched, with bifurcating branch points appearing uniformly throughout 
the outgrowth. Angiogenesis occurred along the sides (C) and from severed arborizing arterials (D). 
 
D.4. Perfused Vascular Explant Bioreactor (PVEB) Mouse Aorta Assay 
The PVEB enabled long-term (up to two weeks) culture of the whole aorta while maintaining a perfusa-
ble connection to the aorta lumen. The PVEB also facilitated angiogenic outgrowth from a perfusable 
and a perfused aorta. Sections D.4.1 and D.7. provide details of these observations.  
 
D.4.1. PVEB Mouse Aorta Assay without Flow 
Catheterized aortas that were embedded in Matrigel and cultured with complete EBM-2 inside the PVEB 
routinely produced angiogenic outgrowths that resembled those grown in the whole aorta angiogenesis 
assay (Section D.3.) Tubular networks were largely similar to those observed in the whole aorta angio-
genesis and the mouse aortic ring assays: densely vascularized and highly branched with bifurcating 
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branch points appearing uniformly throughout the outgrowth (Fig.D.3.). Angiogenesis occurred in vent-
ed PVEBs (i.e., having the lid and top gasket removed from the assembly) and sealed PVEBs. Evaporative 
loss of media from the abluminal space was noticeable in the vented PVEB. In the sealed PVEB, angio-
genesis did not occur if the media added to the abluminal space had not been equilibrated to 5% CO2 
beforehand. The angiogenic outgrowth in the PVEB without flow occasionally contained regions whose 
morphology differed from that observed in the mouse aortic ring and whole aorta angiogenesis assays. 
In these regions, outgrowths extended from the aorta without traversing much into vertical axis. The 
tubules appeared smoother and fainter than those occurring in the aortic ring assay. They are highly 
branched, and branch points appeared uniformly throughout the outgrowth. These branch points were 
typically multifurcated, unlike those in outgrowths occurring more routinely in angiogenesis assays 
(which were typically bifurcated). Although variation in the extent and rate of angiogenesis was ob-
served, the PVEB mouse aorta angiogenesis assay absent flow produced angiogenic outgrowth typically 
by day 6 in culture. Prolonged culturing of the aortic ring assays produced angiogenic sprouts that were 
highly branched and disorganized, with several discontinuities. The morphological changes that accom-
pany prolonged culturing typically occur by day 8 in culture.   
After seven days in culture, aortas were retrieved from the PVEB, fixed in 10% formalin for 24 hours, 
sliced, and H&E stained (middle row of Fig. D.4). Morphological features of the stained aorta were iden-
tical to those observed in the whole aorta angiogenesis assay. The aorta that was cultured in the PVEB 
contrasted strongly with the aorta subjected to prolonged exposure to ambient conditions (room tem-
perature and low CO2 and humidity). 
 
D.5. Small Molecule and Microsphere Perfusion Experiments 
Mindful of the mass transfer characteristics (potentially mimicking that in vivo) engendered in the in-
traluminal perfusion of a vascular explant, initial steps were taken to model mass transport of small 
molecules in the PVEB. Finite element analyses of Stokes-Poiseuille and Darcy’s Law flow equations in 
section D.5.2. provide a model of bulk fluid flow in the intraluminal and abluminal spaces of the PVEB, 
respectively. Finite element analyses of Fick’s diffusion and convectional mass transport modeled small 
molecule, salute transport in the PVEB. Section D.5.3. details how fluorescent microspheres facilitated 
analysis of the transport of larger particles (0.04 µm) in the PVEB.  
 
D.5.1. Hollow Fiber Dye Rinse Out 
To quantify transport across a hollow fiber in a PVEB, the abluminal space of PVEB2 was loaded with flu-
orescein solution in PBS, and rinsed via perfusion of the hollow fiber (with 400 µL/min) with clean PBS. 
The eluent samples contained dilute amounts of fluorescein. The fluorescent intensity of eluent samples 
from the PVEB2 were initially high, but decreased toward an asymptotic (average) intensity of 12.5x103 
± 385 arbitrary units, eleven minutes after perfusion was initiated (Fig.D.6.). The initial fluorescent in-
tensity of fluorescein in the abluminal space was 142x103 arbitrary units. These data when used in equa-
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tion (1) give 6x10-8 m2s-1 as an estimate of small molecule permeability per length of hollow fiber. This 
estimate of solute permeability was utilized in the COMSOL model of small molecule transport in the 
PVEB. By the end of the rinsing experiment the intensity of the abluminal space had dropped to 134x103.  
  
Figure D.3. The PVEB mouse aorta angiogenesis assay absent flow. Aortas, housed in the PVEB without flow, produced angio-
genic outgrowth by day 6 in culture (A). Angiogenic outgrowth typically favored severed arterials but also occurred along the 
sides of the aorta. By day 8 in culture (B) the angiogenic outgrowth began to assume the more disorganized morphology shown 
in Figure D.1 (C6). Images of specimens inside the PVEB contained an oval shaped shadow that correlated with the rounded 
opening in the top of the reactor. Tubule networks sprouting from the C) sides and D) severed arterials were morphologically 
similar to those in the (Fig. D.1) aortic ring and (Fig. D.2) whole aorta angiogenesis assays. Angiogenesis extended vertically into 
different focal planes (E and F). The angiogenic outgrowth contained regions whose morphology differed from that observed in 
the mouse aortic ring and whole aorta angiogenesis assays (G and H). Angiogenesis in these regions extended from the aorta 
without traversing much into vertical axis. The tubules appeared smoother and fainter than those in the aortic ring assay. They 
are highly branched, and branch points appeared uniformly throughout the outgrowth. These branch points were typically mul-
tifurcated, unlike those in outgrowths occurring more routinely in angiogenesis assays (which were typically bifurcated).  
A.  
B.  
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D.5.2. COMSOL model of Small Molecule Transport in the PVEB 
Numerical analysis (utilizing finite element method in COMSOL) of fluid flow and solute mass transfer in 
the PVEB2 is shown in Fig D.7. The surface plots that were generated show slight transmembrane pres-
sure difference as the driving force for filtrate flow. Filtrate fluid velocities were approximately 2 nm/s, 
six orders of magnitude less than perfusate velocity (approximately 1 cm/s at the centerline). The model 
depicted nonzero tangential fluid velocity in the abluminal space along the wall of the hollow fiber.  
In computing a solution to the fluid flow model on a mesh consisting of 11984 elements, 11051 degrees 
of freedom were solved for by COMSOL 3.4., resulting in convergence standard to the COMSOL code. 
Filtrate flux across the hollow fiber wall caused perfusate fluid velocities to deviate, but no more than 5 
percent along the axis of the hollow fiber. Glucose concentration decreased nonlinearly with increasing 
distance from the hollow fiber.   
  
 
D.5.3. Perfusion of the Aorta with Microspheres 
To investigate the potential of the PVEB to independently control properties of the aorta lumen and 
abluminal space, fluorescent microspheres were loaded into the lumen of the aorta that had undergone 
angiogenic sprouting. Aortas that were cultured six days in the PVEB without intraluminal perfusion pro-
duced angiogenic outgrowth that fluoresced when the aorta lumen was filled with a 1% (w/w) solution 
of 0.04 µm diameter microspheres and incubated 36 hours. Fluorescent illumination was observed in 
the aorta, severed arborizing arterials, regions of the nascent vasculature, and regions of the abluminal 
space. The aorta was twisted during culture Fig. D.8. (A and B). While watching the aorta on the micro-
scope, microspheres were injected into the left side of the aorta. The red hue of the microsphere solu-
tion did not go beyond the twist in the aorta. Instead, it was observed in the abluminal space adjacent to 
Figure D.4. H&E staining of an aorta 
cultured six days in Matrigel (top 
row) or in the aorta bioreactor 
without flow (middle row) pro-
duced dark hemalum stains, indica-
tive of live tissue, throughout the 
aorta slice. A dead aorta (bottom 
row) is indicated as such by the lack 
of hemalum staining of the cell 
nuclei. An aorta cultured in the P-
VEB for at least six days without 
flow was fixed in the 10% buffered 
formalin and stained with H&E. This 
aorta was manually separated from 
the glass it was cultured against, so 
most of the sprouts were lost be-
fore staining. Arteries that extend 
from the aorta appear in these slic-
es. In the top row there is a small 
puncture or rupture in the elastic 
lamina (tunica media) of the aorta. 
Cells extend into this rupture and 
slightly behind.  
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the twist in the aorta. Microspheres were carefully injected into the right side of the aorta and the red 
hue of the microsphere solution reached the twist in the aorta but did not go further. 
 
D.6. Impedance Measure-
ment 
Mechanical properties of vas-
cular explants have been 
conducted on vessels main-
tained short term (up to 7 
hours)106. To investigate the 
potential of the PVEB to mon-
itor a mechanical property of 
the aorta in long-term cul-
ture, impedance to fluid flow 
imparted by the aorta was 
monitored during PVEB 
mouse aorta angiogenesis 
experiments. Manometers, 
utilized to determine imped-
ance, provided readings as 
long as they connected to the 
operating perfusion circuit 
(up to 72 hours). Two charac-
teristic curves shown in Fig. 
D.9. describe the temporal dependence of aortic impedance: 1) Impedance imparted by the aorta grad-
ually increased for 8 to 14 hours, then decreased to less than its initial volume. From there, it would con-
tinue to decrease, albeit gradually. 2) More commonly, the impedance imparted by the aorta would in-
crease gradually until it overwhelmed the manometer (i.e., the aorta produced a head in excess of two 
meters). Since the manometer was open, perfusate would get diverted out of the manometer instead of 
flowing through the PVEB.  
Hematoxylin and eosin (H&E) staining (Fig D.5.) revealed morphological and staining differences be-
tween aortas that maintained high impedance to flow and aortas that gradually decreased in imped-
ance. The medial region of aortas that maintain high impedance to flow stained violet and pink with 
dark spots scattered throughout (Fig. D.5. top row). This resembled hematoxylin and eosin staining of 
aortas cultured without flow. H&E stains of the tunica media of aortas (Fig. D.5.) which peaked then 
gradually decreased in impedance were smoother and lacked the dark spots observed in stains of aortas 
cultured without flow.   
Figure D.5. H&E staining of two aortas cultured four days in the PVEB with flow (top 
two rows) and of a dead aorta (bottom row). The hydraulic empedence of the aortas 
was monitored while culturing. Different hydraulic impendance curves were observed 
for the top two aortas (Fig.D.9). The dead aorta and one of the perfused aortas lack 
hemalum staining of the cell nuclei. The aortas were manually separated from the 
glass they were cultured against, so most of the sprouts were lost before staining. 
Arteries that extend from the aorta appear in these slices.  
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Figure D.7. Model of fluid flow and solute mass transfer in the PVEB2 with one hollow fiber (B,C and D) and two hollow fibers 
(E, F and G) computed using finite element method in COMSOL 3.4. Surface plots of pressure (B and E) distribution describe the 
abluminal space as slightly less pressurized than the lumen of the hollow fiber (for the half of the hollow fiber proximal to the 
inlet). In the half of the hollow fiber close to the outlet, abluminal space is slightly more pressurized. The pressure difference 
along the length of the hollow fiber was 2.3 Pa in the PVEB with one hollow fiber. Surface and vector field plots (C and F) de-
scribe a fluid velocity in the abluminal space as uniform and less than 2 nm/s. In contrast the centerline fluid velocity in the 
hollow fiber was several orders of magnitude larger (approximately 1 cm/s). The model depicted nonzero tangential fluid veloc-
ity in the abluminal space along the wall of the hollow fiber. The two hollow fiber PVEB2 with countercurrent flow created a 
dead zone (i.e. lacking fluid flow) in the center of the abluminal space of the reactor. Glucose availability (D and G) decreased 
with increasing distance from its source, the hollow fiber. In computing the flow regime, 11051 degrees of freedom were solved 
for by COMSOL 3.4. 
Figure D.6. The fluorescent intensity of elu-
ent samples from the perfused hollow fiber 
(with 400 µL/min of clean PBS) of the PVEB2 
were initially high, but decreased toward an 
asymptotic (average)intensity of 12.5x10
3
 ± 
385 arbitrary units, eleven minutes after 
perfusion was initiated. The fluorescent in-
tensity of fluorescein in the abluminal space 
was 142x10
3
 arbitrary units.  With these 
data, Equation (1) gives 6x10
-8
m
2
s
-1
 as an 
estimate of small molecule permeability per 
length of hollow fiber.  
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Figure D.8. Aortas that were cultured six days in the PVEB without intraluminal perfusion produced angiogenic outgrowth that 
fluoresced when the aorta lumen was loaded with a 1% (w/w) solution of 0.04µm diameter microspheres incubated 36hours. 
Fluorescent illumination in the TRITC emission band pass of wavelengths (590 to 650 nm) was observed A) in the aorta, severed 
arborizing arterials (indicated by arrows in B)), regions of the nascent vasculature, and regions of the abluminal space. Micro-
spheres were loaded via syringe into both ends of the aorta, while monitoring the aorta on a microscope (10x objective). The 
arrows in A) indicate the direction of fluid flow that occurred during injection of the microspheres. Microspheres exuded into 
the abluminal space where the aorta was obstructed by a twist. Regions of the aorta (severed arterials and angiogenic out-
growth) with catheter subjacent did not fluoresce. The fluorescence in the angiogenic outgrowth followed the morphological 
patterns of vascular sprouts (C and D). Fluorescent images of the vascular sprouts followed the same pattern as those in the 
phase contrast images or, they formed smaller patterns which fit inside the patterns of the vascular sprouts in the phase con-
trast images. E) Vascular sprouts along the edge of the aorta fluoresced less often than sprouts near the severed arteries. F) If 
too much pressure is applied to the syringe when injecting microspheres into the aorta lumen, microspheres would be pushed 
out of the aorta and damage the vascular sprouts. Aortas not exposed to the fluorescent microspheres did not fluoresce.  
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Figure D.9. Two characteristic curves of the temporal dependence of impedance to fluid flow imparted by the aorta. A) Imped-
ance imparted by the aorta gradually increased for 11 hours, then decreased to less than its initial value followed by a gradual 
decrease from there. B) The impedance imparted by the aorta climbed gradually beyond the range of the manometer. Since the 
manometer was open, perfusate would get diverted out of the manometer instead of flowing through the PVEB.  
 
D.7. Angiogenic Outgrowth from a Perfused Mouse Aorta 
Aortas cultured inside the PVEB with 50 µL/min intraluminal perfusion of EGM-2 produced angiogenic 
outgrowths. These outgrowths resembled those grown in the whole aorta angiogenesis assay. Tubular 
networks were largely similar to those observed in the whole aorta angiogenesis assay, and they were 
highly branched with bifurcating branch points appearing uniformly throughout the outgrowth. A differ-
ent morphology, identical to that discussed in section D.4.1., was observed in some regions of the angi-
ogenic outgrowths. Although variation in the extent and rate of angiogenesis was observed, the PVEB 
mouse aorta angiogenesis assay with flow produced angiogenic outgrowth typically by day 6 in culture 
with initial sprouting occurring by day 4 from severed arterials. Angiogenic sprouting seemed to prefer 
the severed arterials over the sides and ends of the aorta. If the lumen of the aorta is not flushed prior 
to culturing, extant blood cells, platelets and debris would exude through severed arterials or other 
holes in the aorta wall into the abluminal space.  
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Figure D.10. Angiogenic outgrowth from a perfused aorta. A) The mouse aorta was cultured for six days while also perfusing the 
aorta lumen with 50 µL/min of EGM-2. The arrow indicates the direction of flow. Regions of the angiogenic outgrowth (B 
through H) were similar to that in the PVEB mouse aorta assay without flow. Angiogenesis in the PVEB with flow seemed to 
favor the severed arborizing arterials (B through E), although angiogenesis occurred along the sides of the aorta as well. The 
angiogenic outgrowth in the PVEB with flow contained regions (I and J) whose morphology differed from that in the aortic ring 
assay, and bore similarities to that shown in Fig. D.4. (G and H).  
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CHAPTER V 
 
DISCUSSION 
 
 
Interest in angiogenesis is growing as researchers realize its impact on several diseases. The picture of 
angiogenesis is incomplete, however, and although angiogenesis studies have produced useful insights 
for understanding and treating disease, they suffer from limitations in the current armamentarium of 
angiogenesis assays. In general, in vitro angiogenesis assays permit detailed study of a biological process 
that poorly represents physiological angiogenesis, while in vivo angiogenesis assays limit access to the 
variables that influence angiogenesis. This trend is more pronounced in studies of the interaction be-
tween angiogenesis and hemodynamic stimuli. This study sought to address limitations of current in 
vitro and in vivo angiogenesis assays by designing and implementing a device that incorporates into the 
vascular explant assay measurement and actuation of mechanical and chemical stimuli (engendered in 
blood flow). The perfused vascular explant bioreactor (PVEB) permitted long-term culture of and facili-
tated angiogenic outgrowth from a perfused vascular explant in vitro. Results of this study support the 
hypothesis that the PVEB will facilitate angiogenic outgrowth from a vascular explant whose lumen is 
accessible to perfusion, and that this enhancement will allow measurement and actuation of mechanical 
and chemical stimuli (those accompanying blood flow) in a vascular explant angiogenic culture. This en-
hancement to the body of angiogenesis assays will allow researchers to uncover more of the angiogenic 
process, and insights gained from the use of the PVEB may inform the development of future disease 
treatments. In the following sections, I describe and interpret the results of the study, state the signifi-
cance of the findings, and propose future improvements to and applications of this technology. 
 
E.1. Interpretation of the results 
 
E.1.1. Long-Term Viable Culture of Perfused or Perfusable Aorta In Vitro 
Hematoxylin and eosin staining of the whole aorta that possessed angiogenic sprouting produced dark 
spots indicative of stained intact nuclei. This is typical of live tissues. Hematoxylin, when in complex with 
iron (III) or aluminum (III) ions, produces a dark colored stain. The hematoxylin-metal complex stains the 
nucleus by binding to arginine-rich nucleoproteins such as histones123. Fragmentation of the chromoso-
mal materials, via apoptosis or necrosis, causes a lack of hematoxylin staining. Eosin, an acidic pink stain, 
stains the cell contents. Dark dots present in the hematoxylin and eosin stains of the aorta indicated the 
presence of intact nuclei (a marker of live cells). Hematoxylin and eosin staining of aortas that were cul-
tured without perfusion for six days and aortas that were cultured with perfusion for four days had the 
same morphology and dark staining dots (Fig. D.4. and D.7.). In contrast, aortas that were intentionally 
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killed via prolonged exposure to ambient temperature and CO2 levels lacked the dark dots. Hematoxylin 
and eosin staining of aortas cultured in this study suggests that the PVEB can maintain long-term viabil-
ity of a perfused and perfusable aorta in in vitro culture. An uncertainty inherent in hematoxylin and eo-
sin stains is that hematoxylin will stain other arginine-rich content in the cell, thereby generating false 
positives.  
The aorta and large arteries are supported by a layer of elastin fibers in the tunica media called the elas-
tic lamina. Hematoxylin and eosin stains of the elastic lamina in the aorta feature layers of wavy, ribbon-
like structures that stain pink124. Interestingly, the wavy, ribbon-like morphology of the elastic lamina 
was largely absent in hematoxylin and eosin stains of dead aortas. The smooth muscle cells that line the 
aorta contain a resting (i.e., in the absence of tensional load on the wall) vascular tone. I suspect that 
this resting contractile force in the smooth muscle causes it to contract the elastic lamina into bundles 
or ribbon-like structures. The dead aorta has lost this capability and the elastic lamina unfolds as the 
aorta takes on a passive cylindrical shape.  
The elastic lamina of aortas cultured in the presence of perfusion appeared less ribbon-like than that of 
aortas cultured in the absence of perfusion. If the wavy morphology of the elastic lamina correlates with 
smooth muscle cell activity, then this would imply that perfusion of the lumen of the aorta in the PVEB 
had a deleterious effect on aortic smooth muscle cell function or vessel viability. Some procedural un-
certainties that may have contributed to this result are inaccuracies of the temperature in the reactor 
and perfusate. Perfused aortas were cultured in the Bioscience Tools miniature incubator. The incubator 
presented spatial variations ranging from 34-37 degrees. The perfusate temperature was not measured, 
but circulated from a media reservoir which rested on top of a 37°C heating element, then down a 3–
feet-long room-temperature path to the incubator and 4 times around the heating element within the 
incubator (Fig. C.4.). In contrast, the non-perfused aortas were cultured in conventional tissue culture 
incubators which maintain 37°C throughout. I speculate that the temperature of the Bioscience Tools 
incubator (and concomitantly, the PVEB) and/or perfusate drifted out or the livable range for mammali-
an tissues.  
 
E.1.2. Angiogenic Outgrowth from a Perfused or Perfusable Aorta In Vitro. 
Aortic ring assays conducted in this study produced proliferative outgrowths that were similar in mor-
phology to that reported by Nicosia et al. as angiogenic outgrowth in the aortic ring assay121, 125. Nicosia 
(who pioneered much of the development of the aortic ring assay) described various morphological fea-
tures that distinguish angiogenesis from the proliferative outgrowth of fibroblast resident in the aorta 
(e.g., the bifurcating branch points). These heuristics suggest that the outgrowths observed in this study 
were angiogenic.  
Sato et al. engineered a Tie-2::GFP mouse that uniformly fluoresces throughout the vasculature126. This 
mouse expresses green fluorescent protein (GFP) under the direction of the endothelial specific receptor 
tyrosine kinase Tie-2 promoter. The Tie-2 promoter is active principally in proliferating vascular endo-
thelial cells and, to a lesser extent, quiescent endothelial cells. Aortas from this mouse produced (in the 
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aortic ring assay) fluorescent outgrowths that were morphologically similar to those in other aortic ring 
assays. Since Tie-2 is expressed principally in the vascular endothelium, this experiment identifies the 
outgrowth as endothelial and distinguishes it from expansion and tube formation by resident non-
fluorescent fibroblasts in the PVEB127. The morphology and fluorescent illumination of angiogenic 
sprouts shown in Fig. D.1. demonstrates angiogenesis in the aortic ring assay. Figures D.2, D.3, D.5, and 
D.10 depict outgrowth from catheterized whole aortas, and aortas cultured in the PVEB with or without 
intraluminal perfusion. These outgrowths contained regions that are morphologically similar to the an-
giogenic outgrowth that occurred in the aortic ring assay. These data suggest that angiogenesis occurred 
in the PVEB and support the hypothesis that the PVEB will facilitate angiogenic outgrowth from a vascu-
lar explant whose lumen is accessible to perfusion.  
Fluorescent illumination varied throughout the angiogenic outgrowth. This may result from spatial varia-
tions in nutrient oxygen availabilities. For example, Tie-2 mRNA expression declines in hypoxia (in rat 
lung, liver, cerebellum, and heart microvasculature)128. Fainter fluorescence may also have occurred in 
vessels that were smaller (i.e., producing less of a signal). The quiescent cells of the endothelium fluo-
resced as much if not more than the angiogenic sprouts; however, Tie-2 is down-regulated in quiescent 
endothelial cells (i.e., those lining the aorta wall). This is explained by Thomas Sato and colleagues, who 
noted that the non-proliferating cells that line the aorta permit slow accumulation of Tie-2 (and GFP), 
whereas proliferating cells thin their Tie-2 or GFP content with every division127. When using Tie-2::GFP 
mice to identify angiogenesis one should consider that Tie-2 expression also characterizes a sub-
population of CD11b+ myeloid tumor-infiltrating cells called Tie-2 expressing monocytes (TEMs)130. These 
cells form in the bone marrow and circulate in the peripheral blood. As monocytes, TEMs can localize in 
the endothelium or extravascular tissue; therefore, TEMs conceivably may be in the vascular explant. 
However, TEMs are incapable of forming the tubule networks depicted in the aortic ring assay. 
Proliferative outgrowths from aortas cultured in the PVEB were, in general, morphologically similar to 
angiogenic outgrowths that were identified as angiogenesis in the aortic ring assay. Nicosia et al. distin-
guished vascular endothelial cells from fibroblasts by their greater thickness and more cohesive tubule 
networks and their bifurcating branch points125. An alternate morphology, shown in Fig. D.3. (G and H), 
that lacked these characteristics was observed in the PVEB. I speculate that these were fibroblasts. The 
morphologically was similar to that which was identified, by other labs, as fibroblasts in the aortic ring 
assay130. The outgrowth bearing this morphology stayed within a thin layer on the z-axis, presumably on 
the glass underpinning the reactor. In angiogenesis, fibroblasts migrate away from the aorta before the 
endothelial cells130. I speculate that regions of aorta that were pressed against the glass made cellular 
movement along the glass more probable, and that fibroblasts were more capable of outward migration 
than were the trailing endothelial cells. This may have given rise to the regions bearing the alternate 
morphology. The alternate morphology was not observed in aortas cultured on polystyrene culturing 
dishes.  
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The PVEB facilitated the growth of functional angiogenic sprouts.  
To identify functional nascent vessels in the PVEB mouse aorta assay, fluorescent microspheres were 
loaded into the lumen of the aorta. As a result, the aorta lumen, severed arterials, and parts of the angi-
ogenic outgrowth fluoresced (under the TRITC band pass). There was clear contrast between the fluo-
rescence in the vasculature and in the adjacent Matrigel. Clusters of microspheres that had escaped into 
the abluminal space appeared randomly distributed and cast a generally diffuse fluorescence haze. The 
fluorescence in the abluminal space was not as bright as that in the aorta and in the angiogenic out-
growth. The fluorescence of aortas not exposed to the fluorescent microspheres was very low and indis-
tinguishable from that of the background or abluminal space. These data suggest that microspheres 
were inside the nascent vasculature. If so, these microspheres arrived at their position via a contiguous 
network of angiogenic sprouts that were accessible to the lumen of the aorta (i.e., the vasculature was 
patent). Patent vascular sprouts were observed predominantly in the proximity of severed arterials. An-
giogenic outgrowth along the side of the aorta and outgrowths bearing the alternate morphology (Fig. 
D.3. (G and H)) did not fluoresce when the aorta was loaded with microspheres.  
The sharp contrast in fluorescence between the angiogenic outgrowth and the adjacent Matrigel in this 
experiment suggests that the angiogenic outgrowth was not leaky to particles greater than 0.04 µm. This 
agrees with literature which states that most healthy vessels in the body contain 10 nm pores between 
the endothelial cells that line the vasculature21. Davis et al. review the formation of patent endothelial 
tubes in in vitro 3D assays131. Tubule formation of endothelial cells occurs in a 3D extracellular matrix 
and minimal media supplemented with fetal bovine serum and angiogenic growth factors. The aortic 
ring features these, as well as fibroblasts, monocytes, and pericytes which enhance the formation and 
stabilization of vascular tubes131. I was initially uncertain whether angiogenic outgrowth from the cathe-
terized aorta would have connections to the lumen of the aorta, and whether those connections would 
be identifiable using these microspheres. Endothelial cells in a confluent layer plated on a thick layer of 
collagen will migrate into the collagen, forming hollow tubes that maintain a patent connection with the 
collagen surface. It is conceivable that a similar patent connection is maintained between the migrat-
ing/tube-forming endothelial cells and the intimal wall of the aorta. It is accepted that in the aortic ring 
assay angiogenesis occurs at the ends of the aortic segment, where endothelial cells in the tunica intima 
have access to the abluminal space73. However, if nascent tubes grow from the ends or from severed 
arterials, there is the possibility that microspheres would diffuse out of the aorta without entering the 
angiogenic sprouts. This did not occur. Fluorescent illumination of severed arterial sprouts abruptly 
stopped at the ends of the arterials. I speculate that the constriction of the arterial lumen and the sur-
rounding Matrigel plugged the end of the arterial, thereby impeding flow of the microspheres into the 
abluminal space from the severed arterial. Non-patent vasculature was also observed, and I speculate 
that it arose from endothelial cells resident in extant fibroadipose tissue on the outside of the aorta.  
As shown in Figure D.8 (C and D), endothelial sprouts formed spokes around a circular cell. This circular 
cell did not fluoresce. I speculate that this was a monocyte that positions itself at the end of two vascu-
lar sprouts and when subjected to blood flow causes the vascular sprouts to form an anastomotic con-
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nection. That microspheres did not occur in that region suggests that the anastomosis did not occur. In 
this experiment, the aorta was cultured in the absence of flow.  
Skill was required to inject microspheres into the lumen of the aorta without damaging (via pressuriza-
tion) the angiogenic sprouts. Fluid that entered the abluminal space as a result of mechanical rupture of 
the vessels formed a blob of fluorescent microspheres that did not diffuse into the surrounding Matrigel 
(Fig. D.8. (E)). The intense fluorescence of the microspheres that escaped, via this mechanism, into the 
abluminal space obscured the fluorescence of the angiogenic sprouts.  
 
Angiogenesis varies in rate and extent 
After six days in culture, aortas typically produced continuous angiogenic outgrowths with several bifur-
cating branch points. Some aortas will have by day 6 begun to display a spatially disorganized out-
growth. This disorganization is vessel regression and apoptosis, which occur with prolonged culturing in 
the absence or depletion of pro-angiogenic signals121. Larger slices of aorta tended to regress before 
small slices (from the same mouse). I speculate that the larger slices more rapidly depleted the pro-
angiogenic signals from the culture. Variability in the rate and extent of angiogenesis is a documented 
limitation of the vascular explant assay. The extent of angiogenesis was quantitated in this study; how-
ever, notable variability was observed in the angiogenic outgrowths grown in the PVEB. The mice uti-
lized in this study were largely “trash” mice with unknown genetic back ground. This genetic variability 
may have translated to observed variability in the extent of angiogenesis. Though variable, the extent of 
angiogenesis (by day 6 in culture) tended to be greater in the aortic ring assay than in the PVEB. Aortas 
cultured in the PVEB without intraluminal perfusion tended to produce more angiogenic outgrowth than 
aortas cultured with intraluminal perfusion. This trend may be the result of the increased preparatory 
time for the PVEB mouse aorta assay. It takes roughly forty minutes to load the explant and load the 
aorta into the PVEB. During this time, exposure to subphysiological temperature and CO2 pressure de-
creases the angiogenic potential of endothelial cells in the aorta132. Catheterization blocks the main es-
cape route for endothelial cells in the aortic ring assay (i.e., the ends). Endothelial cells can also escape 
through the severed arborizing arterials and punctures/tears in the aorta wall, but it is expected that the 
wall of the aorta is a barrier to endothelial cells undergoing angiogenesis. 
Angiogenesis in the PVEB occurred along the sides of the aorta and from severed arborizing arterials. In 
many experiments, angiogenesis appeared more frequent near severed arterials, although quantitation 
of this effect was not conducted. The severed ends of vascular explants provide an escape route from 
the tunica intima for migrating endothelial cells. I speculate that in the PVEB, angiogenesis occurs from 
severed arterials because the severed arterials provide intimal endothelial cells an escape route into the 
abluminal space. Angiogenesis occurs along the side of the aorta as well. This may result from microvas-
culature in extant fibroadipose tissue or from holes/tears in the aorta incurred during explantation. Both 
of these phenomena would place endothelial cells in contact with the abluminal space.  
In regions near the suture knot (Fig. D.2.), angiogenesis was sparse or not present; however experiments 
(Fig. D.3) in which suture thread was not used produced angiogenic outgrowths in the regions of the 
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aorta that had underlying catheters, suggesting that silk threads have a role in the inhibition of angio-
genesis. I speculate that the sutures compressed the aorta and prevented adequate growth factor, nu-
trient and oxygen exchange, thereby compromising the angiogenic potential and the viability of the tis-
sue. Another explanation for the decrease in angiogenesis near the silk thread knot is the higher concen-
tration of salts and the of presence residual sterilizing solvents in the thread. Ethicon thread alone is bi-
oinert. Prior to experimentation, silk thread is sterilized in ethanol then stored in PBS until use. Ethanol 
desorption from the thread is limited by the solubility of ethanol in the thread. Ethanol retained in the 
thread (particularly shortly after sterilization) does not dissolve the salts in PBS, and can precipitate salts 
from the PBS and cause salt crystals to be deposited on the suture thread133. Once on the aorta, this su-
ture thread serves as a potentially toxic source of ethanol and excess salt. To alleviate this concern, one 
might consider sterilizing the suturing thread via autoclaving. 
 
Less angiogenic outgrowth was observed from aortas subjected to intraluminal perfusion. 
Angiogenic outgrowth appeared to occur to a lesser extent from aortas that were subjected to flow than 
aortas that were left static. Quantification of the angiogenic outgrowth should be carried out in order to 
determine if there is a statistical difference in the rate and/or extent of angiogenic outgrowth from the 
aorta when perfused versus the static aorta. Intraluminal perfusion generates mechanical stimuli (shear 
stress, pressurization or compression, and transmural pressure differences which distend the vessel). 
Chemical stimuli that are direct consequences of flow include transendothelial concentration differences 
and standing gradients of concentration in the interstitium. The mechanical and chemical stimuli engen-
dered in blood flow have an impact on angiogenesis; however, their effect is undercharacterized. A gen-
eral consensus regarding the impact of flow on angiogenesis has yet to be reached. The activation or 
inhibition of angiogenesis in response to shear stress, for example, depends on the magnitude and tem-
poral pattern of the shear stress. High shear stress, in excess of 15 dyne/cm2, induces quiescence, 
whereas low or oscillating wall shear stresses are typically identified in arteriogenesis134. Endothelial cell 
(and/or vasculature) behavior in the presence of the mechanical stimuli is also context-dependent: in 
vivo, increases in fluid flow via injection of prazosin caused increased angiogenic ingrowth in the rabbit 
ear chamber135. In contrast, in vitro studies of the effect of shear stress on angiogenes yielded varying 
results that depended on the source (along the vascular tree) of the endothelial cells and extracellular 
matrix used. Tressel et al. report an inhibitory effect of shear stress on HUVEC tubulogenesis in Matrigel, 
whereas shear stress enhanced HUVEC mediated angiogenesis in collagen136, 137. The impact of shear 
stress on angiogenesis in the presence of pericytes, smooth muscle cells, fibroblasts and monocytes 
(cells present in the vascular explant assay) has not been researched in depth. In vitro, endothelial cell 
monolayer cultured on collagen that was loaded with smooth muscle cells showed reduced proliferation 
in the presence of shear stress138. I suspect that unique circumstances provided by an intact perfused 
aorta in vitro caused the somewhat unexpected reduction of angiogenesis in the presence of flow. 
Chemical factors engendered in the perfusion may have also contributed. For instance, VEGF, though 
pro-angiogenic, has been shown to maintain endothelial cell quiescence when presented as an auto-
crine signal to endothelial cells subjected to blood flow4.  
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Hydraulic impedance measurements conducted on the perfused aorta revealed that the aorta strongly 
impeded fluid flow and generated a backpressure in excess of 150 mmHg (Section D.7.). The backpres-
sure generated by the aorta exceeds mean arterial blood pressure for normotensive mice. I speculate 
that perfusion of the aorta and/or the aorta’s response to perfusion created an in vitro condition that 
mimics aspects of hypertension. A principal observation in hypertensive animal models and patients is 
rarefarction (i.e., decreased amount of capillaries). The cause of hypertensive rarefarction is unclear. 
Insufficient stimulation of angiogenesis overtime possibly generates capillary rarefarction and hyperten-
sion139. The response of arterioles to hypertension causes downstream capillaries to collapse and over 
time to regress139. Hypertension generates pro- and anti-angiogenic signals139. These signals are not en-
tirely recapitulated in the PVEB. For instance, endocrine signaling pathways which modulate angiogene-
sis, e.g., the renin-angiotension pathway, were absent from the PVEB139. An explanation for the per-
ceived decrease in angiogenesis that resulted from intraluminal perfusion of the aorta is that hyperten-
sion-responsive signals extant in the PVEB had an overall anti-angiogenic effect.  
 
E.1.3. Actuation and Measurement of the Mechanical Stimuli In the PVEB  
Mechanical stimulation of the aorta in long-term in vitro culture was accomplished via intraluminal per-
fusion. The peristaltic pump that delivered media to the PVEB was calibrated prior to use, and therefore 
the volumetric flow rate of perfusate entering the aorta was not monitored. A mechanical response of 
the aorta to perfusion (i.e., hydraulic impedance to fluid flow) was monitored long-term (>20 hours). 
Manometers were placed upstream and downstream of the device, thereby providing a measurement 
of axial pressure difference across the aorta for a particular flow rate. This is proof of principle that a 
mechanical stimulus can be incorporated into the vascular explant assays using the PVEB. 
Perfusion of the aorta with 50 – 100 µL of complete EBM-2 media resulted in two characteristic hydrau-
lic impedance curves (Fig. D.9.) : 1) The hydraulic impedance imparted by the aorta would gradually in-
crease until, at 4 to 16 hours in culture, it generated a backpressure that overwhelmed the upstream 
manometer (i.e., in excess of 150 mmHg); 2) the hydraulic impedance imparted by the aorta would in-
crease, decrease to less than its initial value, then continue to decrease from there. Hematoxylin and 
eosin stains (Fig. D.5.) of an aorta that maintained high hydraulic impedance contained dark hematoxylin 
stained dots characteristic of live tissue. In contrast, hematoxylin and eosin stains of aortas whose im-
pedance decreased to less than its initial value lacked the dark hemalum stains characteristic of live 
cells. This suggests that the characteristic hydraulic impedance curves correlate with the state (live or 
dead) of the aorta. A dead aorta (i.e., incapable of active force generation) would behave like a passively 
deformable viscoelastic tube. The elastic properties of the aorta would cause it to distend until the 
transmural pressure difference is balanced by the tension generated in the stretched aorta walls. The 
aorta would continue to distend via viscoelastic creep. Hydraulic impedance would decrease with in-
creasing radius of the distended aorta.  
Hydraulic impedance is dependent on the geometric features of the aorta. These include bends, tapers 
and forks in the aorta, but the most important influence on the hydraulic impedance of the aorta is its 
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radius. The impedance of a vessel is roughly inversely proportional to the fourth power of its radius. The 
aorta is the major conduit for systemic blood flow. Connected directly to the heart, it experiences pulsa-
tile shear and pressurization in vivo. In response, the aorta largely passively distends and recoils in order 
to maintain throughout the cardiac cycle a constant flow to downstream arteries and arterioles. Princi-
pal function of the aorta does not require or give rise to active dilation or constriction, and the aorta 
typically has a low hydraulic impedance. In contrast, the aorta (i.e., a live aorta) cultured in the PVEB 
generated a backpressure in excess of 150 mmHg (more than the mean arterial blood pressure for the 
mouse, 80mmHg)140. Vasodilation and vasoconstriction are important to maintaining mean arterial 
blood pressure and adequate blood flow to the target organs. It is carried out by resistance arteries (or 
arterioles). However, the aorta retains some measure of constriction and/or dilation potential. In vivo, 
the aorta has demonstrated contractile capabilities. In vitro, the aorta has demonstrated vasocon-
striction in response to endothelin-1, a vasoactive protein secreted by the endothelium in response to 
shear stress, adrenaline, hypoxia and ischemia141. Endothelin-1 signals to the ETA receptor on smooth 
muscle cells, affecting vasoconstriction. Vasodilation of the mouse aorta in vitro in response to shear 
stress and other dilatory factors was demonstrated as well142. Shear stress can trigger both dilation and 
constriction of the aorta in vitro. I speculate that the vasoactive response of the aorta to shear stress 
depends in part on the magnitude of the shear stress. Jen et al. induced vasodilation of the aorta using 
physiological values for thoracic aortic shear stress (50dyne/cm2)142. Since the PVEB was designed to 
study angiogenesis (a phenomenon located in the microvasculature), we used a flow rate that would 
achieve a shear stress that was comparable to that in the post capillary venules (i.e. orders of magnitude 
lower at app. 1 dyne/cm2). I speculate that the low shear stress of the PVEB aorta angiogenesis culture 
induced the vasoconstrictive response and not a vasodilation response. Alternate explanations for the 
aorta constriction which generated the observed high impedance exist. The constriction may also be a 
myogenic response of the aorta to stretching of the aorta wall by the catheter inserts. Extant platelets in 
the aorta may generate hemostatic vasoconstrictive response to vessel injury incurred during dissection. 
As modeled in Fig. D.7., perfusate leaves the aorta and re-enters it near the exit of the PVEB. The aorta is 
malleable, and it is conceivable that the momentum or driving force of fluid reentering the downstream 
end of the aorta could cause it to collapse, thereby occluding axial flow.  
The PVEB offers actuation and measurement of spatially averaged mechanical properties. Figure D.7. 
demonstrates that local shear forces can be predicted using a mathematical model of the PVEB, if the 
perfused vessel (or hollow fiber) has a defined rigid shape and the porosity of the vessel and the matrix 
material in the abluminal space are precisely known. However, the thoracic aorta has an unpredictable, 
deforming, and non-uniform geometry. The movement of fluid into and out of the aorta via severed ar-
terials and other holes in the aorta impairs precise control of local shear stress, transmural pressure dif-
ference, and pressure experienced by the aorta. This suggests that the PVEB can actuate a spatially av-
eraged mechanical stimulus (i.e., perfusate flow rate into the PVEB) but lacks, in its current implementa-
tion, spatial control of the mechanical stimuli engendered in perfusion. In response to fluid flow, shear 
stress, and transmural pressure difference, arteries (e.g., the aorta) modulate their hydraulic imped-
ance, thereby protecting downstream arterioles and capillaries. Impedance is a spatially averaged prop-
erty arising from spatially varying properties of contour and the inner diameter of the aorta.  
   
78 
 
E.1.4. Solute and Particulate Mass Transport in the PVEB  
Nutrient and oxygen concentrations in the interstitium form spatial patterns that are a direct conse-
quence of blood flow to nearby capillaries. The spatial presentation of oxygen, nutrients, and growth 
factors is a chemical stimulus engendered in blood flow. A mathematical model of the mass transfer of a 
small molecule test substance (e.g., glucose) from a leaky tube (hollow fiber), as in Fig. D.7., suggests 
that in the cases where the diffusion, convection, and consumption of a test substance follow known 
formulas or values, the spatial distribution of the test substance can be controlled by controlling the 
concentration of the perfusate. Concentration differences between the abluminal space and hollow fi-
ber lumen resulted in silico in neatly patterned gradients of concentration. Since the aorta has non-
uniform, unpredictable, and time-varying (when perfused) geometry, and mass transfer across the wall 
or out of the aorta through holes is not uniform, gradients in the concentration of a test substance can-
not be defined as suggested in Fig. D.9. However, the PVEB may be capable of defining a concentration 
difference of a macromolecule or microparticle between the lumen and abluminal space in the PVEB. 
 
Mathematic model of small molecule diffusive mass transport in the PVEB 
In the mathematical model of small molecule diffusive mass transport in the PVEB, the hollow fiber was 
selected as the model of the vascular explant. Small molecule permeability of the hollow fiber mem-
brane was measured to be 6x10-8 m/s. This is consistent with measurements of other hollow fibers or 
porous membranes (10-8 – 10-10)143. In this measurement dilute solutions were used and therefore os-
motic pressure differences were neglected. This measurement was obtained by perfusing the hollow 
fiber lumen, and convective transport of the fluorescein across the hollow fiber membrane presumably 
occurred as perfusion pressurized regions of the hollow fiber. Convective mass transport across the hol-
low fiber would have inflated our measurement of small molecule diffusive permeability, and a more 
rigorous measurement would be required in applications requiring high accuracy. Ultimately, this per-
meability term was not incorporated into the mathematical model of mass transport in the PVEB. A 
measure of the hydraulic permeability of the hollow fiber is also needed in order to sufficiently model 
the hollow fiber’s impact on mass transport in the PVEB2. However, if the hollow fiber walls were thin 
relative to the geometry of the PVEB, and the hydraulic and diffusive permeabilities of the extracellular 
matrix material that fills the abluminal space were less than or equal to those of the hollow fiber, then 
one might justify neglecting the hollow fiber’s impact on mass transport in the PVEB. Klein et al. report 
the hydraulic permeability of commercially available hollow fibers as 8.5-4.2x10-7m/atm-s143. In compari-
son, the hydraulic permeability (LP) of collagen (which was used in the mathematical model) was com-
puted by the following equation to be 1.3x10-7m2/atm-s; K is Darcy’s Law Coefficient for water in colla-
gen and the viscosity of water144 
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The similar values of permeability between the hollow fiber and the surrounding extracellular matrix 
material suggest that the hollow fiber can be neglected without a severe impact on the accuracy of the 
mathematical model.  
The mathematical model of mass transport in the PVEB predicted that fluid would flow through the ma-
trix material in the abluminal space of the PVEB at roughly eight orders of magnitude slower than along 
the lumen of the lumen of the hollow fiber. Nutrient availability decreased gradually with increasing dis-
tance from the hollow fiber, in ways similar to the theorized Krogh cylinder of nutrients that surrounds a 
capillary tube120. The model predicts a nearly constant solute concentration in the lumen of the hollow 
fiber. The spatial patterns of fluid flow and nutrient availability predicted by the model did not accurate-
ly reflect mass and solute transfer in the PVEB with an aorta. Perfusing the aorta with fluorescent dyes 
or microspheres would cause non-uniform fluorescent illumination of the abluminal space. It appeared 
that the fluorescent materials would exit the aorta near the ends of the aorta and at severed arterials. 
Fluid flow in the abluminal space seemed to stem from severed arterials. The ability of the mathematical 
model of mass transport in the PVEB as computed using COMSOL to predict bulk fluid and small mole-
cule transport patterns relied on the regular geometry of the hollow fiber and the spatially uniform, or 
determined, permeability of the abluminal space. The irregular geometry and the heterogeneous barrier 
the aorta presents, and the spatial and temporal variations in the permeability of the Matrigel in the 
abluminal space, cannot be adequately predicted using the model.  
Mass transport of fluid flow in the abluminal space in the PVEB (with the aorta) is influenced by spatial 
and temporal variations in the permeability of the Matrigel. This problem exists in other three-
dimensional angiogenesis assays which incorporate mechanical stimuli (e.g., shear stress, hydrostatic 
pressure) and utilize matrix materials to facilitate angiogenic migration and tube formation steps. For 
instance, matrix metalloproteases (MMPs) which become active in cell migration in angiogenesis locally 
degrade the surrounding matrix. Fibroblasts synthesize matrix material substrates to provide traction to 
migrating cells. These processes alter the permeability of the matrix in unpredictable ways, and pose an 
obstacle to future models of mass and solute transport in the PVEB and other three-dimensional angio-
genesis assays. Imaging techniques that allow precise characterization of blood vessel geometries exist 
and have been utilized in mathematical models of blood vessel properties. These techniques may be 
applicable to future studies that utilize the PVEB.  
 
E.2. Significance 
This study details the long-term maintenance of and angiogenic outgrowth from a perfused or perfusible 
vascular explant in vitro. This enhancement to the conventional vascular explant assay expands the ca-
pabilities of the current armamentarium of angiogenesis assays. With this technology, researchers may 
discover new properties of and mechanisms of angiogenesis. Insights gained from studies that utilize the 
PVEB may prove necessary to the treatment of several diseases, including cancer, heart disease, and 
ischemia (i.e., leading causes of death in the United States).  
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The study of angiogenesis and diseases associated with pathological angiogenesis is slowed by the limi-
tations of the currently available assays. In vitro angiogenesis assays allow detailed study of a biological 
process that does not fully recapitulate angiogenesis in vivo. In contrast, in vivo models of angiogenesis 
limit access to several mechanisms and variables that drive angiogenesis. The vascular explant assay is 
considered the best in vitro mimic of in vivo angiogenesis. It provides near-physiological spatial organiza-
tion of cells and allows recapitulation of several of the paracrine and juxtacrine signals that direct angio-
genesis. The vascular explant assay facilitates more “steps” of angiogenesis and generates vascular 
sprouts that are functionally similar to those in vivo. The angiogenesis in the PVEB produces vasculature 
that is morphologically identical to that in the vascular explant assay. This suggests that the physiologi-
cally relevant features of the aortic ring assay were retained in the PVEB. If this is the case, then the ad-
dition of flow potentially makes this PVEB an even better in vitro mimic of in vivo angiogenesis. In vitro 
qualities of the vascular explant assay (e.g., time-lapsed imaging, precise control and measurement of 
angiogenic stimuli, absence of confounding inflammatory responses) are maintained in the PVEB.  
The connection between hemodynamic factors and angiogenesis is known54-56, 146 . Changes in hemody-
namic factors have been implicated in several diseases that stem from pathological angiogenesis (e.g., 
cancer, hypertension, and inflammatory pathologies). However, the details of the interactions between 
hemodynamic factors and angiogenesis are largely uncharacterized. Investigations of these interactions 
were largely conducted in vivo, where the detailed study of the mechanisms is limited. In vitro angio-
genesis assays that incorporate the mechanical and/or chemical stimuli that directly result from blood 
flow are required in order to better understand the hemodynamic influences on angiogenesis (and asso-
ciated diseases). The PVEB may fill that need. The PVEB mimics aspects of hemodynamic angiogenic 
stimuli in the most physiologically relevant model of angiogenesis. Results of this study suggest that vas-
cular function (vasoconstriction and angiogenesis) were modulated by long-term intraluminal perfusion. 
Since the PVEB is amenable to molecular biology and culturing techniques conducted in the vascular ex-
plant assay, continued study of the effect of long-term intraluminal perfusion and vascular function us-
ing the PVEB can yield meaningful insights about the detailed mechanisms of these interactions. Insight 
gained from studies of vascular function and angiogenesis using the PVEB may prove necessary to the 
development of treatments for diseases that affect angiogenesis.  
 
E.3. Future Directions 
The angiogenic outgrowths grown in the PVEB were morphologically similar to those of the aortic assay 
and displayed features of healthy (in vivo) vasculature. They appeared patent to the aorta lumen, and 
were non-leaky to particles greater than 0.04 µm. The PVEB allows researchers to characterize angio-
genic outgrowth from a vascular explant in ways not possible in the conventional vascular explant assay. 
An obvious next step in the development and implementation of the PVEB is to better characterize and 
quantitate angiogenesis in the PVEB. 
Perfusion with fluorescent dyes, nanoparticles, and microspheres is commonly utilized to assess the ex-
tent and functional quality of angiogenesis in vivo83, 147. Patent vessels are identified in in vivo angiogen-
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esis assays by fluorescent illumination via injection of fluorescent material into upstream arteries or ves-
sels. Malformed (e.g., arising from tumor angiogenesis) and damaged vasculature can be identified in 
vivo by its leakiness to large particles. For instance, the microvasculature endothelium typically contains 
10 nm pores but tumor microvasculature contains fenestrae that cause leakage of particles greater than 
50-100 nm71. The perfusion access provided by the PVEB allows researchers to, for the first time, similar-
ly assess the functional qualities of the nascent vasculature in in vitro vascular explant angiogenesis as-
says. I recommend perfusing or charging the aorta with microspheres and nanoparticles of varying size 
to assess the functional quality of nascent vasculature in the PVEB. The size of the largest particle that 
leaks from the vasculature would provide a measure of the pore size in the nascent vasculature endo-
thelium 
In this study perfusion of the aorta resulted in a noticeable decline in angiogenesis. This effect was not 
quantitated, therefore it is uncertain whether the perceived decrease in angiogenesis is significant. 
Quantification strategies should be explored in future work. Though no standard technique for quanti-
tating the angiogenesis in the vascular explant assay exists, Nicosia et al. describe various methods of 
scoring angiogenesis in the vascular explant assay125. Some of these methods are gaining ground and 
should be modified for use in the PVEB. Similarly, quantification strategies should be employed to de-
termine what fraction of the angiogenic outgrowth is patent.  
The vascular explant assay carries out nearly all of the “steps” of angiogenesis. The final steps of vessel 
regression (adaption to tissue needs) and vessel stabilization, or vessel maturation, are mediated in part 
by blood flow. The PVEB recapitulates aspects of fluid flow, and it is plausible that nascent vessels in the 
PVEB would mature further than those in the vascular explant assay. I recommend incorporating ways of 
assessing vessel maturity in the PVEB. The amount of pericytes that bind to a nascent vessel is a com-
mon marker of vessel maturity. Pericytes are identified via histochemical staining cell markers (desmin, 
calponin, and proteoglycan NG2)121. Aortas cultured in the PVEB produced outgrowths that featured, in 
regions, a distinct second morphology. I speculate that this was proliferative expansion of fibroblasts in 
the PVEB. To settle uncertainties about this, one should stain the vasculature for fibroblast-specific 
markers and markers specific to other cell types resident in the vascular explant assay (macrophages, 
monocytes, dendritic cells, endothelial cells, and smooth muscle cells). Staining of angiogenesis in the 
vascular explant assay poses a significant obstacle: attempting to remove the specimen from its cultur-
ing dish or reactor distorts or obliterates the nascent vasculature. A “thin prep” assay was developed to 
allow whole mount staining of the angiogenic outgrowth from a vascular explant. This method should be 
adapted to use in the PVEB. 
The PVEB provides researchers a measure of control over hemodynamic stimuli in the vascular explant 
model. In this study, the PVEB was utilized to facilitate angiogenesis from an aorta that was either per-
fused with 50µL/min EGM or cultured without perfusion. The effect of shear stress and pressures gener-
ated by fluid flow depend on their magnitude and temporal pattern. Therefore, I recommend using the 
PVEB to investigate the effects of a wider range of perfusate flow rates and temporal patterns. Several 
molecules that induce angiogenesis (e.g., VEGF) also inhibit angiogenic maturation steps, and vice versa 
(Ang-1 which activates angiogenic maturation steps inhibits endothelial cell proliferation required for 
initiation of angiogenesis.) Nitric oxide, produced in response to shear stress, has a role in the earlier 
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and later ‘steps’ of angiogenesis. By starting intraluminal perfusion of an aorta in the PVEB after day 4 or 
day 6 in culture, may allow us to elucidate details about the role of shear stress on different steps of an-
giogenesis.  
Currently, the PVEB offers only spatially averaged measurements and actuation of mechanical/chemical 
stimuli resultant of intraluminal perfusion. Frequently, researchers employ mathematical models to bet-
ter characterize the spatial variation of the stimuli in mechanotransduction assays and assays that incor-
porate chemical gradients. The mathematical model of the mass transport in the PVEB must be im-
proved before it can provide local measures of the mechanical/chemical stimuli engendered in intralu-
minal perfusion of the vascular explant. One drawback of this mathematical model is that it approximat-
ed the vascular explant as a rigid uniform geometry. Optical image processing strategies exist that can 
be used to better model the geometry of the vascular explant116. A precise three-dimensional character-
ization of the aorta geometry may require MRI imaging of the vascular explant148. Two-photon micros-
copy might also accomplish more precise three dimensional characterization. I speculate that mass 
transport in the PVEB can be adequately modeled by incorporating more precisely characterized vessel 
geometries.  
In vivo, angiogenesis in postnates typically occurs from microvasculature and post-capillary venules. In 
comparison to other vascular explants, the aorta poorly represents the phenotype of angiogenic vessels. 
In addressing this, researchers have used smaller arteries, embryonic vessels, the saphenous vein, and 
the vena cava to better model in vivo angiogenesis in the vascular explant assay. I recommend incorpo-
rating these vessels into the PVEB. The PVEB may have to be scaled in order to accommodate this. A fur-
ther modification to the PVEB should be done, in order to allow co-culture of the aorta and vena cava.  
Ultimately, the PVEB should be utilized to investigate pathological angiogenesis. For example, cancer 
progression accelerates when the vasculature innervates the primary tumor. Tumors recruit new vessels 
by secreting pro-angiogenic cytokines, then use the vessels to supply their oxygen and nutrient needs, 
and metastasize. Tumor angiogenesis differs considerably from physiological angiogenesis. Tumor vascu-
lature that results is malformed, leaky, and less stable or mature. Blood flow and other hemodynamic 
stimuli are also abnormal in tumor vasculature71, 90. Massive effort is aimed at elucidating the molecular 
details of tumor angiogenesis. Hemodynamic factors influence tumor angiogenesis, and their impact 
should be studied more. The addition of tumors or cancer cells to the abluminal space in the PVEB 
would provide a platform for studying molecular mechanisms of tumor angiogenesis, functional qualities 
of the resulting tumor vasculature, and the impact of hemodynamics on angiogenesis and tumor vascu-
lature.  
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